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Part I
EARLY RELAPSE DETECTION 
AND ITS INFLUENCE ON 
LONGEVITY

Chapter 1
Putting routine follow-up 
after treatment for cancer 
into perspective
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Chapter 1
In the Netherlands, 1 in 2 men and 1 in 3 women face the diagnosis of cancer at 
least once during their life.1 Although the case fatality rate has decreased over the 
years, still only half of the cancer patients survive their disease.2 Translating this into 
numbers, 420,000 patients were living with cancer in the Netherlands in 2009.2 It is 
anticipated that these numbers will increase to approximately 660,000 patients in 
2020, mainly as a result of the ageing population.3 This means that 4% of the general 
population will undergo a form of cancer care, either treatment or follow-up.
The follow-up programmes are cancer-specific and mostly provided by the medical 
disciplines involved in the patient’s primary treatment. In general, the follow-up 
visits include medical history taking, physical examination and routine imaging or 
tumour marker testing. For example, women treated for ovarian cancer are examined 
both clinically and with the tumour marker CA125 every 3 months during the first 
two years after primary treatment; every 4 months in the third year of follow-up; 
every 6 months in years four and five; and annually after five years.4 The objective 
of all these checkups is to detect a cancer relapse as early as possible in order to 
facilitate early treatment and enhance longevity. Notwithstanding the capability of all 
these sensitive and sophisticated tests, the effectiveness of routine follow-up care 
can be questioned.
THE QUEST FOR EVIDENCE-BASED FOLLOW-UP 
PROGRAMMES
Ten years ago, the Dutch Ministry of Health, Welfare and Sports addressed the need 
for efficacy evaluation of cancer follow-up care. They asked the Health Council of the 
Netherlands to provide a framework on how to evaluate the effectiveness of cancer 
follow-up. In 2007, the Health Council published their final report ‘Follow-up in 
Oncology. Identify Objectives, Substantiate Actions’.3 Three aims of routine follow-
up care after treatment for cancer with curative intent were discerned: a patient-
oriented one, treatment monitoring, and a medical oriented objective. The first of 
these, primarily in the first year following treatment, comprises the provision of 
information, psychosocial support and guidance if needed. The second focuses on the 
monitoring and treatment of short and long-term side effects of primary treatment. 
The time frame required to monitor toxicity depends on the type of treatment given 
and the timing and duration of the expected side effects. The third aim has a medical 
orientation and covers the routine follow-up exams which are provided to detect 
and treat a relapse early-on and to lengthen a patient’s survival duration. Regarding 
this third aim, the Health Council Committee stated that there is limited evidence 
available on the impact of routine follow-up on life expectancy. More research is 
needed on the impact of earlier detection of relapses on a patient’s life expectancy 
and, if effective, which tests to include, at which interval, and for how long.
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The first research step in designing an effective evidence-based follow-up programme 
is performing a systematic literature review. Evidence regarding all the aims of routine 
follow-up has to be retrieved and critically appraised. This approach will identify 
gaps in knowledge and guide the development of follow-up programmes. Although 
the optimal follow-up programme is expected to differ between cancers, the Health 
Council Committee presented a generic guideline for a follow-up programme 
comprising four parts: the three patient-oriented aims and a schedule for medical 
evaluation, see Figure 1.1.
Figure 1.1. General programme for cancer follow-up. Modified from the Health Council 
of the Netherlands.3
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OBJECTIVE AND OUTLINE OF THE THESIS
The increasing number of cancer survivors will result in an enormous number of 
people in follow-up care, pushing existing facilities, resources and healthcare budgets 
to their limits.3,5 Together with the lack of evidence-based follow-up programmes, 
this underlines the need for an investigation into follow-up care effectiveness.5
In the first year following treatment, psychosocial care and addressing short-term 
side effects of cancer treatment are the most important aims of follow-up care, see 
Figure 1.1. After the first year, early detection of relapses becomes the first priority of 
follow-up care in hospitals and is mainly scheduled in years 1-5. No specific advice 
on the method and timing of medical evaluation and early detection of late effects 
of treatment is given in current follow-up guidelines.6 As a result, follow-up mainly 
includes routine follow-up exams aiming to detect relapses early.
For most cancer types, there is little evidence for the effectiveness of routine follow-
up examinations on longevity. As a result, most follow-up schemes are based on 
consensus between medical specialists rather than on clinical studies. The Radboud 
University Nijmegen Medical Centre, therefore, initiated a project to evaluate the 
effectiveness of early detection of relapses after treatment for cancer. In 2008, the 
Dutch Cancer Society granted the research project ‘Evaluation of routine follow-up 
controls in patients treated for cancer; the effects on life expectancy assessed for five 
common cancer types’. The five cancer types were ovarian, breast, lung, bladder and 
skin melanoma. These cancers were selected based on their relatively high incidence 
and varying levels of prognosis (poor – good; see Table 1.1).
To evaluate the effectiveness of routine follow-up examinations in patients treated 
for cancer, four determinants of early relapse detection on longevity were defined:
1. The time-dependent risk of cancer relapse and the pattern of follow-up   
 examinations in clinical practice.
2. The mode and proportion of relapses detected early.
3. The earliness of detection that can be achieved by follow-up tests.
4. The impact of early detection on length of survival.
All these determinants have to be quantified in order to evaluate current programmes 
and to simulate the impact of alternative follow-up scenarios, as well as to anticipate 
the effects of new diagnostic tests and treatment modalities. These determinants are 
the objectives of this thesis.
This thesis consists of three sections. In the first section (Chapter 2), an overview 
is given of the principles of early detection of relapses. In addition, a conceptual 
framework is formulated on how to study the impact of routine follow-up on patients’ 
survival. This framework has been developed to answer the four study objectives 
outlined above.
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Table 1.1. Population cancer incidence rates and 5-year relative survival figures in the 
Netherlands2
5-year relative survival (2003-2007)
Incidence rate
(2007)
Poor survival
(0-50%)
Moderate survival
(50-80%)
Good survival
(80-100%)
Very low incidence
(<10 per 100,000 PY)
Oesophagus ♀♂
Stomach ♀♂
Pancreas ♀♂
Brain ♀♂
Acute lymphocytic
leukaemia ♀♂
Kidney ♀
Acute myeloid  
leukaemia ♀♂
Cervix ♀
Low incidence
(10-20 per 100,000 PY)
Ovarian ♀ Kidney ♂
Non-Hodgkin
lymphoma ♀
Uterus ♀
Skin melanoma ♂
Intermediate incidence
(20-50 per 100,000 PY)
Lung ♀ Colorectal ♀
Bladder ♀♂
Non-Hodgkin
lymphoma ♂
Skin melanoma ♀
High incidence
(50-100 per 100,000 PY)
Lung ♂ Colorectal ♂
Very high incidence
(≥100 per 100,000 PY)
Breast ♀
Prostate ♂
♂, men; ♀, women; PY, person-years.
14
Chapter 1
The second part of my thesis will describe five applications of the framework for 
ovarian and breast cancer. Ovarian cancer is presented as an example of a tumour 
site with poor prognosis based on its high recurrence rate, but with CA125, the widely 
applied tumour marker, as a potential device for detecting relapses early. Chapter 3 
comprises a systematic literature study on the early detection of relapsed ovarian 
cancer. It addresses the question to what extent current follow-up programmes are 
evidence-based, evaluated by the study objectives of this thesis. The risk of ovarian 
cancer recurrence and the pattern of follow-up care in clinical practice are addressed 
in Chapter 4. In this retrospective observational study, we assess the proportion of 
recurrences detected early. In addition, we evaluate the difference in survival time 
between recurrences detected in the asymptomatic versus symptomatic phase. The 
information on both the proportion of relapses detected early and the survival time 
in relapsed patients is important to be able to calculate the overall effectiveness of 
follow-up. In Chapter 5 we analyse the effectiveness further using a Markov simulation 
study. The clinical course of ovarian cancer is modelled from primary treatment to 
recurrence to death and gives an estimate of longevity. Using the Markov model, we 
simulated the influence of alternative follow-up scenarios on life expectancy.
In the second half of part II, we move from ovarian cancer to breast cancer. Over 
the last decades, breast cancer treatment outcomes have improved and screening 
practices have been widely implemented. As a result, the prognosis following 
breast cancer treatment is fairly good. Breast cancer is a common disease and most 
patients undergo regular follow-up examinations for a long period of time. Chapter 6 
discusses the changes seen in the risk of breast cancer relapse between three periods: 
1972-1979, 1980-1986 and 2003-2004. In Chapter 7 we describe the pattern of 
breast cancer follow-up care today. It also presents our findings on the proportion 
of relapses detected early, as well as the contribution of physical examination and 
mammography in the preclinical detection of breast cancer relapses.
Current follow-up schedules are consensus-based; it is unknown which combination, 
timing and duration of tests is optimal. Further, the schedules are generally ‘one-
size-fits-all’, serving all patients with one surveillance programme. However, the 
probability of cancer relapse may vary greatly from one individual to another due 
to a unique mix of tumour characteristics, stage, treatments given and patient 
characteristics. Part three of this thesis deals with theoretical considerations for 
evidence-based and stratified follow-up care, and suggests directions for future 
research and clinical practice. Chapter 8 provides an overview of the incidence, relative 
survival of cancer, comorbidity rate and risks of second primary cancers for patients 
diagnosed with either ovarian, breast, lung or bladder cancer or skin melanoma in 
the Netherlands. Using these data we estimate the proportion of patients with an 
indication for minimal follow-up. In Chapter 9 we propose methods to design the 
ideal follow-up schedule, including considerations towards a more personalised 
follow-up. We close the chapter with our recommendations for future research.
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SUMMARY
Patients treated for cancer with curative intent are still at risk of developing a 
cancer relapse. Routine follow-up is offered to these patients with the aim to start 
treatment early and thereby improve the patient’s life expectancy. Routine follow-
up can, however, only increase patients’ life expectancy if relapses can be treated 
effectively, if tests are available which are able to detect a relapse in the preclinical 
detectable phase and if treatment outcomes are better when relapses are treated 
in the preclinical phase compared with the symptomatic phase. The effectiveness 
of a follow-up programme is associated with the absolute risk of relapse and 
the actual follow-up frequency of testing in practice, as it defines the number of 
relapses detected preclinically. The survival benefit of an earlier relapse detection 
can be evaluated using observational studies. Optimal follow-up strategies can best 
be selected with medical decision analysis for various scenarios and evaluated by 
comparison research.
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The presence of effective relapse treatment options and sensitive follow-up tests 
does not mean by definition that routine follow-up will extend survival time. 
Empirical studies need to determine whether treatment outcomes are better if 
treatment is provided in the preclinical phase compared with the start of treatment 
after manifestation of symptoms. When no survival benefit is observed, the timing of 
treatment is immaterial or the lead time is too short to influence treatment outcome.
Figure 2.1. Occurrence of cancer relapse: illustration of sojourn time and lead time.
PRINCIPLES OF THE EFFECTIVENESS OF CANCER 
FOLLOW-UP
Routine follow-up examination is a type of screening which aims at increasing 
patient’s life expectancy through early detection and treatment of a relapse.2 It is 
self-evident that routine follow-up can only influence patients’ survival time when 
effective options for relapse treatment are available and when relapse treatment is 
initiated immediately following early detection.
An illustration of the course of cancer relapse is given in Figure 2.1. Relapses are 
preferably detected before patients present themselves with clinical symptoms, that 
is, in the preclinical detectable phase.3 The duration of the preclinical detectable 
phase is named the sojourn time (Figure 2.1). The actual advancement in diagnosis 
achieved by routine testing is called the ‘lead time’. Routine follow-up can only result 
in survival benefit if the application of a follow-up regimen, comprising tests and 
tumour markers, is successful in detecting the relapse in its preclinical phase. In 
addition, the lead time should be significantly long to have any impact on treatment 
response.
Patients treated for cancer may face cancer relapse despite the curative-intent of 
primary treatment. All patients, therefore, undergo regular follow-up examinations 
by medical specialists aiming at the early detection and treatment of a cancer relapse 
and thus hoping to prolong life expectancy. Evidence on the impact of routine 
follow-up on life expectancy is, however, limited and requires effect size evaluation.1 
Before evaluating the effectiveness of routine cancer follow-up, it is important to 
understand when and how routine follow-up may improve longevity. In this chapter, 
we will outline the principles of effectiveness research and the different research 
methods available with their advantages and limitations.
Treated for 
cancer
Start 
detectable 
preclinical 
phase
Clinical 
relapse
Lead time
Sojourn time
Survival duration
Death
T T
T = routine test
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Whereas all patients are routinely tested, routine follow-up can only result in a 
longevity benefit in patients in whom a relapse is detected preclinically. The impact 
of follow-up on life expectancy on a population level therefore depends on the 
relapse rate and the content of the follow-up schedule. The absolute risk of relapse 
defines the proportion of patients who may benefit from routine testing. The number 
and timing of follow-up visits and tests, that is the follow-up schedule, define the 
absolute number of relapses detected preclinically and the advancement in diagnosis 
achieved.
METHODS TO EVALUATE THE EFFECTIVENESS OF 
CANCER FOLLOW-UP
The impact of early relapse detection and treatment on survival time can be studied in 
patients by intervention-research and observational studies. Based on the results of 
these studies, the most promising follow-up schedule from a large set of alternatives 
can be selected by simulation studies. We will describe these methods below and 
outline the strong points and most important limitations.
Interventions
Intervention studies can provide the strongest evidence for the impact of a specific 
follow-up programme on life expectancy by comparing various schedules. Different 
follow-up programmes should be allocated at random among a large number of 
patients and include the current follow-up scenario as a control. This type of study is 
named a randomised controlled trial (RCT).
RCTs are extremely expensive and labour-intensive and are therefore not suitable 
for hypothesis generation. The most promising scenarios need to be selected from 
the endless numbers of follow-up alternatives before performing a RCT. In addition, 
the difference in effectiveness between two follow-up programmes is expected to be 
small. As a result, large numbers of patients with a long follow-up period are needed, 
which underlines the need for a priori selection of the most promising programme. 
Furthermore, exploring the impact of a routinely used test by excluding the test 
during follow-up may be unethical, unless previous observational or modelling 
studies strongly suggest no impact of routine testing.
Observational studies
Observation is the second approach that can be used to study the impact of early 
relapse detection and treatment on survival time. In observational studies, the effect 
of routine follow-up on life expectancy is investigated using individual patient data 
from current clinical practice. Relapsed patients are categorised in two groups. Group 
1 consists of patients with relapses detected preclinically; routine follow-up can be 
considered successful in these patients. Group 2 comprises symptomatic relapsed 
patients, where routine follow-up failed to detect the relapse preclinically. Comparing 
the survival duration in patients with their relapse detected preclinically with those 
detected symptomatically can give a clue on the survival benefit gained by routine 
follow-up examinations.
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A limitation of the observational approach is the non-randomised character of the 
study design. The survival duration in patients in Group 1 versus Group 2 may differ 
for reasons other than the timing of relapse diagnosis. In epidemiology, such ‘other 
reasons’ are known as biases. Among the forms of bias we discern lead time bias, 
length-time biased sampling, self-selection bias and over-diagnosis bias, which are 
specific for screening.4
Lead time bias
Lead time induced bias occurs when a patient’s survival duration is calculated from 
the time of relapse detection. In this case, patients with their relapse detected 
preclinically have, by definition, a longer survival time than those with their relapse 
detected in the clinical phase (Figure 2.1). Difference in survival duration between 
preclinically and symptomatically detected relapses therefore include lead time. Lead 
time bias can be prevented by using a common point in time as the starting point 
of survival time, for example, date of primary tumour diagnosis or start of routine 
follow-up.
Length-time biased sampling
Length-time bias depicts the concept that slow-growing relapses have a longer 
preclinical phase and are thus more likely to be detected preclinically. As patients 
with slow-growing relapses may have a better prognosis than those with fast-
growing tumour relapses, a survival difference may therefore be caused by the more 
favourable prognosis rather than by an earlier initiation of treatment. Length-time 
biased sampling may partly be corrected for by adjustment for known prognostic 
factors like tumour stage, histology or grade. One can also explore the impact of 
length-time biased sampling on study findings by sensitivity analysis.5
Self-selection bias
In mass screening self-selection bias may occur when not all invited persons 
attend screening. Persons who do not attend a screening visit at a predefined 
time may differ in prognosis compared with people who do attend screening. In 
routine follow-up, self-selection bias may be present in patients with, for example, 
coexisting diseases. These patients may be examined for relapses less intensively 
and thus relapses may be more likely to be detected in the clinical rather than the 
preclinical phase. If such selection phenomenon are present, the effectiveness of 
routine follow-up may be overestimated, because the symptomatic group includes 
more patients with coexisting diseases, which has bearing on longevity, than the 
asymptomatic group. Another possibility is that patients with advanced cancer have 
more follow-up visits and tests, due to their higher risk of relapse, leading to an 
overrepresentation of advanced cancer in the preclinical group. This scenario can 
result in an underestimation of the effectiveness of routine follow-up. Thus, self-
selection may include different scenarios and the degree and the direction of the bias 
is hard to predict and to adjust for.
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Over-diagnosis bias
Over-diagnosis is one of the major concerns in mass screening as it causes 
overtreatment. Over-diagnosis refers to the detection of cancer in the preclinical 
phase which would never have become symptomatic in a patient’s lifetime. This may 
be caused either by tumour remission or regression or death from other causes during 
the preclinical phase. Occurrence of death before a relapse becomes symptomatic 
will be small in patients with aggressive tumours. Patients previously diagnosed with 
a tumour associated with a good prognosis may undergo unnecessary treatment, 
especially when patients are older or have coexisting diseases.
The comparison of survival outcome between patients with their relapse detected 
preclinically and detected symptomatically cannot provide a fair estimate of the 
absolute gain in life expectancy by routine follow-up. As explained earlier in this 
chapter, the impact of routine follow-up on the life expectancy on the patient cohort 
level depends on the relapse rate, the proportion of relapses detected in the preclinical 
phase and the life time gained by an earlier treatment. Using these parameters, it is 
possible to calculate the life expectancy of a patient cohort using models from the 
field of medical decision making.
Modelling
Medical decision analysis is a systematic approach used to calculate the optimal 
strategy from a series of alternatives.6 In medical decision analysis a mathematical 
model is designed to simulate the patient’s disease course. Here we discern two 
types of models: conventional decision trees and Markov models. A decision tree is 
a visual representation of all possible alternatives and the consequences that may 
follow each strategy.7 Conventional decision trees work well in analysing questions 
including a limited number of possible disease courses and a short time horizon. 
In Figure 2.2, an example of a decision tree for cancer follow-up is given. The tree 
includes two scenarios: follow-up and no follow-up. These scenarios are presented 
after the decision node (□) and marks the point where a medical decision has to 
be made. Depending on the scenario, relapses are detected asymptomatically or 
symptomatically, which is preceded by a chance node (○).
Figure 2.2. A conventional decision tree for the course of cancer after treatment with 
curative intent.
Asymptomatic relapse
Symptomatic relapse
No relapse
Symptomatic relapse
No relapse
Follow-up
No Follow-up
Treated for 
cancer with 
curative intent
5-yr survival
5-yr survival
5-yr survival
5-yr survival
5-yr survival
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Markov models differ from decision trees in that the uncertain events are modelled 
as transitions between defined health states, instead of modelling uncertain events 
at chance nodes. The time horizon of the analysis using a Markov model is divided 
into equal time intervals, for example 1 year, which are the Markov cycles. In Figure 
2.3, a cycle representing a Markov model is illustrated. The model comprises three 
states: no evidence of disease, relapse and death. At the start of the simulations 
all patients have no evidence of disease. During the first cycle, patients may have 
relapsed or died, or they remained disease-free. During the following cycles patients 
who remained disease-free may relapse or die. Patients who relapsed in one of the 
previous cycles may die. The number of cycles needed for the simulation of a cohort 
of patients following a specific follow-up scenario depends on the cycle length and 
time horizon chosen. Due to the use of cycles, Markov models are most useful when 
the decision problem involves risk over time, when the timing of events is important 
and when events may happen more than once, which is rather cumbersome using 
a conventional decision tree.7 Risk of cancer relapse generally decreases over time, 
some relapse types may be treated with curative intent and relapses may occur 
more than once.8 Modelling routine follow-up after treatment for cancer is therefore 
preferably done using a Markov simulation approach.
Data needed to simulate the disease course from primary treatment onwards in a 
cohort of patients can be obtained by individual patient data from medical records 
or published data from reviews, intervention and observational research, but can 
also be estimated based on expert opinion. The required data are often not available 
or subject to bias. The impact of the uncertainty of the clinical information on the 
simulation results can be explored by sensitivity analyses.7
No relapse
Relapse
Survive
Die
Survive
Die
NED, no evidence of disease
Figure 2.3. A Markov model for the course of cancer after treatment with curative intent.
Follow-up
No Follow-up
Treated for 
cancer with 
curative intent
NED
Relapse
Death
M
M
NED
Relapse
Death
Death
Relapse
End of the Markov cycleStart of the Markov cycle
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In summary, we recommend to study the impact of early relapse detection on 
longevity with a cohort study and determine the following parameters:
• the actual follow-up schedule applied in practice,
• the risk of cancer relapse,
• the proportion of relapses detected in the preclinical phase and
• the difference in survival time between relapses detected preclinically and  
 symptomatically.
The most promising follow-up schedule from a series of alternatives is advised to be 
selected using simulation studies. If the optimal follow-up schedule is convincingly 
more superior than the current schedule, immediate implementation should be 
considered. In situations where the sensitivity analysis showed that the uncertainty 
of the clinical information has a large impact on the model results, clinical studies 
should be performed to retrieve valid estimates of the detailed information needed. If 
the effectiveness of the optimal and the current follow-up schemes are similar and if 
it appears to be hard to convince clinicians to change their follow-up practice based 
on decision analytical analyses alone,8 we advice to compare the optimal follow-up 
programme with the current follow-up programme using a randomised controlled 
trial.
25
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ABSTRACT
Introduction
Patients treated for ovarian cancer with curative intent receive an intensive follow-
up programme in the years after treatment. However, the aimed improved survival 
through early detection of recurrence is subject to debate. Theoretically, the survival 
benefit depends on the lead time and the preclinical detection rate and on the 
effectiveness of recurrence treatment. This systematic review aimed at determining 
the effectiveness of early detection of recurrent ovarian cancer.
Methods 
A systematic literature search in PubMed, EMBASE, Medline, and the Cochrane Library 
was performed for articles published in 1985 to 2009 in English, German, or Dutch, 
excluding editorials, letters, and case-reports.
Results 
In total, 67 papers were included. Of 4 observational studies and 1 randomized 
controlled trial, only 1 observational study reported a better survival for patients 
who attended routine follow-up compared with those who did not. The sensitivity 
of cancer antigen 125 for a preclinical recurrence, based on 38 papers using 35 
U/ml as cut-off level, was 65%, with a median lead time of 3 months (range, 1-7 
months). Seven studies showed that, on average, 67% (ranging from 20% to 80%) of 
the 798 relapsed patients had no clinical symptoms when recurrent ovarian cancer 
was diagnosed.
Conclusions 
Routine follow-up may detect 2 of 3 recurrences asymptomatically with a lead time 
of 3 months. Recurrence treatment may extend survival by several months, but 
published studies did not show a survival advantage of early detection by routine 
follow-up examinations. Therefore, the content and aims of routine follow-up should 
be reconsidered, whereas routine cancer antigen 125 testing with the aim to improve 
life expectancy should be omitted.
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INTRODUCTION
Currently, routine follow-up in patients treated for ovarian cancer with curative intent 
is standard practice.1 Besides providing psychosocial care and evaluating (late) effects 
of primary treatment, detection of new manifestations of cancer, that is recurrence 
or metastases, in an early phase is an important goal of routine follow-up.2 This 
latter goal, being the main subject of this review, is the most important reason for 
gynaecologic cancer patients to attend the frequent routine follow-up visits.3
The purpose of early detection of recurrent cancer, preferably asymptomatically, is 
to prolong life expectancy through early initiation of recurrence treatment.2 Recently, 
a randomized controlled trial (RCT) by Rustin et al,4 in which treatment of recurrence 
was initiated by cancer antigen 125 (CA125) elevation, failed to show a survival 
benefit through early treatment of recurrent ovarian cancer.
Routine testing for recurrent ovarian cancer is only worthwhile if recurrences can be 
treated effectively. In 2007, Fung-Kee-Fung et al5 published a systematic review on 
systemic recurrence treatment, which revealed that chemotherapy may extend overall 
survival by several months. Besides treatment efficacy, the effectiveness of routine 
follow-up in ovarian cancer patients depends on the advancement in diagnosis 
of recurrent ovarian cancer to an early, preclinical phase. This can be evaluated 
by assessing the lead time, that is, the time interval between the detection of a 
recurrence by an elevated tumour marker level, named biochemical recurrence, and 
the detection because of clinical evidence, that is, clinical recurrence. Furthermore, 
the profitability of routine testing depends on the proportion of patients in whom the 
recurrence can be detected preclinically.
The aim of this review is to determine the potential survival benefit of routine follow-
up in ovarian cancer patients treated with curative intent by evaluating the evidence 
regarding early detection and lead time.
METHODS
Literature search strategy
A systematic literature search in PubMed, EMBASE, MEDLINE, and the Cochrane 
Library was performed for articles published between January 1985 and December 
2009, in English, German, or Dutch, excluding editorials, letters, and case reports. 
The search strategy can be found in Supplemental data 3.1. Reference lists of the 
included papers were searched for missing papers.
Selection criteria
We selected studies including patients treated for epithelial ovarian cancer, allowing 
patients with primary peritoneal or fallopian tube cancer to be included. Inclusion 
of retrieved publications was not restricted with respect to type of and response 
to primary treatment. Articles studying the lead period of routinely used tests to 
diagnose recurrent ovarian cancer at an early, that is, preclinical, phase were included. 
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Tests performed to verify the suspicion aroused by other routine tests were excluded. 
Clinical trials and observational studies on the asymptomatic detection rate and the 
effect of routine follow-up on survival were selected. Studies that did not evaluate 
survival outcomes by life table analysis or Kaplan-Meier methods were excluded.
Effect estimates
The effect estimates of routine follow-up are separately reported for clinical trials 
and observational studies. Lead time estimates of routinely used diagnostic tests are 
outlined, as is the proportion of patients with preclinical abnormal test results, that 
is the sensitivity. The median lead times observed were weighted for sample size and 
averaged. The mean preclinical detection rate was calculated by the product of the 
sample size and preclinical detection rate divided by the total number of patients 
with recurrent ovarian cancer. The mean proportion of asymptomatically detected 
recurrences was calculated based on the sum of patients detected asymptomatically 
divided by the sum of patients with recurrent cancer. 
RESULTS
Literature search
Searching for articles on follow-up examinations and survival effect retrieved 
4497 articles, of which 58 met the inclusion criteria. Nine studies were added after 
scrutinizing the reference lists. As a result, this review was based on 67 articles. In 
5 studies, the survival benefit was studied, 7 articles reported the asymptomatic 
detection rate, and 59 studies presented the lead time for various tumour markers. 
Supplement data 3.2 provides a flowchart of the selection of the articles.
Survival
The effect of routine follow-up after primary treatment was studied in 1 RCT and 4 
observational studies (Table 3.1).6-10 The double-blind RCT by Rustin et al6 revealed 
that immediate treatment based on an elevated tumour marker CA125 level did 
not result in a better survival time despite the 5-months earlier start of recurrence 
treatment.
The 4 observational studies operationalised early versus late treatment in different 
ways: asymptomatic versus symptomatic recurrence,7,8 radiographical versus clinical 
detection,10 detection by CA125 or x-ray versus gynaecologic examination or 
ultrasound,9 and treatment within 30 days compared to treatment more than 1 month 
after diagnosis.9 None of these comparisons resulted in a statistically significant 
survival effect. However, von Georgi et al9 observed a favourable prognosis in patients 
participating in routine follow-up compared with patients not attending follow-up 
visits.
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Lead time
The period between the biochemical detection and the otherwise clinical detection of 
recurrent epithelial ovarian cancer, that is, the lead time, was estimated in 59 studies 
for 24 different potential tumour markers.
Cancer antigen 125 was the most studied tumour marker. Table 3.2 provides an 
overview of the 38 articles on the lead time of CA125 with 35 U/ml as cut-off 
point.8,11-47 In 65% of all ovarian cancer patients recurrent cancer could be detected 
biochemically before clinical evidence of recurrence, with a median lead time of 3 
months. At least 18 (47%) of 38 studies were performed retrospectively. Twenty four 
studies (63%) selected patients in complete clinical remission after treatment and 10 
studies (26%) included patients with elevated CA125 at primary diagnosis only.
In addition, 16 articles reported the lead time or preclinical detection rate using 
various alternative definitions of biochemical relapse and cutoff for CA125. Cutoff 
points studied were 25 U/ml,48 38.5 U/ml,49 60 U/ml,50 65 U/ml,14,51-54 and 551 U/
ml55 resulting in median lead time estimates of 3 to 4 months. Of all recurrences, 70% 
to 100% were detected preclinically.
Other definitions of elevated CA125 used were 2.5 times increase,56 a doubling within 
3 months,57 a doubling above 35 U/ml,58 3 progressively rising CA125 levels in the 
reference range,59 a 5-U/ml increase,60 and early signal of progressive disease.60 
Median lead times observed ranged between 2 and 6 months with a preclinical 
detection rate ranging between 62% and 92%. In addition to the observational studies, 
1 RCT by Rustin et al4,6 observed a median lead time of 5 months defining preclinical 
relapse as a doubling of CA125 levels greater than 35 U/ml.
Mano et al61 examined various definitions of biochemical recurrence, ranging from 
10% to 200% increase and cutoffs levels between 25 and 100 U/ml. No data on median 
lead time were available, but mean lead time increased from 11 days to 6 months 
with decreasing cutoff values.
Besides the tumour marker CA125, other markers have also been examined for their 
potential to detect recurrent ovarian cancer in an early phase. These tumour markers 
are presented in Table 3.3. 11,13,14,18-20,22,24,25,34,35,43,49,53-55,62-68 The findings regarding 
lead time seem compatible with CA125, being 2 to 5 months. The preclinical detection 
rates vary between 36% and 100%.
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Patient selection† Recurrences
Author, yr
R/P
Design
Clinical
Remission
only‡
Elevated
CA125 at
primary
diagnosis
only N
Preclinical
detection,
%
Lead time,
Median
(range)
mo
Chan, 20088 R Yes No 80 86% 2 (0-23)
Havrilesky, 200811 P Yes No 27 96% ND
Thakur, 200312 R No Yes ND ND 7§ (ND)
Yeh, 200213 R No No 32 50% 3 (1-8)
Oehler, 199914 ND No No 6 0% NA
Garzetti, 199715 R No Yes 9 78% ND (1-6)
Gadducci, 199616 R Yes Yes 41 NA* 3 (2-27)
Sugiyama, 199617 R Yes Yes 22 95% 3§ (1-11)
Devine, 199518 R Yes No 11 64% 5§ (1-12)
Sliutz, 199519 ND Yes No 12 33% 4§ (1-24)
Devine, 199420 ND Yes No 5 60% 4 (2-7)
Gard, 199421 R No No 57 72% 4§ (ND)
Kobayashi, 199322 P Yes No 24 50% ND
Makar, 199323 R Yes No 52 73% ND (1-ND)
Ward 199324 R Yes No 20 50% 4 (1-24)
Fioretti, 199225 ND Yes Yes 15 93% 5 (1-14)
Högberg, 199226 P Yes Yes 15 73% ND
Markowska, 199227 ND No No 12 50% ND (3-6)
Capstick, 199128 P Yes Yes 7 100% 5 (2-12)
Hising, 199129 P No No 29 41% 3§ (1-10)
Moskovic, 199130 R Yes Yes 21 33% 1 (0-2)
Quaranta, 199131 P Yes No 9 100% 2 (1-7)
Burg, van der 199032 P No No 49 63% 5 (1-30)
Bruzzone, 199033 ND No No 41 41% ND (1-9)
Kamiya, 199034 P Yes No 35 32% ND (ND-7)
McGuckin, 199035 P No No 14 50% 5§ (1-10)
Bartel, 198936 P Yes No 3 33% 7 (NA)
Sheedan, 198937 P Yes No 8 88% 4 (1-17)
Podczaski, 198938 R Yes No 5 20% 3 (NA)
Zanaboni, 198939 P Yes Yes 23 57% 5 (2-13)
Alvarez, 198740 R No No 30 80% ND (0-6)
Brioschi, 198741 R Yes No 26 69% ND (1-ND)
Schilthuis, 198742 R No No 22 68% 4 (1-17)
Schwartz, 198743 P Yes No 12 83% 5 (3-12)
Sevelda, 198744 R No Yes 43 58% 3 (1-8)
Zanaboni, 198745 R No No ND n = 6 ND (1-14)
Malkasian, 198646 R Yes No 6 50% 4 (2-5)
Niloff, 198647 ND Yes No 35 94% 3 (ND)
Total 817 65% 3 (0-30)**
Table 3.2. Thirty-eight articles assessing the lead time between the elevation of CA125 
concentrations greater than 35 U/ml and clinical detection of recurrent ovarian cancer
NA, not applicable; ND, not documented; R, retrospective; P, prospective. § data are the mean.
† By definition biochemical remission after primary treatment, that is CA125 less than 35 U/ml.
‡ Biochemical and clinical remission after primary treatment. * Selection of patients with 
elevated levels of CA125 during follow-up but no clinical evidence of recurrence.
** Average median lead time weighted for study size.
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Recurrences
Tumour marker Author, yr N
Preclinical
detection,
%
Lead time,
median
(range)
mo
Individual tumour markers
Andostenedione Mahlick, 198662 13 38% ND (1-4)
CA130 Kobayashi, 199322 64 50% ND
CA15-3 Devine, 199420 5 60% 4 (1-6)
Fioretti, 199225 9 67% 2 (1-6)
CA19-9 Fioretti, 199225 5 80% 3 (2-4)
Fioretti, 198753 1 100% 3 (NA)
Total* 6 83% 3 (2-4)
CA72-4 Fioretti, 199225 11 82% 5 (1-12)
Cancer-associated specific antigen (CASA) Oehler, 199914 10 20% 3 (3-4)
Devine, 199518 11 64% 2 (1-10)
Sluitz, 199519 12 17% 2§ (1-6)
Devine, 199420 5 80% 2 (1-4)
Ward, 199324 20 65% 4 (2-25)
Total* 58 48% 3 (1-25)
McGuckin, 199035 14 64% 6§ (2-10)
Cyclic 3’,5’-guanosine monophosphate Turner, 199063 25 48% ND
Interleukin 6 Berek, 199164 ND n = 9 ND (3-4)
Leukocyte adherence inhibition test Ludwig, 198665 ND ND ND (1-2)
Lipid associated sialic acid Schwartz, 198743 12 ND 3 (2-5)
M3/M21 Hefler, 199855 44 43% 3 (2-8)
Ovarian serum antigen McGuckin, 199035 14 57% 4§ (2-7)
Osteopontin Schorge, 200466 ND 90% 3§ (1-7)
Placental-like alkaline phosphatase Haije, 198767 49 0% 0
Progesterone Mahlick, 198662 13 62% ND (1-4)
Tumour-associated trypsin inhibitor Fioretti, 199225 10 40% 5 (1-8)
TPS Yeh, 200213 32 56% 4 (1-7)
Devine, 199518 11 36% 2 (2-4)
Sluitz, 199519 12 50% 5§ (2-18)
Hefler, 199855 27 41% 5 (2-18)
Paulick, 198654 50 ND 5 (ND)
Panza, 198849 5 100% 3§ (1-6)
Table 3.3. Lead time and preclinical detection rate for tumour markers other than CA125 
to detect recurrent ovarian cancer
37
Ovarian cancer follow-up: a review of the literature
3
  Combination of tumour markers
Human epididymis secretory protein 4,
matrix metalloproteinase 7, glycodelin
Havrilesky, 200811 27 56% ND (1-16)
CA125, TPS Yeh, 200213 32 75% 3 (1-7)
Hefler, 199855 27 52% 4 (1-23)
Devine, 199518 11 73% 3 (1-12)
CA125, CASA Devine, 199518 11 73% 4 (2-12)
Devine, 199420 5 80% 4 (2-7)
Ward, 199324 20 80% 5 (2-25)
Total* 36 78% 5 (2-25)
CASA, TPS Devine, 199518 11 73% 2 (1-10)
CA125, CASA, TPS Sliutz, 199519 12 100% 7§ (1-24)
CA125, CA15-3 Devine, 199420 5 80% 4 (1-7)
CASA, CA15-3 Devine, 199420 5 80% 4 (2-6)
CA125, CA19-9, TPS,
immunosuppressive acidic protein
Kamiya, 199034 35 84% ND
CEA, ferritin, TPS, CA125 Lahousen, 198768 21 100% 5 (ND)
ND, not documented; TPS, tissue polypeptide-specific antigen.
§ Data are the mean.
* Average median lead time and preclinical detection rate weighted for study size on studies 
using the same cutoff value.
Recurrences
Tumour marker Author, yr N
Preclinical
detection,
%
Lead time,
median
(range)
mo
Table 3.3. Continued
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Early recurrence detection
Seven studies reported the percentage of patients in whom the recurrence was 
diagnosed in a presymptomatic phase. It ranged from 20% to 80 % 
(Table 3.4).7-9,69-72  On average, 67% of 798 patients with recurrent ovarian cancer were 
detected asymptomatically. In 2 studies, reported by Gadducci et al7 and Von Georgi 
et al,9 routine imaging was part of the follow-up program. In 1 of 4 relapsed patients, 
asymptomatic diagnosis was indicated first by CA125 alone. Seventeen percent of 
relapsed patients were presymptomatically detected by physical examination solely. 
In line with the guidelines, routine follow-up in patients included in the other studies 
included routine examination by patient history taking, physical examination, and 
CA125 testing.8,69,71,72 In more than 50% of asymptomatically detected recurrences 
CA125 rise was the first and only indication of relapsed cancer. Physical examination 
had only a modest contribution (i.e. 8%) in detecting recurrences early.
Recurrences
Author, yr Inclusion period
No. 
Patients 
relapsed
Asympto- 
matically 
detected, 
n(%)
Mode of aymptomatic 
detection, n(%)
ND, not documented; PE, physical examination.
§ See Supplemental data 3.3 for an update of Table 3.4, September 2011.
Table 3.4. Proportion of patients with recurrent ovarian cancer diagnosed in the 
asymptomatic phase§
Gadducci, 20097 Primary tumour
1987-2006
412 331 (80) 49
77
90
115
(15%) PE
(23%) CA125
(27%) imaging
(35%) imaging and
CA125
Chan, 20088 Recurrence
1999-2004
80 36 (45) 0
21
15
(0%) PE
(58%) CA125
(42%) PE and CA125
Menczer, 200669 Primary tumour
1995-2003
43 23 (53) 2
16
5
(9%) PE
(70%) CA125
(22%) PE and CA125
Nordin, 200670 Recurrence
2004-2005
110 32 (29) ND
Fehm, 200571 ND
ND
54 22 (41) 5
6
10
1
(23%) PE
(27%) CA125
(45%) PE and CA125
(0.5%) imaging only
Von Georgi, 20049 Primary tumour
1980-1998
186 134 (72) 28
36
54
16
(21%) PE
(27%) CA125
(40%) x-ray
(12%) ultrasound
Olaitan, 200172 Primary tumour
1997
10 2 (20) 2 (100%) CA125
Total 794 534 (67)
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DISCUSSION
Routine follow-up in patients treated for ovarian cancer aims to detect recurrent 
cancer at an early, asymptomatic phase to improve the life expectancy. The efficacy 
may seem promising as serial measurements of CA125 led to the detection of recurrent 
ovarian cancer 3 months before clinical detection in 65% of patients with recurrence. 
However, the 5 studies addressing the survival impact of routine follow-up did not 
show an improved life expectancy in patients with their recurrences detected earlier.
Well performed RCTs provide the best evidence regarding effectiveness of routine 
follow-up in ovarian cancer patients. Up to now only 1 RCT was performed indicating 
that, with respect to survival, CA125 has no added value in ovarian cancer follow-
up.4 In addition, the early initiation of treatment, based on CA125 elevation, was 
associated with a decreased quality of life caused by the longer treatment period.4 
The net survival benefit of the routine follow-up protocol has not been studied 
because RCTs comparing patients receiving routine follow-up with patients not 
receiving follow-up are considered unethical. Therefore, observational studies were 
done trying to approach this trial by comparing patients diagnosed early by means 
of routine follow-up with patients diagnosed clinically because of symptoms. The 4 
observational studies observed no difference in survival, except for routine follow-
up versus no follow-up9, but patient characteristics were not presented, which could 
question comparability. Although we were not able to pool the results to a summary 
measure, the findings are consistent in suggesting no survival benefit of routine 
follow-up.
The prerequisite for routine follow-up to be useful is to be able to detect the 
recurrence in the preclinical phase. Until recently, the European routine follow-up 
program in ovarian cancer patients includes routine measurement of CA125, physical 
examination and patient history taking.1 Imaging tests are only performed if recurrent 
cancer is suspected. As a result, tumour marker CA125 is the most important test to 
detect recurrent ovarian cancer in its preclinical phase.
The length of the preclinical phase, that is, lead time, is studied in several ways. 
Studies were either prospective or retrospective and observational or experimental. 
A disadvantage of observational studies is the absence of blinding for CA125 
measurements. The medical specialist is aware of the CA125 level of the patients. In 
practice, elevated CA125 levels are an indication for recurrence and consequently, 
imaging is advised. If imaging gives no evidence for recurrent cancer, patients are 
likely to be followed more closely. The period until the next visit will be shorter as 
compared with the predetermined follow-up schedule. As a result, clinical detection 
of recurrence occurs earlier, and lead time estimates are expected to be shorter 
in observational studies compared with a situation in which medical specialists are 
blinded for the CA125 levels of their patients.
The preclinical detection rate is associated with the patient selection criteria because 
patients with elevated CA125 levels at primary diagnoses are likely to have elevated 
CA125 levels at recurrence as well.
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On the basis of the studies included in this review, we can state that routine CA125 
levels are elevated several months before clinical evidence of recurrence. Summarizing 
the observational studies using 35 U/ml as cutoff resulted in a median lead time of 3 
months, but heterogeneity between study populations is present. The RCT by Rustin 
et al4 provides the most valid estimate of lead time, that is, 5 months if CA125 was 
doubled above normal, because CA125 levels were studied prospectively and kept 
blinded for the clinicians. Increasing cutoff values theoretically lead to a shorter lead 
time. However, there were no large differences in median lead time between various 
cut-off values, indicating the low potential for a long preclinical phase. Studies 
including other markers to detect recurrent ovarian cancer showed similar lead times.
In conclusion, tumour markers to detect recurrent ovarian cancer, including CA125, 
are associated with a lead time of only several months. Lower cut-off levels did 
not result in a significantly increased lead time. As initiation of treatment 5 months 
before clinical evidence of recurrence does not lead to an improved survival,4 routine 
testing of tumour markers with the aim to improve life expectancy should not be 
considered clinically relevant.
Besides the length of the preclinical phase, the number of patients diagnosed 
asymptomatically is important regarding efficacy on the population level. On average, 
67% of patients’ recurrences were detected asymptomatically. In the absence of 
routine imaging, CA125 has the largest contribution to this rate. In addition, 65% of 
all relapsed patients had elevated CA125 levels before the clinical detection. This is 
in line with the meta-analysis by Gu et al,73 who reported a pooled sensitivity of 69% 
of CA125 at recurrence diagnosis, that is, with a lead time of 0, based on 15 studies 
using 35 U/ml as cutoff point.
Routine testing in patients is only justified if treatment of recurrent cancer is effective. 
Current chemotherapeutical treatment of relapsed ovarian cancer has no curative 
intent.5 The survival benefit of early initiation of treatment is expected to be small or 
even absent, as shown by Rustin et al.4
We would like to note that the efficacy of recurrence treatment is studied in patients 
with at least 1 previous line of chemotherapy. As in the RCT by Rustin et al, patients 
with surgery alone as primary treatment were excluded. The question remains 
whether these patients may benefit from early initiation of recurrence treatment. But 
because risk of recurrence is low in patients with early stage ovarian cancer, that is, 
10% in stage I,74 follow-up in this subgroup may not be cost-effective.
On the basis of current available evidence, we conclude that routine CA125 testing with 
the aim to improve survival time is not advised. Although this advice is mainly based 
on the results of 1 RCT by Rustin et al,4 the finding is in line with the observational 
studies comparing early with late detection of recurrences. In addition, the short lead 
time and the lack of curative recurrence treatment options corroborates with these 
observations. Therefore, the follow-up programme should be reconsidered.
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Before specific recommendations can be provided on how to follow-up patients 
treated for ovarian cancer, studies focusing on benefit and costs of alternative 
follow-up strategies are needed. Regarding the purpose, follow-up may become 
more efficient if the protocol is adapted to other aims of routine follow-up: providing 
psychosocial care and monitoring late effects of primary treatment.75 After primary 
treatment, ovarian cancer patients may experience distress caused by physical and 
psychosocial problems that affect the patients’ quality of life.75 A survey among 
50 patients showed that, for most needs, more than 50% of patients desired help 
in dealing with their physical or psychosocial problems.75 The routine follow-up 
programme itself may cause psychosocial distress because follow-up tests and visits 
are associated with increased anxiety.3 Although immediate treatment of recurrences 
based on CA125 elevation was associated with a decreased quality of life, CA125 
may be useful in guiding the patients and their physicians in planning of the start of 
recurrence treatment.4 A dialog between the patient and her physician is important 
to provide individualized care, according to the patient’s needs and preferences, and 
to keep patients’ expectations realistic. To relieve medical specialists of this time-
consuming task, alternative follow-up strategies should be explored. Alternative 
follow-up strategies proposed in the past, like nurse-led follow-up,76 follow-up by 
the general physician,77,78 or patient initiated follow-up,70,79 may be considered.
The development of the optimal routine follow-up protocol is a dynamic process 
guided by new scientific findings and the generation of more effective diagnostic and 
treatment tools. For example, improvements in diagnosis and treatment of recurrent 
ovarian cancer may lead to a change in the effect of routine follow-up on survival. 
Large-scale cytoreductive surgery in case of recurrent ovarian cancer may positively 
influence the course of the disease in a subcategory of patients.80,81 As discussed 
by Rustin et al,4 CA125 monitoring may become of use in the timely detection of 
resectable recurrences if second cytoreductive surgery is shown to be effective.
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#1 ovarian neoplasms[mesh]
#2 carcinoma[mesh] OR cancer*[tiab] OR cancers[tiab] OR carcino*[tiab] OR tumor*[tiab] 
OR tumors[tiab] OR neoplas*[tiab] OR malig*[tiab]
#3 ovar*[tiab] OR gynaecolog*[tiab] OR gynecolog*[tiab] OR genital neoplasms, 
female[MeSH:noexp]
#4 #2 AND #3
#5 #1 OR #4
#6 follow-up[ti] OR follow up[ti] OR followup[ti] OR follow-ups[ti] OR follow ups[ti] OR 
followups[ti] OR surveillance[ti] OR routine[ti] OR strategy[ti] OR strategies[ti] OR 
recurrence*[tiab] OR recurrent[tiab] OR relapse*[tiab] OR relapsing[tiab]
#7 radiography[MeSH]) OR x-ray[tiab] OR xray[tiab] OR “x ray”[tiab] OR “CA-125 
antigen”[mesh] OR CA125[tiab] OR CA-125[tiab] OR “CA 125”[tiab] OR positron-
emission tomography[MeSH] OR PET[tiab] OR PET*[tiab] OR computed tomography[tiab] 
OR CT[tiab] OR CT*[tiab] OR “physical examination”[mesh] OR physical 
examination*[tiab] OR “magnetic resonance imaging”[mesh] OR MRI[tiab] OR “magnetic 
resonance imaging”[tiab] OR “medical history taking”[mesh] OR anamnesis[tiab] OR 
“Diagnostic Tests, Routine”[Mesh] OR “diagnostic test”[tiab] OR “diagnostic tests”[tiab] 
OR “Diagnostic Imaging”[Mesh] OR “diagnostic imaging”[tiab] OR ultrasound[tiab] OR 
ultrasonography[tiab]
#8 Limits: English, German, Dutch
#9 #6 AND #7 AND #8
#10 #5 AND #9
Supplemental data 3.1. PubMed search strategy
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Supplemental data 3.2. Flowchart for the selection of relevant articles on the survival 
benefit of routine follow-up and its components
Search for article on:
Routine follow-up examinations 
& survival effect
- PubMed
- EMBASE
- Medline
- Cochrane Library
4497 Titles
281 Full text
58 Full text
4216 excluded based on title 
and abstract
223 excluded
- 19 duplo
- 77 reviews
- 18 in suspected recurrence
- 47 no effect measure
- 28 not on follow-up
- 5 untraceable
- 29 other
9 added based on reference 
lists of included articles
Result: 67 articles
- 5 survival
- 7 asymptomatic detection
- 59 lead time of tumour markers
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Mode of detection Method of detection
Follow-up 
programme§ Author, year
Pooled 
estimate Author, year Pooled estimate
Patient history 
taking, physical 
examination
and CA125
Geurts, 2011*
Chan, 20088
Menczer, 200669
Fehm, 200571
Otailan, 200172
43% 
asymptomatic
Chan, 2008
Menczer, 2006
Fehm, 2005
Otailan, 2001
56% patient complaints
  4% physical examination
24% CA125
16% physical examination
       and CA125
Patient history 
taking, physical 
examination, 
CA125 and 
imaging
Tanner, 2010*
Gadducci, 20097
Von Georgi, 
20049
78% 
asymptomatic
Gadducci, 2009
Von Georgi, 2004
22% patients complaints
13% physical examination
38% CA125
27% imaging
Supplemental data 3.3. Update of Table 3.4 in September 2011. Mode of ovarian cancer 
recurrence detection by follow-up schedule
§ The follow-up schedule applied in the study by Nordin et al70 was unknown.
* Published after 2009 and therefore not included in the review:
Geurts SME, van Altena AM, de Vegt F, et al. No supportive evidence for clinical benefit of routine 
follow-up in ovarian cancer: a Dutch multicenter study. Int J Gynecol Cancer. 2011;21:647-653 
and Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for the detection of recurrent ovarian 
cancer: Survival impact or lead-time bias? Gynecol Oncol. 2010;117:336-340.
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ABSTRACT
Introduction 
Routine follow-up is standard medical practice in ovarian cancer patients treated 
with curative intent. However, no strong evidence exists indicating that prognosis is 
improved. The objective of this study was to evaluate the routine follow-up schedule 
for ovarian cancer patients regarding the adherence to the Dutch protocol, the 
detection of recurrences, and the follow-up’s impact on overall survival.
Methods 
All 579 consecutive patients diagnosed with epithelial ovarian, primary peritoneal, or 
fallopian tube cancer in four Dutch hospitals between 1996 and 2006 were selected. 
Only patients in complete clinical remission after primary treatment were studied. 
Compliance to the Dutch follow-up guideline was assessed in a random sample of 68 
patients. Of the 127 patients with recurrence, the mode of recurrence detection was 
addressed. Survival time since primary treatment was calculated using the Kaplan-
Meier method.
Results 
The patients received more follow-up visits than was recommended according to 
the guideline. The cumulative 5-year risk of recurrence was 55% (95% CI: 43%-67%). 
The survival of patients with recurrent ovarian cancer detected asymptomatically at 
a routine visit (n=51) tended to be better compared with patients with symptomatic 
detection at a routine (n=31) or diagnosed after an interval visit (n=31). The median 
survival times were 44 months (95% CI: 38-64), 29 months (95% CI: 21-38), and 
33 months (95% CI: 19-61), respectively (p=0.08). The median time from primary 
treatment to recurrence was similar for the three groups: 14 months, 10 months, and 
11 months, respectively (p=0.26).
Conclusions 
Follow-up in line with (inter)national guidelines yields a seemingly longer life 
expectancy if the recurrence was detected asymptomatically. However, this result 
is expected to be explained by differences in tumour biology and length-time bias.
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INTRODUCTION
Routine follow-up is standard medical practice in patients treated for ovarian cancer 
with curative intent. One prominent objective of the follow-up protocol is the 
early detection and treatment of recurrent cancer with the aim of improving life-
expectancy.1 For ovarian cancer patients themselves, early detection of a possible 
recurrence of cancer is the most important reason for attending a routine follow-up 
programme.2 Unfortunately, available evidence does not corroborate that intensive 
routine follow-up indeed improves prognosis.
The current policy of tests and visit frequencies is based on consensus among medical 
specialists.3,4 Nevertheless, several studies exploring current practice revealed a large 
variation in the number of follow-up visits.5-7 And so far no study has been conducted 
to examine the actual adherence to the follow-up schedule as recommended in the 
guidelines.
In the Netherlands, patient history taking, physical examination, and CA125 
measurement were advised to be done at every scheduled visit.4 As a result, early 
asymptomatic detection is achievable by CA125 testing, but in clinical practice 
treatment may be postponed until clinical evidence of recurrence occurs.8 The net 
effect of these follow-up visits remains unknown. Recently, three studies have 
been published that examined the effect of routine follow-up on survival.9-11 Two 
projects were observational multicentre studies, both mentioning a high proportion 
of asymptomatically detected recurrences at routine follow-up visits.10,11 However, 
the findings on the survival difference between routine and interval recurrences were 
inconsistent. Rustin et al conducted a randomized trial that revealed no survival 
benefit of immediate treatment based on CA125 elevation over delayed treatment 
until signs or symptoms of recurrent disease occurred.9 As a result routine CA125 
testing with the aim to improve survival is no longer advised.
Therefore the aim of the present study is firstly to evaluate the follow-up protocol in 
a population based cohort as compared with guideline recommendations. Secondly, 
the rate of asymptomatic recurrence detection related to real life visit frequency and 
content will be assessed, and thirdly, the extent to which routine visits are related to 
a survival benefit.
PATIENTS AND METHODS
The source population of this multicentre study included 579 consecutive patients 
with epithelial ovarian, primary peritoneal, or fallopian tube cancer diagnosed in four 
hospitals in the East of the Netherlands between January 1996 and January 2006. 
The four hospitals were the Radboud University Nijmegen Medical Centre and the 
Canisius-Wilhelmina Hospital, both in Nijmegen, the Gelderse Vallei Hospital in Ede, 
and the Rijnstate Hospital in Arnhem.
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Patient and tumour characteristics and mortality data were obtained from the Cancer 
Registry of the Comprehensive Cancer Centre East. Diagnosis of recurrent ovarian 
cancer was defined as a doubling of CA125 concentration above 35 U/ml on two 
occasions or if clinical evidence of recurrence emerged.
Only patients in complete clinical remission after primary treatment were evaluated. 
Complete clinical remission was defined as no evidence of residual disease on 
computed tomography and CA125 concentration below 35 U/ml. If computed 
tomography was not performed, physical examination and ultrasound were used to 
evaluate treatment response.
The routine follow-up practice was evaluated, for efficiency reasons, in a random 
sample consisting of 25% of the initial cohort of ovarian cancer patients. Sixty-
eight patients were in complete remission after primary treatment. The impact of 
routine follow-up on survival was assessed in all patients with recurrent ovarian 
cancer (n=127). The number of actual follow-up examinations, as well as the mode 
of recurrence detection, was retrieved from the medical files in 2009.
Endpoints
The Dutch guideline for epithelial ovarian cancer provides a routine follow-up 
protocol comprising follow-up visits every three months in year one and two, every 
four months in year three, and every half year in years four and five.4 Patient history, 
physical examination, and CA125 tests are advised to be taken at each visit. Only if 
recurrent cancer is suspected, is additional imaging, such as computed tomography 
or ultrasound, recommended. The follow-up protocol was evaluated by counting 
the number of actual follow-up visits compared with the recommended number, 
taking the follow-up period into account. Visits carried out for reasons other than 
monitoring for relapse, such as comorbidity and wound care, were excluded. The 
follow-up period was defined from the date of the last primary treatment until a first 
recurrence or the last follow-up visit.
The routine follow-up protocol is intended to detect recurrent ovarian cancer in an 
early disease phase, i.e. preferably when the recurrence is still asymptomatic. Since 
recurrences may be diagnosed between two scheduled visits, the mode of recurrent 
ovarian cancer detection was categorized into three groups: I) asymptomatic 
recurrences detected at a routine visit, II) symptomatic recurrences detected at a 
routine visit, and III) symptomatic recurrences detected at an interval visit. The latter 
situation comprises a diagnosis set at an unscheduled visit initiated by the patient 
(interval) because of symptoms indicating a recurrence.
Data analyses
To study the impact of routine follow-up on life expectancy, the overall survival of 
patients with an asymptomatic recurrence was compared with the survival of patients 
with routine and interval detected symptomatic recurrence.
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Risk of recurrence and death were calculated with the Kaplan-Meier survival analysis 
technique. The last date of primary treatment was chosen as the date at which survival 
time started because at that time the response to initial treatment, i.e. complete 
remission, was addressed. This date also marks the start of the follow-up period 
in which patients are at risk of developing recurrent cancer. The log-rank test was 
applied to calculate the statistical significance of differences in survival curves of the 
recurrence detection groups.
To explore potential violation of a valid comparison of the various modes of detection 
and survival, we considered the influence of delayed treatment that was postponed 
until clinical evidence of recurrence or symptoms arose.
RESULTS
Patients
In the four hospitals, 579 consecutive patients were diagnosed between 1996 and 
2006. The flow chart for patient selection in this study is displayed in Figure 4.1.
The characteristics of both the random sample of the follow-up cohort and the 
patients with recurrences are shown in Table 4.1. The cohort of patients in complete 
remission in which routine follow-up was studied had more favourable prognostic 
characteristics than patients who developed a recurrence. The former group had 
more often early stage disease, fewer grade 3 tumours, less chemotherapy as primary 
treatment, and less residual disease after surgery.
Figure 4.1. Flow chart for selecting ovarian cancer patients in complete clinical remission 
to evaluate the routine follow-up protocol and detection of recurrence.
No complete remission, 68
Complete remission, 68
Random sample
from 4 hospitals 
N=137*
All patients with 
recurrent ovarian 
cancer N=205*
No complete remission, 74
Complete remission, 127
Patients 
diagnosed with 
ovarian cancer in 
4 Dutch hospitals 
between 
1996 and 2006 
N=579
Interval detection 
N=31
Routine detection
N=87
Unknown
N=9
Sympt
N=31
Sympt
N=31
Asympt
N=52
Unknown
N=4
* Medical records missing for 1 and 4 patients, respectively
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Recurrence detection
Routine
follow-up
cohort
sample
n=68
Routine,
asymptomatic
n=52
Routine,
symptomatic
n=31
Interval,
symptomatic
n=31
Age, median (range) 58 (38-83) 61 (23-80) 62 (38-77) 58 (40-85)
CA125>35U/ml at diagnosis (%)
Yes
No
54
14
(79)
(21)
42
10
(81)
(19)
26
5
(84)
(16)
25
16
(81)
(19)
Type of tumour (%)
Epithelial ovarian
Primary peritoneal
Fallopian tube
Unknown
59
4
1
3
(87)
(6)
(1)
(4)
46
5
1
0
(88)
(10)
(2)
26
1
1
3
(84)
(3)
(3)
(10)
25
3
2
1
(81)
(10)
(6)
(3)
FIGO stage (%)
Early (I-IIA)
Advanced (IIB-IV)
Unknown
24
42
2
(35)
(62)
(3)
8
44
0
(15)
(85)
3
28
0
(10)
(90)
4
26
1
(13)
(84)
(3)
Histological type (%)
Serous
Mucinous
Endometrioid
Other
Adenocarcinoma NOS
27
7
15
8
11
(40)
(10)
(22)
(12)
(16)
30
2
6
4
10
(58)
(4)
(12)
(8)
(19)
12
1
11
4
3
(39)
(3)
(35)
(13)
(10)
14
1
8
2
6
(45)
(3)
(26)
(6)
(19)
Tumour grade (%)
Grade 1
Grade 2
Grade 3
Unknown
9
18
28
13
(13)
(27)
(41)
(19)
6
14
22
10
(12)
(27)
(42)
(19)
3
3
20
5
(10)
(10)
(65)
(16)
3
8
15
5
(10)
(26)
(48)
(16)
Primary treatment (%)
Surgery only
Chemotherapy only
Surgery and chemotherapy
11
1
56
(16)
(1)
(82)
6
2
44
(12)
(4)
(85)
1
1
29
(3)
(3)
(94)
0
0
31 (100)
Residual disease after surgery (%)
< 1 cm
≥ 1 cm
Unknown
57
8
3
(84)
(12)
(4)
43
6
3
(83)
(12)
(6)
24
7
0
(77)
(23)
24
6
1
(77)
(19)
(3)
Recurrence treatment (%)
Yes
No
Unknown
45
7
0
(87)
(13)
25
4
1
(83)
(13)
(3)
24
7
0
(77)
(23)
Surgery at recurrence (%)
Yes
No
8
44
(15)
(85)
5
26
(16)
(84)
6
25
(19)
(81)
Chemotherapy at recurrence (%)
Yes
No
Unknown
39
13
0
(75)
(25)
25
6
0
(81)
(19)
17
13
1
(55)
(42)
(3)
Radiotherapy at recurrence (%)
Yes
No
0
52 (100)
1
30
(3)
(97)
2
29
(6)
(94)
Table 4.1 Primary tumour characteristics in patients with ovarian cancer in complete 
clinical remission: a random sample of the inception cohort and patients with recurrent 
cancer
NOS, not otherwise specified.
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Routine follow-up protocol
The median follow-up time was 30 months (range: 3 to 124). The scheduled number 
of routine follow-up visits in the representative 68 patients would be 613 routine 
visits. Observed were 690 follow-up visits of which 622 were routine, 44 interval, 
and 24 of unknown plan. In Table 4.2 the scheduled and actual numbers of follow-
up visits are shown per year of follow-up. Within the follow-up period, 37 patients 
with recurrent ovarian cancer were detected. This corresponds with a five-year risk 
of recurrence of 55% (95% CI: 43% - 67%) (Figure 4.2).
Table 4.2 Number of follow-up visits for ovarian cancer patients in complete clinical 
remission and risk of recurrence.
Year of follow-up
1 2 3 4 5 6+
Patients at start of follow-up year 68 45 37 31 21 12
Number of follow-up visits, mean
Guideline 4 4 3 2 2 1
Expected, guideline based† 3.5 3.6 2.7 1.8 1.5 1.8
Actual† 4.4 3.1 2.6 2.4 1.6 4.1
Risk of recurrence 32% 15% 16% 6% 0% 0%
† adjusted for follow-up time.
Figure 4.2 Risk of recurrence with 95% confidence interval in 68 patients in complete 
clinical remission after primary ovarian cancer treatment.
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Survival benefit
In patients with initially complete remission, 127 were diagnosed with a recurrence. 
Of those, 87 recurrences (69%) were detected at a routine visit and 31 (24%) at an 
interval visit (Figure 4.1). For nine patients, the type of visit could not be determined. 
Of the 87 patients in whom the recurrence was detected at a routine visit, 52 (60%) 
did not have clinical symptoms.
The five-year survival rate calculated in 68 patients initially in complete remission 
was 59% (95% CI: 46% - 72%). For one patients with an asymptomatically detected 
recurrence last date of primary treatment was unknown. The survival time in patients 
with recurrences detected asymptomatically at a routine follow-up visit (group I, 
n=51) was longer as compared with patients having routine (group II, n=31) or 
interval (group III, n=31) detected symptomatic recurrences (Figure 4.3A, p=0.08). 
The median survival times were 44 months (95% CI: 38 - 64), 29 months (95% CI: 21 
- 38), and 33 months (95% CI: 19 - 61), respectively.
The median time to recurrence was almost similar in all three groups: 14 months 
(95% CI: 10 - 19), 10 months (95% CI: 9 - 14), and 11 months (95% CI: 8 - 19), (Figure 
4.3B, p=0.26).
Patients with asymptomatically detected recurrences tend to have a more favourable 
primary tumour biology compared with symptomatic patients (Table 4.1). 
Asymptomatic patients had more serous tumours, fewer grade 3 tumours, less often 
chemotherapy as primary treatment, and less residual disease after surgery. The 
proportion of relapsed patients undergoing second cytoreductive surgery did not 
differ by mode of detection, but chemotherapy was less often started in patients with 
their recurrence detected at an interval visit (Table 4.1).
In 11 patients (21%) with asymptomatic recurrences detected at a routine visit, the 
treatment of the recurrence was delayed until clinical evidence of progressive disease 
occurred. One patient refrained from recurrence treatment. Survival was significantly 
worse in patients with delayed treatment, the median survival times being 38 months 
(95% CI: 19 - 57) versus 57 months (95% CI: 41 - 70) if treated immediately (p=0.04).
For patients with symptomatic recurrences detected at a routine visit, treatment was 
delayed in four (13%) patients, declined by one patient, and unknown in one patient. 
The survival time was similar in patients treated immediately or delayed; the median 
survival times were 29 (95% CI: 21 - 39) and 27 (95% CI: 17 - 58) months, respectively.
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Figure 4.3 Post primary treatment survival (A) and recurrence-free survival (B) by mode 
of recurrence detection in ovarian cancer patients in complete clinical remission after 
primary treatment.
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DISCUSSION
In clinical practice in East Netherlands, ovarian cancer patients received a more 
intensive surveillance programme compared with the guideline. Although routine 
follow-up is aimed to detect recurrent ovarian cancer in its early phase, only 52 of 
127 (41%) recurrences were detected asymptomatically. The survival time tended to 
be longer in patients in whom a recurrence was detected in the asymptomatic phase 
and for those treated immediately after asymptomatic recurrence detection.
Routine follow-up protocol
Ovarian cancer patients had more visits than was recommended according to the 
Dutch guideline. During the first year of follow-up, more visits were observed 
because medical specialists may provide the first follow-up visit 6 weeks after 
primary treatment instead of after 3 months.4 Routine examinations may be provided 
by both the gynaecologist and the medical oncologist, which is a second explanation 
for the higher observed frequency.
Routine follow-up can only extend life expectancy if recurrences are treated 
immediately following diagnosis. However, treatment was delayed in at least 20% of 
patients with asymptomatically detected recurrences. In these patients routine follow-
up cannot result in a better life expectancy, which may have led to an underestimation 
of the attainable survival effect. On the other hand, some patients may not seek help 
if they have complaints. For those patients, a scheduled appointment may assure that 
a recurrence is timely detected.
The recurrence rate is highest during the first year of follow-up and levels off after 
three years (Table 4.2). Therefore, a less intensive follow-up protocol after 3 years of 
routine follow-up is justified. Routine follow-up continues to take place after 3 years 
presumably because of patients’ concerns about cancer recurrence and death, even 
after many years of follow-up.12,13
Mode of recurrence detection
In this study, 69% of all recurrences were detected at a routine visit. This percentage 
is slightly lower compared with that reported by Gadducci et al10 and by Tanner et 
al,11 who observed routine detection rates of 80% and 82%, respectively. Although the 
follow-up frequency was similar in all studies, the difference in rates can probably 
be explained by the use of computed tomography as a routine test in Italy and the 
United States, whereas this is not standard practice in the Netherlands.
In our study, of all patients with their recurrence detected at a routine examination, 
two third were asymptomatic at the time of detection. This is in contrast with the 
retrospective studies of Gadducci10 and Tanner,11 where all patients with recurrences 
detected at routine visits were classified asymptomatic, even though Gadducci10 did 
not base recurrence diagnosis only on elevated CA125 levels.
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Considering the value of CA125 levels with respect to treatment efficacy, we also 
analyzed the prognostic value of CA125 levels at diagnosis in a subcohort of our 
patients (data not shown). Our cohort sample consisted of 68 patients. There 
were no differences in survival time and recurrence-free survival between patients 
with normal (n=14, 5 relapsed) and elevated (n=54, 32 relapsed) CA125 levels at 
diagnosis. However, the sample size is too small to draw valid conclusions regarding 
the prognostic value of CA125 levels at diagnosis.
Survival benefit in the literature
In this Dutch multicentre study, ovarian cancer patients with a routinely detected 
asymptomatic recurrence tended to live longer than patients with symptomatic 
recurrences, which is concordant with the findings of Tanner.11 However, Rustin9 and 
Gadducci10 did not find a differential survival of routine follow-up in ovarian cancer 
patients. To determine whether our results are attributable to routine follow-up or to 
bias, we will discuss some potential violations of a valid comparison between patients 
with asymptomatically and symptomatically detected recurrences.
The starting date of overall survival may be subject to discussion. We have chosen last 
date of primary treatment as starting point of the survival analyses, since response 
to treatment, and thus meeting the inclusion criteria, is evaluated at this date. A 
disadvantage of this date is the shorter survival in patients receiving chemotherapy 
in relation to those receiving surgery as primary treatment. However, the median 
treatment period was five months for patients in whom the recurrence was detected 
symptomatically and those detected asymptomatically (data not shown). Date of 
diagnosis or date of surgery are alternatives for the start of the survival time.11 The 
disadvantage of those time points is the extension of the survival time in patients who 
received chemotherapy as primary treatment. Patients who relapse or die during the 
treatment period are excluded from the analysis because they were not in complete 
clinical remission after treatment. Since neither last date of primary treatment nor 
date of surgery act upon the mode of recurrence detection, lead time bias is not an 
issue in this study.
The next violation is confounding bias, which is presumably present in this study 
since patients with asymptomatically detected recurrences seem to have a more 
favourable primary tumour biology compared with symptomatic patients. In addition, 
recurrence treatment differed between interval and routinely detected recurrences. 
The size of the mode of detection groups did not allow for a valid adjustment for the 
potential confounding factors. However, we believe length-time biased sampling is a 
stronger distorting factor. Length-time bias depicts the concept that slow-growing 
recurrences have a longer asymptomatic phase and are thus more likely to be detected 
asymptomatically. Patients with slow-growing recurrences probably have a better 
prognosis than fast-growing tumour recurrences. This concept is applicable as the 
median time to recurrence was 14 months in asymptomatically detected recurrences, 
which was not earlier than the 10 and 11 months as observed in patients detected 
symptomatically (Figure 4.3B). This was also observed by Tanner,11 which may explain 
the better survival in patients detected asymptomatically, even after adjustment for 
confounding factors.
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In addition, misclassification bias may have occurred. Retrospective classification of 
relapsed patients into the (a)symptomatic phase is not straightforward. Patients with 
their recurrence detected at an interval visit are very likely to be symptomatic. Yet 
recurrences detected at a routine visit include asymptomatic as well as symptomatic 
patients. Patients were classified as asymptomatic when no indication of specific 
symptoms was present in the medical file or letters. Documentation of symptoms 
suggestive for recurrent ovarian cancer led to the categorization of symptomatically 
detected recurrence. In the latter situation patients may have been unaware of 
symptoms before the planned visit, but become conscious of them due to the patient 
history taking. These patients have incorrectly been categorized as symptomatically 
detected recurrences, since they were in fact detected early because of routine 
follow-up. These patients may have experienced benefit of routine follow-up which 
cannot be examined, because these patients cannot be differentiated from the actual 
symptomatic patients. Moreover, routine follow-up may have led to delayed diagnosis 
and consequently delayed treatment in these actual symptomatic patients with their 
recurrence detected at a routine visit. Symptomatic patients may have postponed 
seeking help until the next scheduled visit, which could have led to overestimation of 
the observed survival effect.
Recommendations
Current available evidence, including this study, does not provide support for a 
survival benefit due to routine follow-up.9-11 Therefore, future trials regarding the 
effectiveness of routine follow-up should include outcome measures for efficacy 
concerning the other aims of routine follow-up, i.e. treatment of late effects of 
primary treatment and provision of attention to psychosocial problems. The latter is 
of particular importance since 90% of gynaecological cancer patients clinically free of 
disease have a need for supportive care.14 Since not providing routine follow-up is 
considered unethical, the clinical relevance of routine follow-up should be studied by 
comparing alternative follow-up scenarios, e.g. the trial on CA125,9 intensive versus 
current routine follow-up schedule,15 family physician versus medical specialist,16 or 
nurse led follow-up.17
We showed that the current routine follow-up schedule of ovarian cancer patients 
detected two out of three recurrences at a routine follow-up visit. Routinely detected 
asymptomatic recurrences tended to have a better prognosis compared with routine 
or interval detected symptomatic recurrences. However, this difference is likely to 
be explained by misclassification bias, confounding bias, and length-time biased 
sampling. In conclusion, this study corroborates with previous findings of no survival 
benefit of routine follow-up in ovarian cancer patients.
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ABSTRACT
Introduction
The clinical benefit of routine follow-up in patients treated for ovarian cancer is 
subject to debate. In this study, the magnitude of the potential survival benefit of 
routine examinations was evaluated by Markov modelling.
Methods 
The clinical course of ovarian cancer was simulated using a four-state non-stationary 
Markov model. Risk of recurrence and mortality probabilities were derived from 
individual patient data and Statistics Netherlands. The life expectancy was simulated 
for three follow-up scenarios: a current, withholding (all recurrences detected 
symptomatically), and perfect follow-up programme (all recurrences detected 
asymptomatically). The impact of effective recurrence treatment in the future was 
modelled by varying the mortality ratio between patients with asymptomatically 
versus symptomatically detected recurrences. The model was validated using 
empirical data.
Results
The mean life expectancy of patients, aged 58 years and in complete clinical remission 
after primary treatment, was 10.8 years. Varying the transition probabilities with 
±25% changed the life expectancy by up to 1.1 years. The modelled life expectancy for 
the withholding and perfect follow-up scenarios was also 10.8 years and insensitive 
to model assumptions. In patients with stage IIB-IV, the life expectancy was 7.0 
years, irrespective of follow-up strategy. A mortality ratio of 0.8 for patients with 
asymptomatically versus symptomatically detected recurrences resulted in a gain in 
life expectancy of 5 months for withholding versus perfect follow-up.
Conclusions 
Routine follow-up in ovarian cancer patients is not expected to improve the life 
expectancy. The timing of detection of recurrent ovarian cancer is immaterial until 
markedly improved treatment options become available.
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INTRODUCTION
Routine follow-up after treatment for cancer is standard medical practice. In the 
Netherlands, follow-up in patients treated for ovarian cancer consists of visits every 
3 months the first two years, every 4 months during the third year, and every 6 
months in year four and five after primary treatment.1 Each visit should include patient 
history taking and physical examination, and until recently CA125 measurement was 
advised.
One important objective of the follow-up programme is the early detection and 
treatment of recurrent cancer aiming to improve life expectancy.2 However, the 
effectiveness of routine follow-up is subject to debate, mainly due to the lack of 
supporting evidence.3-5 Recently, a randomized controlled trial (RCT) showed no 
survival benefit of early initiation of recurrence treatment based on CA125 elevation 
as compared with treatment at time of clinical evidence of recurrence.4 Markov 
simulation models can be applied to simulate the life expectancy of a cohort of cancer 
patients.6,7 The advantage of Markov modelling is that the effectiveness of different 
follow-up schedules can be simulated without performing RCTs. RCTs may be time 
and resource consuming because the effects are expected to be small and may face 
ethical constraints, for example in case of no active follow-up.
In the present study we develop a Markov model for ovarian cancer follow-up with 
the aim to evaluate alternative follow-up scenarios. The course of ovarian cancer 
under current follow-up can be modelled using available individual patient data.6 The 
impact of withholding routine examinations can be simulated as a situation in which 
all relapses are detected based on clinical symptoms. In addition, the maximum gain 
in life expectancy through routine follow-up, where all recurrences are detected in 
its asymptomatic phase, can be simulated as well.
In summary, the purpose of this study was to simulate the life expectancy in ovarian 
cancer patients treated with curative intent in case of the current follow-up scheme, 
and compare this with withholding follow-up and with a perfect follow-up programme 
by means of a Markov simulation study.
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PATIENTS AND METHODS
Study population
The study population was described in detail previously.8 Briefly, 579 consecutive 
patients diagnosed with epithelial ovarian, primary peritoneal, or fallopian tube 
cancer in 4 hospitals in East Netherlands between 1996 and 2006 were included. Of 
those we studied a representative 25% sample retrospectively in 2009 (n=137), as 
well as all relapsed patients (n=205). We selected only patients in complete clinical 
remission after primary treatment, resulting in 68 patients eligible to determine 
recurrence risk and 114 relapsed patients to calculate mortality rates. The patient 
characteristics are shown in Table 5.1. Patients had a median age of 58 at diagnosis 
and 35% were diagnosed in an early stage. Five-year risk of recurrence was 55% and 
5-year overall survival was 59%.
Table 5.1. Patient characteristics at primary diagnosis for ovarian cancer in complete 
clinical remission after primary treatment
Representative
sample8,
n=68
Relapsed
patients8,
n=114
Validation
set13,
n=316
Age at diagnosis, median (range) years 58 (38-83) 61 (23-85) 59 (24-85)
FIGO stage, n (%)
Early (I-IIA)
Advanced (IIB-IV)
Unknown
24
42
2
(35)
(62)
(3)
15
98
1
(13)
(86)
(1)
123
191
2
(39)
(60)
(1)
Histological type, n (%)
Serous
Mucinous
Endometrioid
Other
Adenocarcinoma NOS
Unknown
27
7
15
8
11
(40)
(10)
(22)
(12)
(16)
56
4
25
10
19
(49)
(3)
(22)
(9)
(17)
126
34
60
36
59
1
(40)
(11)
(19)
(11)
(19)
(0)
Tumour grade, n (%)
Grade 1
Grade 2
Grade 3
Unknown
9
18
28
13
(13)
(27)
(41)
(19)
12
25
57
20
(10)
(22)
(50)
(18)
51
78
146
41
(16)
(25)
(46)
(13)
Primary treatment, n (%)
Surgery only
Chemotherapy only
Surgery and chemotherapy
11
1
56
(16)
(2)
(82)
7
3
104
(6)
(3)
(91)
73
6
237
(23)
(2)
(75)
Five-year risk of recurrence†, % 55
Five-year survival rate†, % 59 31 56
NOS, not otherwise specified.
† calculated by Kaplan Meier survival analysis, since last date of primary treatment.
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λ= transition probability, µ= background mortality probability
Figure 5.1. Four-state Markov chain model for ovarian cancer patients in complete clinical 
remission after primary treatment.
Markov model
The clinical course of patients in complete clinical remission after treatment was 
modelled using a non-stationary Markov model.9 The model used consists of 
three disease states: complete clinical remission, asymptomatic recurrence, and 
symptomatic recurrence, and one absorbing state: death from all causes (Figure 5.1). 
The cycle length was defined as 3 months, corresponding to the time interval between 
follow-up visits in the first two years of follow-up. The Markov cohort analysis was 
terminated after 40 years of follow-up.
Key assumptions of the Markov model included were: 1) background mortality, µ 
(Figure 5.1), was comparable to the general population; 2) treatment of recurrent 
ovarian cancer aimed at palliation and extending life expectancy rather than cure10; 
and 3) patients with recurrence die of the disease,4 as a result, background mortality, 
µ (Figure 5.1), was significantly small and not modelled in relapsed patients.
Risk of asymptomatically detected recurrences (λ1, Figure 5.1) and risk of 
symptomatically detected recurrences (λ2, Figure 5.1) were based on 68 ovarian 
cancer patients. Cumulative risk of recurrence was non-stationary and followed a 
power function beyond one year of follow-up (Table 5.2), defined as the best and 
most plausible curve fit in SPSS. Therefore, the cumulative risk of recurrence included 
in the model comprised the actual individual patient recurrence data for follow-
up year 1 and estimates derived from the power function for the following years. 
Recurrence-free survival was defined per 3 months, up to 10 years of follow-up.
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The survival in relapsed patients was calculated based on the Kaplan Meier 
survival curve including 114 patients with recurrent ovarian cancer, stratified for 
asymptomatically (λ3, Figure 5.1) and symptomatically detected recurrences (λ4, 
Figure 5.1). Mortality rates beyond 5 years were derived from an exponential function 
(Table 5.2),11 with coefficients derived from the best curve fit method in SPSS.
The background mortality (µ, Figure 5.1) was derived from life tables published by 
Statistics Netherlands for the year 2009.12
Markov cohort simulation
The course of ovarian cancer under the current follow-up regimen was compared 
with two alternative follow-up scenarios by studying the gain in life expectancy. The 
withholding follow-up scenario, where all recurrences were detected symptomatically, 
was simulated by delaying the diagnosis of initially asymptomatically detected 
recurrences with 3 months, corresponding to the median lead time between CA125 
elevation and the clinical detection of recurrent ovarian cancer.5 The mortality rate 
was assumed to be similar to the initially symptomatically detected recurrences 
(λ4, Figure 5.1). In the perfect follow-up scenario, all symptomatically detected 
recurrences were diagnosed 3 months earlier in the asymptomatic phase with the 
corresponding mortality rate (λ3, Figure 5.1).
Simulations were performed using the characteristics of a cohort of ovarian cancer 
patients aged 58 years, which was the median age of the included patient cohort 
(Table 5.1), using the modelling programme TreeAge Pro 2009 Suite (release 1.0.2). 
In addition, we calculated risk of recurrence and mortality probabilities stratified for 
early (FIGO stage I-IIA ) versus advanced (FIGO stage IIB-IV) ovarian cancer in the 
same way.
Sensitivity analyses
For the current follow-up scenario, a deterministic one-way sensitivity analysis was 
performed to examine the impact of model uncertainty on the life expectancy estimate 
by varying the transition probabilities with 25%, corresponding with a plausible range 
of alternative values.6
In addition, the impact of the assumptions made to model the effect of the withholding 
and perfect follow-up scenarios on life expectancy was studied (Table 5.3). Estimates 
of lead time and mortality rates may have been subject to length-time biased 
sampling: slow-growing recurrences are expected to have a longer asymptomatic 
phase and are consequently more likely to be detected in the asymptomatic phase.8 
As a result, initially asymptomatically detected recurrences may have a longer lead 
time period. Therefore, lead time was varied with 3 months. In addition, patients 
in whom the recurrence was detected asymptomatically appeared to have a better 
prognosis based on primary tumour characteristics.8 Therefore, mortality rates were 
varied with 10%.
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Improved treatment options may alter the effectiveness of routine follow-up. 
Alterations in effectiveness were modelled by varying the hazard ratio between the 
mortality rate in patients with their recurrence detected asymptomatically versus 
symptomatically. The corresponding potential survival benefit of routine follow-
up was simulated for the withholding, current, and perfect follow-up scenarios 
by means of altering the mortality rate in patients with their recurrence detected 
asymptomatically.
Validation
The representative sample and relapsed patients included in this simulation study 
were derived from 4 hospitals initially included in a large inception cohort: 1135 
patients diagnosed with ovarian cancer in 11 hospitals in East Netherlands.13 
A validation set was defined as ovarian cancer patients diagnosed in the other 7 
hospitals, consisting of 316 patients in complete clinical remission after primary 
treatment. For these patients mortality data were available, but mode of recurrence 
detection was not registered.
The accuracy of the model results were examined by comparing the 10-year Kaplan-
Meier survival curve derived from the Markov model with those derived from patients 
included in the representative sample (n=68) and validation set (n=316).
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RESULTS
The statistical model parameters with their corresponding survival function are 
presented in Table 5.2. Risk of recurrence estimations were based on 35 out of 37 
relapsed patients and decreased over time. Change in mortality probabilities were 
constant.
Under the current follow-up regimen, the mean life expectancy in ovarian cancer 
patients in complete clinical remission after primary treatment was 10.8 years, 
5-year survival was 57%. There was no difference between the withholding follow-
up, the current follow-up, and the perfect follow-up scenarios as the modelled life 
expectancy estimate was 10.8 years for all three scenarios.
Sensitivity analyses
One-way sensitivity analyses revealed that uncertainty in the risk of recurrence 
detection has the strongest impact on the life expectancy estimates (Table 5.2). 
Varying risk of recurrence with 25% changed the life expectancy estimate with 10%, 
that is from 9.8 to 11.9 years. Changing the mortality probability with 25% resulted 
in a modelled life expectancy ranging between 10.6 and 11.2 years.
Sensitivity analyses on assumptions made to model withholding and perfect follow-
up led to changes in the life expectancy between 0.1 and 0.3 years (Table 5.3).
Varying the mortality rate in patients with asymptomatically detected recurrences 
revealed that a hazard ratio of 0.8 is expected to result in a gain in life expectancy of 
5 months for withholding compared with perfect follow-up (Table 5.4). This survival 
gain increases with a decreasing hazard ratio.
Table 5.4. Sensitivity analyses: altering the hazard ratio between mortality rate in 
asymptomatically and symptomatically detected recurrence by varying mortality rates in 
relapsed ovarian cancer patients detected asymptomatically
Mortality probability in relapsed patients Results follow-up scenarios
Transition probability Hazard ratio† Life expectancy (years)
Symptomatic Asymptomatic Withholding Current Perfect
0.096 0.096 1.0 10.8 10.7 10.7
λ3=0.096 λ4=0.089 Best estimate‡ 10.8 10.8 10.80.096 0.086 0.9 10.8 10.8 10.9
0.096 0.077 0.8 10.8 11.0 11.2
0.096 0.068 0.7 10.8 11.2 11.5
0.096 0.058 0.6 10.8 11.4 12.0
0.096 0.049 0.5 10.8 11.7 12.6
0.096 0.039 0.4 10.8 12.2 13.6
0.096 0.030 0.3 10.8 13.0 15.1
0.096 0.020 0.2 10.8 14.4 17.8
† Hazard ratio, mortality rate asymptomatic recurrence divided by mortality rate symptomatic 
recurrence; rate = - Ln (1 – probability).
‡ Based on individual patient data.
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Validation
Patients included in the representative sample had similar characteristics as the 316 
patients from the validation set (Table 5.1), still, patients included in the validation 
set tended to have more early stage tumours and less chemotherapy at primary 
treatment, but had a poorer survival rate. The empirical data showed a similar 10-
year survival pattern as compared with the Markov simulation study (Figure 5.2). 
Notably, the Markov model tends to overestimate the survival probability during the 
first 3 years of follow-up.
Figure 5.2. Overall survival in ovarian cancer patients in complete clinical remission after 
primary treatment. Individual patient data: representative sample (—, black, n=68) and 
the validation set (---, n=316) versus modelling results (—, grey).
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Early and advanced stage
From the representative sample, 24 patients, with a median age of 58 years, were 
diagnosed with early stage ovarian cancer (Table 5.1). Six patients relapsed, making 
a 3-year risk of recurrence of 25% (95%CI: 8%-43%). Of the 114 relapsed patients, 15 
were initially diagnosed in an early stage (Table 5.1). Eight recurrences were detected 
asymptomatically and 7 symptomatically. Unfortunately, these numbers were too 
small to determine the transition probabilities.
Forty-two patients, median age 60 years, were diagnosed in an advanced stage 
(Table 5.1). Thirty-one patients relapsed, yielding a 3-year risk of recurrence of 69% 
(95%CI: 55%-83%). Among all 114 relapsed patients, 98 had advanced-stage ovarian 
cancer at primary diagnosis (Table 5.1) of which 44 were detected asymptomatically 
and 52 symptomatically. Mode of recurrence detection was unknown for 2 patients. 
The mean life expectancy of these patients was 7.0 years and 5-year survival 42%, 
irrespective of follow-up scenario. The 10-year survival rate derived from the Markov 
cohort simulation was similar for the representative sample (n=42) and the validation 
set (n=191) (data not shown).
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DISCUSSION
This simulation study showed that patients aged 58 years at diagnosis and in 
complete clinical remission after primary treatment for ovarian cancer have a mean 
life expectancy of 10.8 years. Life expectancy in case of withholding follow-up, i.e. 
all recurrences detected symptomatically, and a perfect follow-up scenario, i.e. all 
recurrences detected asymptomatically, was also 10.8 years. New treatment options 
may alter the effectiveness of routine follow-up if the response to treatment is 
significantly better in patients with their recurrence detected asymptomatically as 
compared with patients with their recurrence detected symptomatically.
A strong point of this study is the use of individual patient data. The use of 
mathematical functions to estimate the transition rates and the small patient numbers 
may be limitations. The mortality probability in relapsed patients was assumed to 
be proportional, whereas it is expected to decrease with an increasing length of 
relapse-free survival. The impact of the use of mathematical functions to estimate 
survival duration is, however, expected to be small, as the 10-year survival curve 
derived from the Markov model simulation was similar to the Kaplan-Meier survival 
curve derived from the representative patient sample, which indicates a good internal 
validity of the model.
In addition, the 10-year survival curve derived from the validation set showed a good 
agreement with the simulation results, especially during follow-up years 4 to 10. One 
can argue whether this comparison represents an external validation, because the 
patients included in the validation set were derived from the same patient population 
as the patients included in this simulation study. Gadduci et al14 performed an Italian 
multicentre observational study which was similar to our study.8 The mortality rate in 
relapsed ovarian cancer patients was quite similar in both studies: 0.082 as reported 
by Gadduci et al14 versus 0.089 and 0.096 in our study. In addition, Gadduci et al14 
observed no difference in survival time in patients detected asymptomatically and 
symptomatically as well. These observations suggest a good external validity of the 
model.
The life expectancy of 10.8 years, however, should be interpreted with caution. We 
have simulated the course of disease in patients aged 58 years. Younger patients 
will have, as a consequence, a longer, and older patients a shorter life expectancy. 
In addition, we assumed all cause mortality to be equal to the mortality of the 
general population. Nevertheless, ovarian cancer patients may have a shorter life 
expectancy due to the intensive primary treatment. Furthermore, we included all 
patients in complete clinical remission after primary treatment, because the follow-
up programme is the same for all patients, irrespective of cancer stage. Risk of 
recurrence was, however, lower in patients diagnosed with early stage ovarian cancer 
than in patients diagnosed with advanced stage cancer, which was also observed in a 
large population-based study.15 Repetition of the Markov cohort simulation showed 
that patients treated for advanced stage ovarian cancer had a mean life expectancy 
of 7.0 years, irrespective of follow-up scenario. The effectiveness of routine follow-
up in early stage cancer patients could not be studied due to the small number of 
patients diagnosed with early stage ovarian cancer and needs further investigation.
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Current symptomatically detected recurrences may be timely detected due to the 
regular appointments with the medical specialist. In practice, withholding follow-up, 
that is abolishing regular contact with the medical specialist, may lead to a larger 
delay in recurrence diagnosis as patients may not seek help if they have complaints. 
The potential gain in life expectancy by regular follow-up visits may, therefore, be 
underestimated.
In addition, length-time biased sampling may have distorted the life expectancy 
estimates in case of withholding and perfect follow-up.8 The impact of this potential 
bias was simulated by altering the lead time and mortality rates, see Table 5.3, which 
did not change the modelled life expectancy significantly.
Our findings were consistent with previous observational studies.5 Tanner et al16 
formed an exception and showed an improved survival duration in patients with their 
recurrence detected in the asymptomatic phase as compared with patients with a 
symptomatic recurrence (HR=0.4). This difference is, however, likely to be explained 
by length-time biased sampling, induced by a difference in relapse characteristics. 
Our model findings were also in line with the simulation study performed by Hopkins 
et al.17 Hopkins observed no improved life expectancy of the current follow-up 
programme as compared with a less intensive follow-up scenario, in which routine 
CA125 testing was excluded. This observation suggested no survival benefit of routine 
CA125 monitoring as part of routine follow-up practice and was later reinforced by 
the results from the RCT by Rustin et al.4 This example of a simulation study by 
Hopkins and a RCT by Rustin shows that Markov simulation studies can give valid 
results when evaluating the effectiveness of routine follow-up examinations.
One explanation for observing no survival gain through routine examinations can be 
the absence of a curative-intent treatment for recurrent ovarian cancer.10,18 Notably, 
most patients with ovarian cancer have already received chemotherapy at initial 
diagnosis. This implies that once there is a relapse, tumour cells have shown to 
be resistant for the most effective systemic treatment that is available. Further, the 
number of systemic treatment lines for ovarian cancer is quite limited in contrast to 
the armamentarium that is available in for instance breast cancer patients.
The effectiveness of routine follow-up is, beside treatment efficacy, associated with 
the advancement in diagnosis of a recurrence through routine testing. In ovarian 
cancer, the median lead time between elevated CA125 levels and clinical evidence 
of recurrence was three to five months.4,5 Given current treatment options, this lead 
time was too short to induce a survival benefit through early initiation of recurrence 
treatment.4
We have shown that routine follow-up is not expected to influence the life expectancy, 
irrespective of follow-up strategy. Therefore, the focus of follow-up should shift to 
the other aims of routine follow-up: providing psychosocial care and monitoring 
the effects of primary treatment.19-21 In addition, an intensive follow-up schedule is 
associated with high surveillance costs17,22 and early initiation of recurrence treatment 
with decreased quality of life.4 We therefore recommend to consider studying 
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alternative, potentially more cost-effective alternative follow-up programmes, like 
for example nurse-led telephone follow-up20,23 or patient-initiated follow-up.24
According to the official European Society of Gynaecologic Oncology statement,25,26 
routine CA125 monitoring should not be abandoned in all patients. CA125 
monitoring may, for example, be part of a clinical trial. Further, it is unknown what 
the impact is of timing of recurrence treatment in patients with early stage ovarian 
cancer at diagnosis and no chemotherapy at primary treatment. In addition, if second 
cytoreductive surgery is found to be effective, timing of surgery may be important. 
The decision on whether to monitor CA125 values may depend on patient preferences 
and should include weighing of the potential harms of routine CA125 monitoring and 
the uncertainties in potential benefit. It is, therefore, essential to facilitate informed 
decision making in patients regarding routine CA125 testing.
Defining the optimal follow-up policy is a ceaseless process guided by new evidence. In 
future, treatment of recurrent ovarian cancer may improve, new diagnostic techniques 
may become available to detect recurrences earlier, or subgroups of patients with 
curable recurrence may become evident.26 The impact of improved recurrence 
treatment options was simulated in this modelling study. Given the current relapse 
rate, a hazard ratio between the mortality rate in patients with asymptomatically 
versus symptomatically detected recurrences of 0.8 or smaller, is expected to be 
associated with a survival gain through routine follow-up. However, a hazard ratio 
of 0.8 is exceptionally low and unrealistic as improvements in recurrence treatment 
are expected to change the mortality rate in both patients with asymptomatically and 
symptomatically detected recurrences. In addition, improved recurrence treatment 
options are anticipated to effect primary treatment as well, and thus risk of recurrence 
and survival duration. Our Markov model can be used to explore the impact of new 
findings on the effectiveness of routine examinations when empirical data become 
available.
In conclusion, routine follow-up examinations are not expected to influence the 
life expectancy of ovarian cancer patients as recurrences are mainly detected in an 
advanced, palliative phase. Future studies should focus on ovarian cancer treatment 
and exploring cost-effective alternative follow-up scenarios.
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ABSTRACT
Introduction
The purpose of this study was to evaluate local and systemic breast cancer control 
by comparing the risk of relapse in breast cancer patients in 2003-2004 with the 
nineteen-seventies and eighties.
Methods
8570 Women diagnosed with invasive breast cancer in 2003-2004 were selected 
from the population-based Netherlands Cancer Registry and compared with 133 
patients treated in 1972-1979 and 174 in 1980-1986. Five-year risk of relapse was 
calculated by the Kaplan-Meier method. Cox-proportional hazards models were 
applied to adjust for tumour size, nodal status and age at diagnosis.
Results 
Patients diagnosed in 2003-2004 had smaller tumours and less advanced nodal stage 
than patients diagnosed in 1972-1986. In 1972-1979, 1980-1986 and 2003-2004, 
treatment included mastectomy in 94%, 72% and 47%; post-mastectomy radiotherapy 
in 75%, 70% and 30%; chemotherapy in 9%, 14% and 37%; and hormonal therapy in 
3%, 3% and 42% of patients, respectively. Five-year risk of locoregional and distant 
recurrence decreased from 37% and 34% to 15%, respectively. The five-year risk of 
second primary breast cancer did not differ and was 1%, 4% and 2%, respectively. The 
improved relapse-free survival in patients diagnosed in 2003-2004 as compared 
with 1972-1979 hardly changed after adjustment (HR=0.38, 95% CI:0.28-0.52).
Conclusions 
Over the last decades, local breast cancer therapies became less rigorous, whereas 
systemic therapy use has increased. Simultaneously, the risk of breast cancer relapse 
has tremendously decreased. New therapies may lead to such small decreases in 
recurrence rates, that the long term side effects in breast cancer survivors become 
more important.
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INTRODUCTION
The breast cancer relapse rate is the key outcome when evaluating local and systemic 
disease control achieved by primary breast cancer management. Changing relapse 
rates may have implications for patient management and post-treatment follow-up. 
In contrast to breast cancer mortality, population-based studies on the time trend 
in relapse-free survival are rare, and generally focus on locoregional recurrence,1,2 
second primary breast cancer3,4 or distant metastasis5,6 separately, instead of studying 
overall time trends on relapse-free survival. Relapse rate estimates derived from 
randomized controlled trials (RCT) may differ from daily practice, as trials are usually 
carried out in specialized clinics. Patients and physicians participating in a trial are 
likely to be more motivated and patient care is expected to be of higher quality.7,8 For 
that reason, population-based outcome research is of pivotal importance to assess 
the real impact of innovations after translation in daily practice.
The purpose of this population-based cohort study is to determine the risk of relapse 
in breast cancer patients treated with curative intent diagnosed in 2003-2004 and 
in 1972-1986.
PATIENTS AND METHODS
Two cohorts of female breast cancer patients operated for invasive non-metastatic 
breast cancer were available. The oldest cohort comprised 307 patients consecutively 
diagnosed from 1972 to 1986 in the St Anna hospital in Oss, the Netherlands. 
Occurrences of relapse and death were registered in 1993. A recent population-
based cohort was selected from the Netherlands Cancer Registry and comprised 
8570 patients diagnosed in 2003 or 2004 in 53 hospitals in the Netherlands. The 
Netherlands Cancer Registry has been complete since 1984, but does not routinely 
register cancer recurrences.9 Based on pathological notification through an automated 
pathology archive, trained registration clerks gathered data from the patients’ files. 
For the incidence years 2003 and 2004, information about relapse and death was 
retrieved until December 31, 2009, corresponding with at least five years of follow-
up since diagnosis. Only first occurrence of either locoregional recurrence or distant 
metastasis was registered.
Patients diagnosed in 1972-1986 were staged according to the TNM classification of 
1977.10 In 2003-2004 the TNM classification of 2002 was used.11 Staging of tumour 
size (T) was similar for both periods, but categorization of patients by lymph node 
status (N) differed between 1977 and 2002 (Table 6.1). Nodal status was, therefore, 
categorized as N0 versus N1-3. Patients with unknown pathological TNM stage were 
classified according to their clinical TNM stage.
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Of patients who had a second primary breast cancer diagnosed within three months 
of the first breast cancer, the tumour with the highest Nottingham Prognostic Index12 
was included for further analyses.
Breast cancer relapse was defined as a local or regional recurrence, distant metastasis 
or second primary breast cancer.13 Relapses diagnosed within three months were 
considered to be diagnosed simultaneously.
Data analyses
To examine the time trend in patient, tumour and treatment characteristics and 
breast cancer relapse rates, the historical cohort was divided in two groups. Analyses 
were consequently reported for three periods: 1972-1979, 1980-1986 and 2003-
2004. The utilization of radiotherapy was stratified by type of surgery.
Table 6.1. TNM in 1977 and in 2002: pathological classification of breast cancer
1977 2002
Tumour size
pT1 ≤ 2 cm ≤ 2 cm
pT2 2.01 - 5 cm 2.01 - 5 cm
pT3 > 5 cm > 5 cm
pT4 Tumour of any size with direct exten-
sion to chest wall or skin
Tumour of any size with direct exten-
sion to chest wall or skin
Nodal stage
pN0 No metastatic ipsilateral axillary 
nodes
No regional lymph node metastasis
pN1 Movable ipsilateral axillary  
metastatic nodes not fixed to one 
another or other structures
Metastasis in 1-3 ipsilateral axillary 
lymph node(s), and/or in ipsilateral 
internal mammary nodes with  
microscopic metastasis detected by 
sentinel lymph node dissection but not 
clinically apparent
pN2 Ipsilateral axillary nodes containing 
metastatic tumour and fixed to one 
another or to other structures
Metastasis in 4-9 ipsilateral axillary 
lymph nodes or in clinically apparent 
ipsilateral internal mammary lymph 
node(s) in the absence of axillary 
lymph node metastasis
pN3 Ipsilateral supraclavicular or infracla-
vicular nodes containing tumour or 
oedema of the arm
Metastasis in 10 or more ipsilateral 
axillary lumph nodes; or in clinically 
apparent ipsilateral internal  
mammary lymph nodes in the pres-
ence of one or more positive axillary 
lymph nodes; or in more than 3 axil-
lary lymph nodes with clinically nega-
tive, microscopic metastasis in internal 
mammary lymph nodes; or in ipsilat-
eral supraclavicular lymph nodes
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Five-year relative survival14 and five-year risk of relapse were calculated using the 
Kaplan-Meier method. Relapse was defined as a second primary breast cancer, 
locoregional recurrence or distant metastasis. Date of surgery was defined as the 
starting point of follow-up. When locoregional recurrence was considered as event 
of interest, patients’ follow-up was censored at date of last follow-up, distant 
metastasis or death. For risk of distant metastasis patients were censored at last 
follow-up date, occurrence of a local or regional recurrence or death. We therefore 
also calculated risk of locoregional recurrence or distant metastasis. Patients with 
second primary breast cancer were censored at time of last follow-up or death. 
Patients with synchronous bilateral breast cancer at primary diagnosis were excluded 
from the risk of second primary breast cancer analyses.
The hazard ratio of five-year risk of relapse in 1980-1986 and 2003-2004 versus 
1972-1979 was adjusted for age at diagnosis, tumour size, nodal status and tumour 
histology using Cox-proportional hazards modelling.
Table 6.2. Patient and tumour characteristics of non-metastatic breast cancer patients by 
period of diagnosis, n (%)
Year of diagnosis
Characteristics
1972-1979
n=133
1980-1986
n=174
2003-2004
n=8570
Age at diagnosis, 
  median (range) years
50 (27-76) 57 (29-82) 58 (20-96)
Age at diagnosis
< 50 years 61 (46) 53 (40) 2265 (26)
≥ 50 years 57 (43) 116 (67) 6305 (74)
Unknown 15 (11) 5 (3) -
Tumour size*
T1 57 (43) 72 (41) 4962 (58)
T2 45 (39) 72 (41) 3152 (37)
T3 12 (9) 14 (8) 317 (4)
T4 19 (14) 16 (9) 134 (2)
Unknown - - 5 (0)
Nodal status*
N0 78 (59) 105 (60) 5074 (59)
N1 31 (23) 43 (25) 2355 (27)
N2 4 (3) 7 (4) 740 (9)
N3 19 (14) 18 (10) 380 (4)
Unknown 1 (1) - 21 (0)
Histology
Ductal 73 (55) 142 (82) 6711 (78)
Lobular 30 (23) 19 (11) 984 (11)
Other 29 (22) 13 (7) 875 (10)
Unknown 1 (1) - -
Bilateral breast cancer
Yes 2 (2) 1 (1) 119 (1)
No 130 (98) 171 (98) 8451 (99)
Unknown 1 (1) 2 (1) -
* In case the pathological status was unknown the clinical status was taken.
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RESULTS
Patient and tumour characteristics
Patient and tumour characteristics by period of diagnosis are presented in Table 6.2. 
Over the last decades, tumour size decreased. The mean tumour size per tumour stage 
did not differ between the periods (data not shown). The use of breast conserving 
surgery has increased over time, from 2% in 1972-1979 and 26% in 1980-1986 to 
53% in 2003-2004 (Table 6.3). Radiotherapy after breast conserving surgery was 
standard practice irrespective of period of diagnosis. Radiotherapy after mastectomy 
decreased from 75% in 1972-1979 and 70% in 1980-1986 to 30% in 2003-2004. 
Women aged below 50 years more often received chemotherapy compared with 
women aged 50 years or over, but for both increasing over time: 15% versus 5% 
in 1972-1979, 36% versus 5% in 1980-1986 and 72% versus 24% in 2003-2004, 
respectively. A similar but smaller trend was observed for hormonal therapy: 7% 
versus 0% in 1972-1979, 2% versus 3% in 1980-1986 and 48% versus 39% in 2003-
2004, respectively. Pathological examination of lymph nodes was not performed for 
26% of patients with cN0 and 9% of patients with cN1-3 in the years 1972-1979, 
whereas these proportions were 5% and 7%, respectively, in 1980-1986, and 2% in 
total in 2003-2004.
Relative survival
Survival data were available for 132 patients (99%) diagnosed in 1972-1979, for 168 
patients (96%) diagnosed in 1980-1986 and for 8570 patients (100%) diagnosed in 
2003 or 2004. Follow-up for survival was at least five years for all but 3 patients 
diagnosed in 1972-1979 and 27 patients diagnosed in 1980-1986. Five-year 
relative survival increased from 75% (95% CI: 65%-83%) to 87% (95% CI: 79%-94%) 
and 93% (95% CI: 92%-93%) for the years 1972-1979, 1980-1986 and 2003-2004, 
respectively.
Relapse-free survival
Follow-up for occurrences of relapse was available for 113 patients (85%) diagnosed 
in 1972-1979, for 166 patients (95%) diagnosed in 1980-1986 and for 8417 patients 
(98%) diagnosed in 2003-2004. Four patients diagnosed in 1972-1979 died without 
signs of relapse within five years after diagnosis. Ten patients diagnosed between 
1980 and 1986 were lost to follow-up. In the 2003-2004 cohort, 749 patients were 
lost to follow-up for relapse within four years after diagnosis, of whom 254 died 
within 3 months after the last follow-up date. Five-year risk of relapse decreased 
from 38% (95% CI: 29%-48%) in 1972-1979 and 35% (95% CI: 28%-43%) in 1980-
1986 to 16% (95% CI: 15%-17%) in 2003-2004. The five-year risk of second primary 
breast cancer was similar for all periods: 1%, 4% and 2%, respectively (Figure 6.1). 
Five-year risk of locoregional recurrence or distant metastasis decreased over the 
three periods: from 37% to 34% to 15% (Figure 6.2). Considering the first site of 
relapse, five-year risk of locoregional recurrence was 24% (95% CI: 16%-33%), 14% 
(95% CI: 9%-19%) and 4% (95% CI: 3%-4%) for the years 1972-1979, 1980-1986 and 
2003-2004, respectively. For patients diagnosed in 2003-2004, five-year risk of 
locoregional recurrence after breast conserving surgery was 3% (95% CI: 3%-4%) and 
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5% (95% CI: 5%-6%) after mastectomy. The five-year risk of distant metastasis as first 
event was 27% (95% CI: 18%-35%), 28% (95% CI: 21%-35%) and 12% (95% CI: 11%-
13%), respectively.
Risk of relapse was lower in 2003-2004 compared with 1972-1979 (HR=0.35), also 
after adjustment for tumour size, nodal status and age at diagnosis (HR=0.38, Table 
6.4). Smaller tumour size and no lymph node involvement were associated with a 
lower relapse rate.
Table 6.3. Treatment characteristics of non-metastatic breast cancer patients by period 
of diagnosis, n (%)
Year of diagnosis
1972-1979
n=133
1980-1986
n=174
2003-2004
n=8570
Surgery
Breast conserving surgery (BCS) 2 (2) 45 (26) 4553 (53)
Mastectomy 125 (94) 125 (72) 4012 (47)
Unknown 6 (5) 4 (2) 5 (0)
Radiotherapy after BCS
Yes 1 (50) 43 (96) 4417 (97)
No 1 (50) 2 (4) 136 (3)
Radiotherapy after mastectomy
Yes 86 (75) 87 (70) 1197 (30)
No 29 (25) 38 (30) 2815 (70)
Chemotherapy
Yes 12 (9) 25 (14) 3181 (37)
No 111 (83) 149 (86) 5389 (63)
Unknown 10 (8) - -
Chemotherapy in patients aged 
< 50 years
Yes 9 (15) 34 (36) 137 (72)
No 48 (79) 19 (64) 628 (27)
Unknown 4 (7) - -
Chemotherapy in patients aged 
≥ 50 years
Yes 3 (5) 6 (5) 1544 (24)
No 51 (89) 110 (95) 4761 (76)
Unknown 3 (5) - -
Hormonal therapy
Yes 4 (3) 5 (3) 3571 (42)
No 120 (90) 169 (97) 4999 (58)
Unknown 9 (7) - -
Hormonal therapy in patients aged 
< 50 years
Yes 4 (7) 1 (2) 1098 (48)
No 54 (89) 52 (98) 1167 (52)
Unknown 3 (5) - -
Hormonal therapy in patients aged 
≥ 50 years
Yes 0 (0) 3 (3) 2473 (39)
No 54 (95) 113 (97) 3832 (61)
Unknown 3 (5) - -
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Figure 6.1. Risk of second primary breast cancer in non-metastatic breast cancer patients 
for the incidence years 1972-1979 (....), 1980-1986 (---) and 2003-2004 (—).
No. at risk
0 1 2 3 4 5 5-year risk (95% Cl)
1972-1979   111   108     99     92     85     80 0.01 (0.00-0.03)
1980-1986   166   163   150   141   129   121 0.04 (0.01-0.07)
2003-2004 8303 8142 7821 7480 7191 6883 0.02 (0.02-0.03)
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Table 6.4. Cox-proportional hazard models for risk of breast cancer 
relapse by period of diagnosis
Variables Hazard ratio (95% confidence interval)
Model 1
Period 1972-1979 Reference
1980-1986 0.92 (0.62-1.37)
2003-2004 0.35 (0.26-0.47)
Model 2
Period 1972-1979 Reference
1980-1986 0.85 (0.57-1.27)
2003-2004 0.38 (0.28-0.52)
Tumour size T1 Reference
T2 1.85 (1.65-2.08)
T3 2.80 (2.27-3.46)
T4 4.38 (3.17-6.06)
Nodal status N0 Reference
N1-N3 1.81 (1.62-2.03)
Age at diagnosis ≥ 50 years Reference
< 50 years 1.08 (0.96-1.21)
Figure 6.2. Risk of locoregional recurrence or distant metastasis in non-metastatic breast 
cancer patients for the incidence years 1972-1979 (....), 1980-1986 (---) and 2003-2004 
(—).
No. at risk
0 1 2 3 4 5 5-year risk (95% Cl)
1972-1979   113   100     82     78     71     68 0.37 (0.28 -0.47)
1980-1986   166   150   133   116   108   101 0.34 (0.27 -0.41) 
2003-2004 8417 8034 7548 7110 6659 4820 0.15 (0.14 -0.15)
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DISCUSSION
This study among 8877 Dutch breast cancer patients treated with curative intent 
showed a decrease in five-year risk of relapse from 38% in 1972-1979 and 35% 
in 1980-1986 to 16% in 2003-2004. This impressive improvement equals a risk 
reduction of 1% per year. The increasing use of systemic therapy in clinical practice 
has, to a large extent, contributed to the improved breast cancer outcome at a 
population level. Especially, since this improvement was largely independent of 
tumour size, nodal status and age. In contrast to systemic therapy, the strategy with 
respect to local treatment became less aggressive. Apparently, the less aggressive 
local approach could safely be implemented and possibly may have been facilitated 
by the availability and increased use of systemic therapy.
In the Netherlands, breast cancer screening was introduced in 1989. Previous studies 
showed that both an earlier diagnosis and the use of systemic treatment are effective 
in preventing breast cancer relapse.13,15,16 Discerning the impact of changed breast 
cancer therapy from that of an earlier diagnosis goes beyond the scope of this study. 
Nevertheless, we attempted to evaluate the effect of an earlier diagnosis by adjusting 
period-specific breast cancer relapse for age at diagnosis, tumour size and nodal 
status. Increasing tumour size and a positive lymph node status were associated with 
an increased risk of recurrence. Adjustment for these factors changed the period 
effect only slightly. Lymph node staging has, however, changed with the introduction 
of the sentinel node biopsy procedure in 1993.17 As accurate staging became 
increasingly important for treatment planning, pathological lymph node examination 
was intensified. This may explain the incomplete correction for lymph node status in 
the present study. The stage migration caused by intensified lymph node examination 
was, however, to some extent prevented to occur by the introduction of a new TNM 
classification in 2002.18 We decided not to adjust for treatment for several reasons. 
First, adjustment for stage includes part of the treatment effect. Furthermore, not 
only frequency of use changed, but the treatments themselves have changed over 
the years as well. In addition, we expect an interaction between therapy and tumour 
stage. Unfortunately, we were not able to consider other important prognostic factors, 
like the mitotic activity index,19,20 tumour grade, hormonal receptor status, HER2 
and resection margin. The differences in histology between the periods may reflect 
changes in pathological assessment and classification rather than true changes. The 
period effect (HR=0.38) after adjustment for tumour characteristics and patient’s age 
therefore includes the issues described above.
The five-year risk of locoregional recurrence as first event decreased from 24% 
in the 1970s to 14% in the 1980s and was only 4% in 2003-2004. This trend was 
also observed in previous Dutch studies.1,2 We can therefore conclude that current 
treatment, despite the increased use of breast conserving therapy, has resulted in 
a good local control. In the late 1980s, a positive resection margin was identified 
as an important risk factor for local recurrence. This had led to more careful breast 
imaging before surgery, routine pathological assessment of the resection margins 
and re-excision in case of a positive margin.21 In addition, adjuvant treatment13 
and a lower tumour stage16 were associated with a decreased risk of locoregional 
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recurrence. Breast cancer treatment is currently changing from maximal tolerable to 
optimally needed.22 We recognize the importance of preventing overtreatment, yet, it 
is important to monitor relapse rates closely to prevent underuse of (axillary) surgery 
or radiotherapy.23
The occurrence of distant metastases has markedly decreased between the 1980s 
and 2003-2004, which was also observed in Canada5 and Sweden.6 This decrease 
may be attributable to an earlier detection at initial diagnosis and the increased use 
of systemic therapy in primary breast cancer treatment. In addition, more and more 
effective chemotherapeutic options have become available.13 The risk of distant 
metastasis is expected to decrease further because other systemic treatment options 
become available, e.g. trastuzumab,24 and more patients are advised to be treated with 
systemic therapy. As prognosis improves, the impact of more and more aggressive 
systemic therapy on survival time will become smaller, whereas the attention for 
long term toxic side effects will increase. Implementation of new systemic treatment 
options should therefore be preceded by a careful consideration of these pro’s and 
con’s.
We observed no large difference in risk of second primary breast cancer between 
the 1970s, 1980s and 2000s, despite the increase in breast cancer incidence in the 
general population. In the United States, second primary breast cancer rate decreased 
since 1985.3,4 The increased risk may have been counterbalanced by the use of 
systemic therapy for the primary tumour.13,25 In addition, contralateral prophylactic 
mastectomy (CPM) in patients at high risk of developing a second breast cancer is 
increasingly performed. In the United States, the CPM rate increased from 0.4% in 
1998 to 4.7% in 2007.26 In the future, increased use of systemic therapy and CPM 
might further counterbalance the increasing population risk of breast cancer.27
The trends in breast cancer treatment observed in our study was also observed in 
previous Dutch studies28-31 and in other countries.5,32-37 Nowadays, treatment strategies 
are quite similar for different countries, although the use of breast conserving 
therapy (BCS) in China was only 30% in 1994-2007.38 Notably, radiotherapy following 
BCS is standard practice in the Netherlands,28-30 but underused in the United States39 
and in Korea40 even though numerous studies have shown a survival benefit from 
adjuvant radiotherapy after BCS.41 Radiotherapy after mastectomy has decreased in 
the Netherlands, which was in line with guideline recommendations.42 In contrast, 
the use of post-mastectomy radiotherapy was lower and increased over time in the 
United States43 and Korea.40 Of patients diagnosed in 2003-2004 in the Netherlands, 
37% received chemotherapy and 42% hormonal therapy. Similar rates were observed 
in Australia32 and Sweden.36
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This population- and hospital-based study reflects changes in breast cancer 
management in practice. We studied risk of relapse in total, and for the different 
sites separately, providing a complete overview of trends in relapse. A limitation 
of this study is that in patients diagnosed in 2003-2004, only first occurrence of 
locoregional recurrence or distant metastasis was registered. Site-specific risk 
estimates for locoregional recurrence and distant metastasis were, therefore, 
underestimated in this study. Another limitation of this study is the use of only one 
hospital as a historical control. Findings were, however, in line with previous Dutch 
studies,1,2,28-30 suggesting good representativeness of our data.
Screening for metastases at primary diagnosis was routine practice in patients 
diagnosed in 1972-1986. Of patients diagnosed in 2003-2004, 83% had stage T1-2 
and N0-1 and screening for metastases was not advised in these patients.42 This 
difference in practice may have resulted in a slight overestimation in the risk of 
distant metastases in patients diagnosed in 2003-2004, but is expected to be small 
because no immediate and increased recurrence rate after primary diagnosis was 
observed (Figure 6.2).
In conclusion, our population based study demonstrates a huge improvement in breast 
cancer outcome when comparing the patients diagnosed in the nineteen seventies 
with those diagnosed in the early twenties. Moreover, as since 2004 the number of 
patients selected for systemic therapy has further increased, it is likely that outcome 
for current patients is even better. On the one hand, this implies that there may still 
be room to reduce the extent of locoregional breast treatment. On the other hand, 
however, it may be time to reconsider the indications for systemic therapy. When 
the benefit of systemic therapy is only 1-2% for subgroups of patients, preventing 
long-term toxicities in cancer survivors may become equally or more important than 
preventing locoregional recurrences. This is, in our opinion, an important challenge 
for clinical practice and future clinical trials.
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ABSTRACT
Introduction 
Routine breast cancer follow-up aims at detecting second primary breast cancers and 
locoregional recurrences preclinically. We studied breast cancer follow-up practice 
and mode of relapse detection during the first five years of follow-up to determine 
the efficiency of the follow-up schedule.
Methods 
The Netherlands Cancer Registry provided data of 6509 women, operated for invasive 
non-metastatic breast cancer in 2003-2004. In a random sample including 144 
patients, adherence to follow-up guideline recommendations was studied. Mode of 
relapse detection was studied in 666 patients with a second primary breast cancer 
(SPBC), locoregional recurrence (LRR) or distant metastasis.
Results 
On average 13 visits were performed during the first five years of follow-up, whereas 
9 were recommended. With one, two and three medical disciplines involved, there 
were 9, 14 and 18 visits, respectively. Seventy-five percent (93/124) of patients 
with a SPBC, 42% (31/74) of patients with a LRR after breast conserving surgery, 
28% (24/86) of patients with a LRR after mastectomy and 7% (16/245) of patients 
with distant metastasis had no symptoms at detection. To detect 1 LRR or SPBC 
preclinically, 1349 physical examinations versus 262 mammography and/or MRI 
tests were performed.
Conclusions 
Follow-up provided by only one discipline may decrease the number of unnecessary 
follow-up visits. Breast imaging plays a major and physical examination a minor role 
in the early detection of SPBCs and LRRs.
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INTRODUCTION
Routine follow-up after curative-intent treatment for breast cancer is standard medical 
practice.1 Routine follow-up aims at providing psychosocial care and monitoring the 
side-effects of primary treatment. Another prominent objective is the early detection 
of a second primary breast cancer (SPBC) or local or regional recurrence (LRR) by 
means of routine physical examination and mammography. Early detection of a 
SPBC or LRR yields a survival benefit when compared with symptomatic relapses.2,3 
Detection of a distant metastasis in the preclinical phase is no primary aim of routine 
follow-up because early initiation of treatment does not prolong survival time.4
The yield of breast cancer follow-up can be estimated by the number of relapses 
detected asymptomatically and depends on the actual number of tests applied in 
practice. Recently, three studies reported more follow-up visits in clinical practice 
than recommended, whereas yearly breast imaging was underused.5-7 The degree of 
over- and underuse varied between the studies. The proportion of relapses detected 
in the asymptomatic phase differs between SPBCs and LRRs and varied over time.8,9 
Studies on whether physical examination or mammography gave the first sign of 
recurrence were limited by sample size or outdated.9,10
The aim of this study was to compare current daily follow-up practice with the guideline 
recommendations and to assess the mode of relapse detection in patients treated for 
invasive breast cancer with curative intent in 2003-2004 in the Netherlands.
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PATIENTS AND METHODS
All women consecutively diagnosed and operated for non-metastatic invasive breast 
cancer in 2003-2004 in four regions of the Netherlands Cancer Registry (NCR) were 
included (Figure 7.1). Patients with a prior history of an invasive cancer of any type, 
with the exception of basal cell carcinoma of the skin, were not eligible.
Patient, tumour and treatment characteristics and incidence of relapse within five 
years after diagnosis were available from the NCR. Detailed information regarding 
follow-up visits, tests and mode of detection were collected retrospectively from 
medical records between September 2010 and May 2011 by registry clerks from the 
NCR.
Patients with unknown pathological TNM staging were classified according to their 
clinical TNM stage. Synchronous bilateral breast cancer was defined as a contralateral 
breast cancer diagnosed within 3 months from the first breast cancer. Characteristics 
of the tumour with the highest Nottingham Prognostic Index were reported as 
the primary tumour.11 All secondary contralateral breast cancers diagnosed more 
than 3 months after the first breast cancer were defined as a SPBC, as were second 
primaries in the ipsilateral breast based on pathological findings. A local recurrence 
was defined as a relapse in the ipsilateral breast, scar, skin or chest wall. A regional 
recurrence was defined as a relapse in the supraclavicular, infraclavicular, internal 
mammary or axillary lymph nodes.12 A distant metastasis included all distant bone 
and visceral relapses, distant lymph nodes and extended skin recurrences. Relapse 
was defined as a SPBC, LRR or distant metastasis. If a new relapse was diagnosed 
within the treatment period of the previous one, both relapses were considered to be 
diagnosed simultaneously.
For efficiency reasons breast cancer follow up practice was studied in 144 breast 
cancer patients who were randomly selected from 15 hospitals (Figure 7.1). The 
hospitals were selected based on geographical location and include university, 
teaching and non-teaching hospitals. Consultations by a surgeon, medical oncologist, 
radiotherapist or oncology nurse were considered as follow-up visits. Patients were 
grouped according to the number of medical disciplines involved at least once during 
follow-up. A visit was registered as a follow-up visit if physical examination was 
performed, in accordance with a judgement on disease status. Visits related to wound 
control or the surveillance of other diseases and those provided by other disciplines 
were excluded. Visits at which only a test was performed, e.g. mammography, were 
not counted, but included in the consultation where the result of the exam was 
discussed with the patient.
Mode of relapse detection was identified in a cohort comprising 6509 patients 
diagnosed in 37 hospitals (Figure 7.1). Selected were 666 patients with a relapse 
diagnosed within 5 years after the primary diagnosis, including all 148 patients with 
SPBCs, all 260 patients with LRRs and 258 patients with distant metastases (44% 
randomly selected for efficiency reasons) as first relapse.
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Figure 7.1. Flow chart for breast cancer patients’ inclusion, selection, registration and 
analysis based on minimal five years of follow-up.
DM, distant metastasis; LRR, locoregional recurrence; SPBC, second primary breast cancer.
Patients diagnosed with non-metastatic invasive breast cancer in the Netherlands in 2003 or 2004
Netherlands Cancer Registry
8 regions, 96 hospitals
Regions and hospitals selected based on geographical location
INCEPTION COHORT, N=6509
Netherlands Cancer Registry
4 regions, 37 hospitals
Netherlands Cancer Registry
2 regions, 15 hospitals
RANDOM COHORT SAMPLE, N=144
127 patients without relapse
17 patients with relapse
Regions and hospitals selected based on geographical location105 patients excluded, 
follow-up unknown 
5351 patients excluded, 
no relapse 
387 patients (66%) with a 
DM excluded at random for 
efficiency reasons
666 patients with relapse selected 
First event: 148 SPBC, 260 LRR, 258 DM (44%)
47 patients excluded during 
registration
Reasons: 12 follow-up 
unknown, 2 missing patient 
records, 10 previous invasive 
cancer, 3 DM at primary 
diagnosis, 3 no relapse, 
17 reason not registered
619 patients with relapse registered
First event: 129 SPBC, 162 LRR, 247 DM, 70 LRR+DM, 
8 SPBC+DM, 2 SPBC+LRR, 1 SPBC+LRR+DM
9 patients excluded from the 
analyses, relapsed during 
primary treatment 5 SPBC, 
2 LRR, 2 DM
BREAST CANCER RELAPSE
610 patients analysed
First event: 124 SPBC, 160 LRR, 245 DM, 70 LRR+DM, 
8 SPBC+DM, 2 SPBC+LRR, 1 SPBC+LRR+DM
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Guideline recommendations
According to the Dutch guideline on breast cancer treatment, which was in use 
between 2002 and 2008, breast cancer patients should be clinically examined every 
3 months during the first year, every 6 months during the second year, and yearly up 
to and including year 5 after primary treatment.1 In addition, annual mammography 
is advised, accompanied with MRI for patients with a BRCA1 or BRCA2 mutation. 
For women aged 60-75 years, mammography may be offered biennially. Since 2008 
yearly mammography was advised to all patients, irrespective of age.13
Data analyses
Start of follow-up was defined as the last date of primary locoregional or 
chemotherapeutic treatment and may, therefore, start before hormonal or targeted 
therapy. The end of follow-up was set at first relapse, death, or last date of follow-
up.
Guideline adherence was evaluated by comparing the mean number of follow-up visits 
and mammograms or MRIs performed with the recommendations. Adherence rates 
for follow-up visits were categorized as less visits than recommended, consistent 
with recommendations and more visits than recommended.7 Patients discharged from 
routine follow-up during the fifth year of follow-up were included in the analyses 
until the end of year five. Patients who stopped to attend routine follow-up for no 
specific reason were considered non-attendant for the remainder of the five-year 
follow-up period. All mammographic and breast MRI examinations performed during 
the follow-up period, i.e. routine or indicated, were included in the analyses. Patients 
with at least 1 mammogram or breast MRI examination per year were considered to 
be compliant to yearly breast imaging. Compliance to breast imaging during the first 
five years of follow-up was defined as at least 4 exams.
Relapses were categorised according to presence of symptoms at diagnosis, 
whether the corresponding visit was routine or interval and which test, e.g. physical 
examination or breast imaging, raised the first suspicion for relapsed breast cancer. 
This mode of relapse detection was outlined by site of isolated breast cancer relapse. 
Mode of LRR detection was displayed by type of primary surgery.
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Table 7.1. Patient, tumour and treatment characteristics at initial breast cancer diagnosis 
in 2003 and 2004
Inception 
cohort
Random 
cohort 
sample
Breast cancer relapse (n=610*)
Characteristic n=6509 n=144
SPBC
n=124
LRR
n=160
DM
n=245
LRR+DM
n=70
Age at surgery, 
median (range) years
58 (20-
96)
57 (28-
88)
58 (31-
85)
55 (20-
89)
57 (24-
90)
56 (24-
90)
Tumour stage, n (%)
pT1 3805 (58) 91 (63) 85 (69) 90 (56) 80 (33) 24 (34)
pT2 2375 (36) 47 (33) 36 (29) 65 (40) 139 (57) 38 (54)
pT3 220 (3) 3 (2) 2 (2) 1 (1) 20 (8) 7 (10)
pT4 106 (2) 3 (2) 1 (1) 4 (3) 6 (2) 1 (1)
Unknown 3 (0)
Nodal stage, n (%)
pN0 3757 (58) 91 (64) 97 (78) 94 (59) 80 (33) 24 (34)
pN1 1805 (28) 36 (25) 17 (14) 46 (29) 71 (29) 21 (30)
pN2 552 (8) 8 (6) 6 (5) 9 (6) 56 (23) 12 (17)
pN3 285 (4) 4 (3) 3 (2) 9 (6) 37 (15) 12 (17)
Unknown 110 (2) 5 (3) 1 (1) 2 (1) 1 (0) 1 (1)
Tumour grade, n (%)
Grade 1 1161 (18) 30 (21) 27 (22) 20 (13) 9 (4) 2 (3)
Grade 2 2649 (41) 60 (42) 64 (52) 63 (39) 89 (36) 24 (34)
Grade 3 1989 (31) 41 (28) 19 (15) 63 (39) 114 (47) 38 (54)
Unknown 710 (11) 13 (9) 14 (11) 14 (9) 33 (13) 6 (9)
Histology, n (%) 
Ductal 5022 (77) 119 (83) 90 (73) 133 (83) 189 (77) 62 (89)
Lobular 737 (11) 17 (12) 22 (18) 8 (5) 29 (12) 4 (6)
Other 750 (12) 8 (6) 12 (10) 19 (12) 27 (11) 4 (6)
Bilateral breast cancer, n (%)
Yes 97 (1) 1 (1) NA 3 (2) 3 (1) 0
Receptor status, n (%)
ER and/or PR positive 2894 (77) 123 (85) 103 (83) 105 (66) 165 (67) 26 (37)
ER and PR negative 627 (17) 18 (13) 13 (10) 45 (28) 74 (30) 34 (49)
Unknown 240 (6) 3 (2) 8 (7) 10 (6) 6 (3) 10 (14)
Not registered 2748
Surgery, n (%)
Breast conserving 3444 (53) 68 (47) 71 (57) 74 (46) 95 (39) 16 (23)
Mastectomy 3060 (47) 76 (53) 53 (43) 86 (54) 150 (61) 54 (77)
Unknown 5 (0)
Radiotherapy, n (%)
Yes 4239 (65) 83 (58) 83 (67) 86 (54) 178 (73) 37 (53)
Chemotherapy, n (%)
Yes 2430 (37) 45 (31) 27 (22) 54 (34) 143 (58) 34 (49)
Hormonal therapy, n (%)
Yes 2722 (42) 64 (44) 26 (21) 45 (28) 113 (46) 18 (26)
DM, distant metastasis; ER, oestrogen receptor; LRR, locoregional recurrence; NA, not applicable; 
PR, progesterone receptor; SPBC, second primary breast cancer.
* The characteristics of 11 patients with relapsed breast cancer were not presented here: 8 
patients had a SPBC and DM, 2 patients a SPBC and LRR and 1 patient a SPBC, LRR and DM.
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RESULTS
The characteristics of the inception cohort and the random patient cohort sample 
were comparable (Table 7.1). In the random sample, genetic testing was performed 
in 12 (8%) patients; in 2 (1%) patients a BRCA1 mutation was found. During the first 
five years 1645 visits were performed: 1552 routine, 83 interval and 10 indefinable 
visits. In the same period 15 patients died, 17 patients relapsed, 1 patient emigrated 
and 1 patient did not undergo further follow-up exams because of comorbidity. 
Among the 17 relapsed patients, 3 (18%) were diagnosed by a medical discipline not 
providing follow-up care. Of the other 14 relapses 5 were detected at a routine visit 
and 9 at an interval visit. This means that 310 routine visits versus 9 interval visits 
were performed to detect 1 relapse.
The mean number of visits decreased during follow-up: from 3.9 in year 1 to 1.8 in 
year 5 (Table 7.2). During the follow-up years 2-5, at least 50% of patients underwent 
more visits than recommended (Figure 7.2). When one discipline performed routine 
follow-up controls, 9.1 visits were performed during the first five years of follow-up. 
The follow-up frequency increased when more disciplines were involved in routine 
follow-up: 13.7 visits in case of two disciplines and 18.0 visits when the surgeon, 
radiotherapist and medical oncologist all provided follow-up care.
Figure 7.2. Adherence to follow-up visits during the first 5 years of post-treatment 
follow-up in 144 breast cancer patients. Guideline recommendation includes: four visits 
during year 1, two visits during year 2, and one visit during the years 3, 4 and 5.
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Table 7.3. Breast imaging during the first 5 years of post-treatment follow-up and 
adherence to guideline recommendations in the random cohort sample comprising 144 
breast cancer patients
Breast imaging YEAR 1
134 patients
YEAR 2
123 patients
YEAR 3
118 patients
No
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Guideline recommendations 1 1 1
≤ 59 years 1 1 1
60-74 years 0.5 0.5 0.5
≥ 75 years 0 0 0
Mammography 134 0.8 (0-2) 77% 123 0.9 (0-2) 88% 118 0.9 (0-2) 81%
Mammography or MRI 134 0.8 (0-2) 78% 123 1.0 (0-2) 92% 118 0.9 (0-2) 85%
Age at diagnosis
≤ 59 years (n=86) 84 0.9 (0-2) 85% 78 0.9 (0-2) 90% 73 0.9 (0-2) 88%
60-74 years (n=38) 37 0.8 (0-2) 78% 34 1.1 (0-2) 94% 34 0.9 (0-2) 33%
≥ 75 years (n=20) 13 0.4 (0-1) 38% 11 1.0 (1-1) 100% 11 0.8 (0-2) 73%
No. of disciplines involved in follow-up
One (n=47) 41 0.5 (0-2) 46% 39 1.0 (0-2) 89% 35 0.8 (0-2) 80%
Two (n=73) 70 0.9 (0-2) 90% 64 1.0 (0-2) 92% 61 1.0 (0-2) 89%
Three (n=24) 23 1.0 (0-2) 100% 20 1.0 (0-1) 95% 19 1.0 (0-2) 95%
NA, not applicable.
§ 34 patients had a follow-up period shorter than 5 years: 15 patients died, 17 patients 
relapsed, 1 patient emigrated and 1 patient did not undergo further follow-up exams because 
of comorbidity. * Adherence was defined as 2 or more breast imaging examinations.
During the first five years of follow-up 533 mammograms and 54 breast MRIs were 
performed. In this period, 8% of patients received less than 4 breast imaging tests, 
32% 4 exams, 48% 5 tests and 13% more than 5 examinations. No clear pattern 
of biennial breast imaging was observed in patients aged 60-74 years (Table 7.3). 
Patients aged 75+ years received less breast imaging tests compared with younger 
patients. Adherence to yearly breast imaging tended to be better when more than 
one discipline were involved. Patients followed up by one discipline were older than 
patients with two or three disciplines involved in follow-up care: the median (range) 
age at diagnosis was 64 (38-86) years, 55 (28-88) years and 51 (33-70) years, 
respectively. 
The mode of relapse detection was assessed in 124 patients with a SPBC, 160 patients 
with a LRR and 245 patients with a distant metastasis (Figure 7.1). SPBCs were mainly 
detected in an early stage: 14% were in situ, 52% stage I, 24% stage II, 5% stage III and 
6% unknown. Three in four SPBCs were detected asymptomatically at a routine visit 
of which 71% (66/93) by local breast imaging alone (Table 7.4). The proportion of 
SPBCs detected asymptomatically decreased with the SPBC stage: 16 (94%) of in situ 
cancers, 49 (77%) of SPBCs detected in stage I, 20 (67%) in stage II, 4 (67%) in stage 
III and 4 (57%) for SPBCs of unknown stage.
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Twenty-two percent of the 245 distant metastases were bone metastases, 44% were 
visceral and 34% bone and visceral metastases. In 93% of the patients with a distant 
metastasis, diagnosis was accompanied with symptoms and 72% (177/245) were 
detected at an interval visit.
In general, there was no trend observed between the number of disciplines involved 
in a patient’s follow-up and the proportion of relapses detected asymptomatically 
(data not shown).
Breast imaging YEAR 4
118 patients
YEAR 5
110 patients
YEAR 1-5§
110 patients
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Guideline recommendations 1 1 4-5
≤ 59 years 1 1 4-5
60-74 years 0.5 0.5 2-3
≥ 75 years 0 0 0
Mammography 118 0.8 (0-2) 82% 110 0.8 (0-2) 83% 110 4.3 (0-6) 85%
Mammography or MRI 118 0.9 (0-2) 86% 110 0.9 (0-2) 86% 110 4.6 (0-7) 92%
Age at diagnosis
≤ 59 years (n=86) 73 1.0 (0-2) 92% 71 1.0 (0-2) 93% 71 4.7 (1-7) 89%
60-74 years (n=38) 34 0.9 (0-2) 85% 31 0.8 (0-2) 77% 31 4.5 (0-6) 97%*
≥ 75 years (n=20) 11 0.5 (0-1) 55% 8 0.8 (0-2) 63% 8 3.8 (2-5) NA
No. of disciplines involved in follow-up
One (n=47) 35 0.9 (0-2) 86% 32 0.9 (0-1) 88% 35 3.9 (0-5) 83%
Two (n=73) 59 0.9 (0-2) 93% 55 1.0 (0-1) 95% 58 4.8 (2-7) 95%
Three (n=24) 19 0.9 (0-2) 89% 17 0.9 (0-1) 88% 17 5.0 (4-6) 100%
Table 7.3. Continued
Of the 160 LRRs, 59% were local, 33% were regional and 8% were locoregional. After 
breast conserving surgery (BCS), 42% of LRRs were detected asymptomatically of 
which 55% (18/31) by local breast imaging modalities (Table 7.4). In patients who 
underwent mastectomy, 28% of LRRs were detected asymptomatically of which 75% 
(18/24) by physical examination.
110
Chapter 7
BCS, breast conserving surgery; DM, distant metastasis; LRR, locoregional recurrence; SPBC, 
second primary breast cancer.
* local imaging includes mammography or breast MRI.
Table 7.4. Mode of first relapse detection in 529 relapsed breast cancer patients: the first 
test that raised suspicion for relapsed breast cancer, n (%)
Mode of detection
SPBC
n=124
LRR after BCS
n=74
LRR after 
mastectomy
n=86
DM
n=245
Asymptomatic 93 (75%) 31 (42%) 24 (28%) 16 (7%)
Detected at a routine 
visit
85 31 22 8
Physical examination 11 13 18 4
Local imaging* 66 17 3 1
Physical examination 
and local imaging
8 1 1 -
Blood tests - - - 3
Chance finding 7 - 2 8
Unknown 1 - - -
Symptomatic 31 (25%) 42 (57%) 62 (72%) 229 (93%)
Detected at a routine 
visit
16 9 16 50
Detected at an interval 
visit
15 33 45 177
Unknown - - 1 2
Unknown - 1 (1%) - -
In summary, 10.8 routine visits (1552 routine visits in 144 patients) and 3.9 breast 
imaging procedures (562 exams in 144 patients) were performed per patient during 
the first five years of follow-up. An asymptomatic recurrence was detected in 2.1% of 
patients (85 SPBCs and 53 LRRs detected asymptomatically in 6509 patients). Forty-
two asymptomatic patients had their LRR or SPBC detected by physical examination 
alone, 86 patients by breast imaging alone and 10 patients by both modalities (Table 
7.4). Correspondingly, 1349 physical exams were performed to detect 1 LRR or SPBC 
before symptoms occur. Regarding breast imaging, 262 mammography’s and/or 
breast MRIs were performed to detect 1 LRR or SPBC early.
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DISCUSSION
We observed an overuse of breast cancer follow-up visits in the Netherlands in 2003-
2011, which was also observed previously in the Netherlands5,6 and Canada.7 Follow-
up frequency remarkably increased with the number of medical disciplines involved 
in routine follow-up. In line with our findings, Grandjean et al6 observed a slight 
underuse of yearly breast imaging in patients diagnosed in 2003 in two hospitals 
in the Netherlands. Adherence was, however, better than in patients diagnosed in 
1989-2002 in the Netherlands5 and in 1998-1999 in Canada.7
In this study, all patient records from the surgeon, radiotherapist and medical 
oncologist were meticulously examined by trained registry clerks from the 
Netherlands Cancer Registry, which is an important strength of this study. The 
retrospective design may, however, have hampered correct classification of follow-
up visits and tests. Degree of adherence should be interpreted with caution. Patients 
may have advanced or delayed visits which may have led to fewer visits in one year 
and more visits in another, whereas the total number of visits during the first five 
years of follow-up may be unchanged. Furthermore, patient-initiated interval visits 
were included in the adherence calculations. One might argue whether these are 
advanced or extra visits. The impact of interval visits on guideline adherence was, 
however, small: on average 0.6 interval visits were observed in five years. Degree 
of adherence to yearly mammography may be overestimated as all mammograms 
and breast MRIs performed in the follow-up period were included. A study in the 
United States showed that 18% of the 319 mammograms were diagnostic rather than 
routine.14 In contrast, inclusion of patients who underwent bilateral mastectomy may 
have resulted in a slight underestimation of adherence to yearly breast imaging. The 
prevalence of patients who underwent bilateral mastectomy was not registered, but 
breast imaging was provided at least once to all but one patient.
Three out of four patients were asymptomatic at SPBC detection. Others reported an 
asymptomatic detection rate varying between 59% and 77%.8,10,15,16 Breast imaging 
plays a prominent role in the early detection of SPBCs, as was reported previously.10,16
Thirty-four percent of LRRs were detected in the asymptomatic phase and this rate 
was higher in patients treated with BCS (42%) than with mastectomy (28%). A similar 
observation was made in 1989-2002: 69% and 30%, respectively.10 In contrast, a 
meta-analysis suggested a trend towards a higher proportion of LRRs detected 
asymptomatically in patients treated with mastectomy (47%) than BCS (36%), and in 
studies reported before 1995 (46%) than in 1995 and later (32%).9 Both findings may 
be explained by the steep increase in BCS since the mid 1980s17,18 and decreased risk 
of LRRs.19,20 After mastectomy, 21% of recurrences were detected asymptomatically 
by physical examination. A slightly higher rate (30%) was observed in the Netherlands 
in 1989-2002.10 For patients treated with BCS, physical examinations seems to be 
of equal value for the asymptomatic detection of LRRs as yearly mammography.10,21
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Since 2012, follow-up is advised to be coordinated by one medical discipline.22 The 
new monodisciplinary approach may improve guideline adherence, as the current 
study showed an overuse of follow-up services when two or three disciplines were 
involved. Routine follow-up, including physical examination and mammography, 
is advised to be performed once a year during the first five years, irrespective of 
age. The decrease in frequency of physical examination during follow-up was 
guided by the findings published by Lu et al10 and Montgomery et al.21 In line with 
the present study, they observed that physical examination has only a modest role 
in the early detection of SPBCs. The decreased risk of LRR over time19,20 and the 
asymptomatic detection rate of approximately 20% minimises the yield of routine 
physical examinations. Lu et al10 observed that during the first five years of follow-up 
1041 physical examinations were done to detect 1 LRR for patients diagnosed in the 
Netherlands in 1989-2002. In the present study, 1349 physical exams were observed 
to detect 1 SPBC or LRR early. Although this seems to justify a less frequent follow-
up programme, the impact on patient outcome is unknown and needs monitoring.
Yearly follow-up may be too infrequent to be able to provide psychosocial care 
adequately and to monitor the side effects of primary treatment, especially during 
the first years following treatment. It is important to incorporate these objectives in 
routine follow-up.23,24 Specialised nurses and general practitioners play an important 
role herein.25-27
Follow-up tests themselves may cause psychosocial and physical harm in 
healthy survivors due to false positive findings, unnecessary investigations and 
overtreatment.28,29 Future studies should target at the determination of the optimal 
combination of breast cancer follow-up tests, timing and duration, based on the 
benefits, harms and costs of routine testing.
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CONCLUSION
In the Netherlands, more follow-up visits are done than recommended. Follow-up 
provided by one discipline may improve guideline adherence. Breast imaging plays a 
major role in the early detection of SPBCs and LRRs. Although physical examination 
detects 20% of LRRs asymptomatically, a less intensive frequency of the physical 
examination seems justifiable. Monitoring the pattern of follow-up care and mode 
of detection remains important in the future as guideline recommendations in the 
Netherlands changed in 2012.
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ABSTRACT
Introduction 
Cancer prevalence is expected to increase by more than 50% in the next 10 years in 
the Netherlands. A shorter cancer follow-up period and less frequent testing, referred 
to further as minimal follow-up, in patients with a relatively short life expectancy 
or low relapse rate can reduce the follow-up burden. In this study, we discuss the 
prospects of stratified follow-up, illustrated by five common cancer types.
Methods 
The Netherlands Cancer Registry provided data on 214,173 patients diagnosed in the 
period 2003-2009 with in situ and invasive breast, invasive ovarian, invasive lung, or 
in situ, Ta or invasive bladder cancer, or invasive skin melanoma. We calculated the 
five-year relative survival rates and five-year risks of second primary cancers. Age 
and cancer specific comorbidity rates were obtained from Jansen-Heijnen et al (Crit 
Rev Oncol Hematol 2005;55:231-240).
Results
Relative survival in early stage breast and bladder cancer and skin melanoma was 
close to 100% and comprised at least 50% of the incident cases. 65% of ovarian and 
84% of lung cancer patients were diagnosed at an advanced stage with five-year 
relative survival rates below 30%. 35% of breast, 47% of ovarian, 63% of lung, 65% 
of bladder cancer and 26% of skin melanoma patients were aged 80+ years or had 
at least 1 comorbidity. Cumulative five-year risks of second primary cancers ranged 
between 1% and 5% for lung cancer in bladder cancer survivors, and for breast cancer, 
prostate cancer and skin cancer in breast, lung, and skin melanoma survivors. Risks 
for other sites were below 1%.
Conclusions 
Advanced stage ovarian and lung cancer patients are candidates for minimal follow-
up and represent 65% and 84% of the incident cases respectively. Factors like patient 
age and presence of comorbidity can also be used as an indication for minimal follow-
up. Additionally, in patients where relapse rate is low or timing of relapse treatment 
is immaterial, minimal follow-up is indicated. Future studies should, however, define 
which patients should be classified as having a short life expectancy or low relapse 
rate, before implementing minimal follow-up in clinical practice.
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INTRODUCTION
Patients treated for cancer with curative intent are offered routine follow-up 
examinations.1 In the Netherlands in 2009, 420,000 people had been diagnosed with 
cancer in the previous 10 years.2 This 10-year cancer prevalence is expected to rise 
to 660,000 persons in 2020. Consequently, follow-up is becoming an increasing 
burden on health care resources and budgets.3-6 To counterbalance the increasing 
number of visits and tests, we propose considering a minimal number of follow-up 
visits and tests with the aim to detect a cancer relapse early, for patients where no 
survival gain of earlier treatment is expected.
In addition to early detection and treatment of cancer relapses, the aims of 
routine follow-up are to monitor and treat cancer related side-effects and provide 
psychosocial care.7 Another important aspect of follow-up is monitoring ongoing 
systemic treatment.1,8 The need for psychosocial care differs between patients and 
is mainly present during the first years following primary treatment.9,10 Occurrence 
and timing of treatment related side-effects depends on the primary treatment given, 
and monitoring consequently differs between patients. Minimal follow-up should 
therefore include screening for unmet psychosocial care needs and side effects, 
mainly needed in the first years following treatment. Routine testing to detect a 
cancer relapse early can be decreased in duration and frequency, or even omitted in 
situations where no survival gain of earlier initiation of treatment is expected.
A short life expectancy may prevent routine follow-up from having any impact on 
survival time. A poor survival probability, despite the current intensive follow-up 
schedules, indicates that currently available treatment options have a limited effect 
on prognosis and only a small impact on treatment timing, if any. Follow-up tests 
are therefore unlikely to have a significant impact on longevity in patients with a 
poor survival probability according to tumour characteristics. High patient age and 
presence of comorbidity also decrease life expectancy. In this study, we discuss the 
prospects of patient stratification according to survival probability, patient age and 
presence of comorbidity.
In populations where relapse rates are low, the majority of patients will not benefit 
from routine testing. The screening tests, or diagnostic tests following positive 
findings can, however, be uncomfortable and even harmful for the patient.7 Occurrence 
of locoregional recurrences and distant metastases is not routinely registered by 
cancer registries, whereas occurrence of second primary cancers are. We therefore 
determined the risk of second primary cancers in cancer survivors, and compared 
these risks with expected false positive rates.
Earlier relapse treatment without any gain in longevity may decrease the patient’s 
quality of life as it extends the period that the patient has to live with knowledge of 
the relapse.11 Identification of the effectiveness of early detection and treatment of 
cancer relapse is, however, beyond the scope of this study.
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We presume that minimal follow-up can be provided to patients with a short life 
expectancy, low relapse rate or where an earlier initiation of relapse treatment does 
not impact patients’ survival duration. The prospects of this stratified follow-up 
approach will be studied for patients treated for breast, ovarian, lung and bladder 
cancer and skin melanoma, who accounted for 40% of the total cancer prevalence 
in the Netherlands in 2009.2 We selected these forms of cancer as they have a large 
variation in survival probability and an incidence of over 10 cases per 100,000 
person-years in the Netherlands.2
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PATIENTS AND METHODS
The population-based Netherlands Cancer Registry provided data from patients 
diagnosed with cancer in the period 2003-2009. Selected were women diagnosed 
with in situ or invasive breast cancer; women with invasive epithelial ovarian cancer; 
patients with invasive lung cancer; patients with in situ, Ta, or invasive bladder 
cancer; and patients with invasive skin melanoma. We excluded patients aged under 
20, those with a previous in situ cancer in the same organ, and those with a previous 
or simultaneous invasive cancer (within 3 months), except for basal cell carcinoma. 
Follow-up was complete until January 1, 2012.
Breast, non-small cell lung and bladder cancer and skin melanoma were staged 
according to the TNM classification, edition 6.12 Ovarian cancers were staged according 
to the International Federation of Obstetricians and Gynaecologists (FIGO) Staging 
System.13 Small cell lung cancer was staged as limited or extensive disease.14 If the 
pathological TNM was unknown, tumours were staged according to their clinical TNM 
stage. Patients registered with an unknown N or M stage were assumed to have no 
signs of affected lymph nodes or distant metastases, and were therefore classified as 
N0 or M0. In patients with a synchronous bilateral cancer diagnosed separately within 
3 months, the characteristics of the tumour with the highest stage were included for 
data analysis. Age was defined as being age at diagnosis.
Incidence rates were calculated per 100,000 person-years using the population 
size obtained from Statistics Netherlands, and age-standardized to the European 
standard population (ESR).
Five-year relative survival from diagnosis onwards was calculated using the SAS 
macro developed by Dickman15 and stratified by gender, age, stage and histology.
We determined the proportion of patients aged 20-49 years, 50-64 years, 65-79 
years and 80+ years per cancer site. Cancer specific comorbidity rates for these age-
groups were obtained from Jansen-Heijnen et al,16 based on the routine registration 
of comorbidity by the Eindhoven Cancer Registry.17
Five-year risk of a second primary cancer was calculated from date of diagnosis of 
the initial cancer using the cumulative incidence function, with all cause mortality as 
competing event.18 We included all in situ and invasive cancers diagnosed more than 
3 months after the primary cancer except for basal cell carcinoma, and including 
second cancers of the same type, except for bladder cancer. This definition differs 
from the IACR19 recommendation which does not consider a second cancer of the 
same type to be a second primary cancer.
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SC, small cell; NSC, non-small cell.
Table 8.1. European standardised incidence rates (ESR) of breast, ovarian, lung and 
bladder cancer and skin melanoma in the Netherlands in 2003-2009
ESR
Per 100,000 person-years
Cancer type Men Women
Breast, in situ - 13
Breast, invasive - 121
Ovarian - 11
Lung, SC 9 6
Lung, NSC 52 26
Bladder, in situ 1 0.2
Bladder, Ta 18 4
Bladder, invasive 16 4
Skin melanoma 16 20
M0, no metastasis at diagnosis; M1, metastasis at diagnosis; SC, small cell; NSC, non-small cell.
† Relative survival rates may exceed 100% if the survival probability in patients is better than in 
the general population. * Proportions may not add up to 100%, because patients with unknown 
tumour stage were not included in this table. § Four-year survival rate due to high mortality rate 
and a small number of patients. 
Table 8.2. Five-year relative survival probabilities of breast, ovarian, lung and bladder 
cancer and skin melanoma by cancer stage in the Netherlands in 2003-2009
Cancer type Cancer type by stage
Site Five-year 
relative 
survival†
Stage % of patients* Five-year
relative survival
Men Women Men Women Men Women
Breast, in situ - 101% In situ - 9% - 101%
Breast, invasive - 88% Stage I - 35% - 99%
Stage II - 37% - 92%
Stage III - 12% - 72%
Stage IV - 4% - 22%
Ovarian - 39% Stage I-IIA - 22% - 84%
Stage IIB-IV - 65% - 27%
Lung, SC 6% 8% Limited 36% 41% 13% 16%
Extended 63% 59% 1% 2%
Lung, NSC 15% 18% Stage I 15% 16% 55% 64%
Stage II 6% 5% 36% 41%
Stage III 29% 26% 11% 14%
Stage IV 39% 42% 2% 3%
Bladder, in situ 89% 80% In situ 4% 2% 89% 80%
Bladder, Ta 98% 98% Ta 51% 46% 98% 98%
Bladder, invasive 56% 42% Stage I 21% 16% 83% 83%
Stage II 10% 12% 49% 43%
Stage III 5% 9% 33% 26%
Stage IV 7% 12% 11% 9%
Skin melanoma 84% 92% M0, ≤1 mm 44% 54% 101% 100%
M0, 1.01-2 mm 21% 21% 91% 95%
M0, 2.01-4 mm 16% 11% 71% 83%
M0, >4 mm 10% 6% 53% 59%
M1 1% 1% 12% 22%§
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RESULTS
In 2003-2009, 91,451 patients were diagnosed with breast cancer, 7,826 with 
ovarian cancer, 61,435 with lung cancer, 30,091 with bladder cancer and 23,370 
with skin melanoma. The incidence rates varied largely between these cancer types 
(Table 8.1). The highest ESR was seen for breast cancer, being 134 per 100,000 
person-years (PY) for women. The lowest ESR was observed for ovarian cancer, being 
11 per 100,000 PY.
The five-year relative survival was more than 80% for invasive and in situ breast 
cancer, in situ and Ta bladder cancer, and skin melanoma (Table 8.2). Ovarian and 
invasive bladder cancer patients had a five-year relative survival close to 50%. For 
lung cancer the five-year relative survival was lower than 20%. Survival probability, by 
definition, decreases with increasing stage. Gender, age and histology had a smaller 
impact on relative survival than stage (data not shown). Relative survival probabilities 
close to 100% were seen in patients treated for early stage breast and bladder cancer 
and skin melanoma, comprising half of the incident cases (Table 8.2). Stage III breast 
cancer and non-metastatic skin melanomas thicker than 2 mm had five-year relative 
survival rates between 50% and 80%, comprising 13% and 21% of the incident cases, 
respectively. A five-year relative survival under 30% was observed for stage IV breast 
cancer and metastasised skin melanoma, comprising 4% and 1% of all incident cases, 
respectively. Among women diagnosed with ovarian cancer, 22% were staged I-IIA 
and had a five-year relative survival of 84%. For ovarian cancer patients staged IIB-IV, 
the five-year relative survival was 27%. Twenty-two percent of non-small cell lung 
cancers were diagnosed as stage I or II and the five-year relative survival was 64% 
and 41%, respectively. For patients with small cell lung cancer and stage III and IV 
non-small cell lung cancer, the five-year relative survival rate was lower than 20%.
Comorbidity rates differ for the five selected cancer sites and increase with increasing 
age (Table 8.3).16 More than 50% of the lung and bladder cancer patients aged 
50+ years and breast and ovarian cancer patients aged 65+ years had at least one 
comorbidity, while up to 73% of the male lung cancer patients aged 80+ years had at 
least one comorbidity. Depending on cancer type, 57% to 96% of patients were aged 
50+ years.
Risks and sites of second primary cancers differ largely between the cancer types 
(Table 8.4). The risks decreased with increasing stage and increased with increasing 
age (data not shown). For breast cancer and skin melanoma, approximately half of 
the second primaries occur at the same site as the primary tumour. A five-year skin 
cancer risk of 1% was seen in women diagnosed with breast cancer, and in men 
and women diagnosed with bladder cancer. Prostate cancer risks of 3% and 2% were 
observed for men with bladder cancer and skin melanoma, respectively. Women 
treated for ovarian or bladder cancer or skin melanoma had a five-year risk of breast 
cancer of 1%. Moreover, patients diagnosed with bladder cancer had a five-year risk 
of lung cancer of 2% in men and 1% in women. For all other second primary cancer 
sites, five-year risks were below 1%.
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DISCUSSION
Routine cancer follow-up with the aim to detect treatable cancer relapses early is 
offered to patients treated with curative-intent.7 In the present study, we did not 
exclude patients who underwent palliative-intent treatment. The treatment intent 
of patients depends on cancer type and stage and is subject to change due to new 
treatment options for distant metastases.14,20 In contrast, in some patients with 
a favourable cancer stage, curative-intent treatment may not be offered due to a 
patient’s physical fitness or comorbidity.14,16
A poor survival probability indicates that the routine follow-up tests have a limited 
impact, if any, on longevity. Stage IIB-IV ovarian cancer patients, which includes 65% 
of ovarian cancer patients, has a five-year relative survival of 27% and is therefore 
a candidate for minimal follow-up. Patients diagnosed with small cell lung cancer, 
stage III or IV non-small cell lung cancer have five-year relative survival rates lower 
than 20%, comprising 73% of all lung cancer patients. Follow-up can be minimised in 
these patients as well. Fourteen percent of bladder cancer patients were diagnosed 
with stage III or IV; with a five-year relative survival close to 30% or under. Reducing 
the number of follow-up visits and tests in stage III and IV bladder cancer patients 
would therefore only have a small impact on follow-up practice. For breast cancer 
and skin melanoma patients, 4% and 1% of patients had stage IV disease with a 
five-year relative survival under 30%. Minimal follow-up based on a poor survival 
in breast cancer and skin melanoma patients will hardly impact follow-up practice. 
Further patient stratification may allow us to select more patient subgroups with a 
poor prognosis.
Patients with a short life expectancy according to age and comorbidity have a 
significant probability to die before the occurrence of a clinical cancer relapse. 
An improvement in longevity through cancer surveillance may consequently be 
hampered. Age and comorbidity rates can be used to identify individuals at high 
risk of non-cancer related death. Further, there is no need for preclinical relapse 
detection, and thus no indication for routine tests, if patients are not or not optimally 
treated at time of cancer relapse, which has been associated with patient age and 
comorbidity.16,21 The life expectancy of individuals aged 80+ years in 2010 in the 
Netherlands is 8 years for men and 10 years for women.22 For most cancer types, 
cancer survivors have a shorter life expectancy than the general population. In breast 
cancer 35% of patients are aged 80+ years or have at least 1 comorbidity. For ovarian, 
lung and bladder cancer and skin melanoma the proportions were 47%, 63%, 65% 
and 26%, respectively. Among all comorbidity types, hypertension, cardiovascular 
disease, diabetes, COPD and previous cancers are most prevalent.23,24 The proportion 
of patients with at least one comorbidity is underestimated because no data were 
available for patients younger than 50 years. In addition, presence of comorbidity 
may be underreported in medical records, especially when presence of comorbidity 
does not impact treatment decisions. Whether a specific comorbidity precludes the 
possibility to benefit from routine follow-up depends on the survival trajectory of the 
cancer and the severity of the comorbidity. Future studies are needed to define the 
clinically relevant definitions for a short life expectancy.
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In patients with a favourable life expectancy, routine tests to detect treatable cancer 
relapses earlier can be indicated if earlier initiation of relapse treatment improves 
patients’ survival duration. An estimation of the effectiveness of early relapse 
treatment goes beyond the scope of this study. Table 8.5 presents the Dutch follow-
up schedules for the five cancer types included in this study.1 The advice on which 
relapse sites to screen for differs by definition, between cancer types. In breast 
and lung cancer and skin melanoma patients, routine follow-up aims at the early 
detection of locoregional recurrences and second primary breast and skin cancers, 
respectively, whereas screening for distant metastases is not indicated. For ovarian 
and bladder cancer patients, screening for second primary cancers in the same organ 
are not included in the follow-up advice. Ovarian cancer follow-up measurements 
aim at the detection of ovarian recurrences, were no discrimination is made between 
locoregional and distant recurrences. In bladder cancer, follow-up tests are advised 
to be done to detect locoregional recurrences and distant metastases.
Table 8.5. Guideline recommendations for breast, ovarian, lung and bladder cancer and 
skin melanoma follow-up in the Netherlands1
§ In patients with a BRCA1/2 mutation.
* In case of urothelial carcinoma.
Cancer type Year 1 Year 2 Year 3 Year 4 Year 5
Breast Patient history taking 1 1 1 1 1
Physical examination 1 1 1 1 1
Mammography 1 1 1 1 1
MRI § 1 1 1 1 1
Ovarian Patient history taking 4 4 3 2 2
Physical examination 4 4 3 2 2
CA125 4 4 3 2 2
Lung Patient history taking 4 2 1 1 1
Physical examination 4 2 1 1 1
X-thorax 4 2 1 1 1
Bladder
Patient history taking 1 1 1 1 1
Physical examination 1 1 1 1 1
Cystectomy Routine blood tests 1 1 1 1 1
Imaging kidneys 1 1 1 1 1
Bladder conserving and 
non-muscle-invasive 
cancers Cytoscopy 1 1 1 1 1
Urine cytology* 1 1 1 1 1
Skin melanoma
Breslow ≤ 1mm No follow-up - - - - -
Breslow > 1mm Patient history taking 4 3 2 2 2
Physical examination 4 3 2 2 2
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Quantifying efficiency
The efficiency of follow-up schedules can be expressed as the number of tests needed 
to detect one cancer relapse, estimated using the relapse rate, test frequency and 
test sensitivity. Unfortunately, population-based data on locoregional recurrences 
and distant metastases were not available. In our study, we present the risks of 
second primary cancers. Using these figures, we will provide a numerical example of 
the consequences of cancer follow-up.
We assume a test sensitivity of 100%, meaning that all relapses are detected through 
follow-up tests. For breast cancer, with a five-year risk of second primary breast 
cancer of 2.6% and yearly follow-up, we estimate that 192 tests are needed to detect 
a second primary breast cancer. Second primary ovarian cancers are very rare because 
generally both ovaries are removed at surgery and tests to detect second primaries 
are therefore not indicated. We estimated the number of tests needed to detect a 
second primary lung cancer at 1286 for both men and women with non-small cell 
lung cancer. In the case of small cell lung cancer, the estimated number of tests 
was 4500 for men and 2250 for women. Second primary bladder cancers were not 
registered by the Netherlands Cancer Registry because second primaries cannot be 
discerned from recurrences. For skin melanoma, the numbers are 271 for men and 
333 for women. The estimated numbers of tests needed to detect one second cancer 
are overestimates, because the follow-up period will not be five years for all patients 
as a result of the occurrence of cancer relapse and death. In contrast, these numbers 
are underestimates because test sensitivity is far from 100%.25-27 Routine tests may 
lead to a survival benefit if relapses are detected preclinically, i.e. before patients 
experience symptoms. Some patients are symptomatic at relapse detection, thus in 
the clinical phase.25,26 The number of tests needed to detect one preclinical relapse 
will therefore be much higher than the estimates presented above.
The large number of tests required to detect one relapse also results in a large 
number of false positive test results. The test specificity is defined by the proportion 
of false positive findings. If we assume a relapse rate of 5% and a test specificity 
of 80%, then approximately 20% of the test results are false positive. For patients 
treated for breast cancer, for example, we estimate that approximately 200 tests are 
needed to detect 1 second primary breast cancer; this is accompanied by 40 false 
positive test results. If we consider yearly screening for lung cancer in breast cancer 
survivors, with a five-year relapse rate of 0.5%, this would require 1000 tests and will 
be accompanied by 200 false positive findings for every lung cancer case.
The acceptable number of tests depends on the impact of false positive findings on 
patients’ outcomes and the size of the benefit achieved by an earlier detection of 
cancer relapse. Five-year relapse risks below 1% and yearly follow-up will generally 
lead to more than 500 tests per relapse diagnosed, of which up to 20% will generate 
false positive results. We therefore would suggest that screening for cancer relapses 
with five-year risks under 1% are not indicated.
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In the present study we observed that absolute five-year risks of second primary 
cancers are generally less than 1% indicating that screening for second cancers are 
not indicated. In breast, bladder and skin melanoma survivors, the five-year risks of 
breast cancer in women, prostate cancer in men and skin cancer do exceed 1%, as is 
the case for lung cancer risk in bladder cancer patients. The value of screening for 
these cancer sites should be investigated more thoroughly.
The number of tests needed to detect a cancer relapse may be decreased by a less 
frequent follow-up or stratified follow-up. By stratified follow-up one can think of 
surveillance in patient subgroups with a substantial risk of second primary cancers 
and minimal follow-up in patient subgroups where risks are extremely low and tests 
may cause more harm than good.
In patients with a very high relative survival probability, relapse rates may be low and 
follow-up may consequently be minimised. Another scenario is that relapse rates are 
significantly high and that relapses can be treated effectively. In the latter scenario, 
a decrease in the number of tests may lower the number of relapses detected early 
and thereby prevent an improved longevity for some patients. Half of the breast, 
bladder and skin melanoma patients were diagnosed in an early stage with a five-
year relative survival probability close to 100%. In these patients follow-up may be 
minimised if relapse rates are low. In patients with a moderate to good prognosis, 
further stratification may select additional patients for minimal follow-up. When 
developing guideline recommendations, it is important to identify the relapse risk, 
whether early detection of cancer relapse is possible and whether earlier initiation 
of treatment improves longevity based on clinical studies. If routine follow-up does 
prolong the survival duration, the optimal follow-up schedule needs to be designed. 
The follow-up schedule should take into account the number of tests needed to 
detect a relapse early and quantify the harms and costs of the tests and compare this 
with the expected benefit in quality adjusted life years.
131
Stratified cancer follow-up
8
CONCLUSIONS
To prevent harm to patients and to decrease the burden of follow-up on health 
care services, the number of follow-up examinations has to be minimised. We have 
shown that the majority of ovarian and lung cancer patients are diagnosed at an 
advanced stage are candidates for minimal follow-up. Patient characteristics like 
age and comorbidity can further be an indication for minimal follow-up. In patients 
with a low relapse rate, the possible harms of routine follow-up tests can be more 
prominent than the benefits. Before implementing minimal follow-up in clinical 
practice, it is important to classify patients who have a short life expectancy or low 
relapse rate based on clinical evidence. In patients with a significant risk of cancer 
relapse, clinical studies should elucidate whether an earlier relapse treatment will 
improve longevity. If considered effective, the optimal follow-up schedule should 
be defined, taking benefits, harms and costs into account. For all cancer patients 
follow-up care should include the monitoring and treatment of side effects and the 
provision of psychosocial care, especially during the first years of follow-up. These 
aims become more important as patients’ outcomes improve.
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The quest for optimal 
cancer follow-up schedules
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In this final chapter we propose ideas for the design of efficient follow-up schedules 
for patients treated for cancer with curative intent. We also discuss whether it is 
worthwhile considering personalising follow-up schedules. We have chosen breast 
cancer as an example because it appeared as an appropriate example based on 
previous chapters. We focus on the impact of routine tests on life expectancy. Other 
aims of follow-up include the provision of information, psychosocial support and 
guidance, and monitoring and treatment of short and long-term side effects of primary 
treatment. The ideal follow-up programme should therefore not simply include a 
schedule of follow-up tests and frequencies, but it should contain recommendations 
on ways to achieve these other purposes of follow-up. In the last part of this chapter, 
we briefly reflect on the other aims of cancer follow-up, and propose directions for 
prioritizing research.
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INTRODUCTION
An increasing number of oncology patients will receive follow-up care.1 In 2010, 
the number of follow-up visits in the Netherlands was estimated at 1.2 million; this 
number is expected to increase to 1.6 million in 2020. These visits usually include 
physical examination and imaging, or measurements of tumour markers to detect 
and treat relapses early.2 Relapses are new manifestations of cancer, including local, 
regional and distant recurrences and second primary cancers.3 Recommendations 
on which relapse sites to screen for differ between cancer types. If we look at 
breast, colorectal and lung cancer follow-up; preclinical detection of locoregional 
recurrences is advised for all three cancer types.2 However, screening for distant 
metastases is not indicated for patients treated with breast or lung cancer, whereas 
it is advised in colorectal cancer patients. Routine tests to diagnose a second primary 
cancer is an issue in breast and colorectal cancer patients, whereas its occurrence is 
very low in lung cancer patients. Current follow-up schedules are consensus-based; 
it is unknown which combination, timing and duration of tests is optimal.
In this thesis we studied the effectiveness of follow-up after treatment for ovarian and 
breast cancer. In ovarian cancer patients, routine follow-up examinations aiming at 
improvement of longevity are not indicated (Chapters 3 - 5). Quality of life is worse if 
treatment of recurrent ovarian cancer is initiated earlier.4 In contrast, patients treated 
for breast cancer may benefit from an earlier detection of locoregional recurrences 
and second primary breast cancers,5,6 although this comes at the expense of many 
extra follow-up examinations. Annually, 1% of breast cancer patients are diagnosed 
with a locoregional recurrence or second primary breast cancer; to detect 1 relapse 
preclinically, 1349 physical examinations and 262 mammography and/or MRI tests 
were performed (Chapter 7). In colorectal cancer, with a five-year relapse rate of 
38%, 370 positive follow-up tests and 11 operations were needed to achieve a 
survival duration beyond five years in 1 patient.7 In non-small cell lung cancer, 40% 
of patients relapsed within five years and 238 visits were needed to select 1 patient 
for curative-intent resection.8 We expect that the low efficiency observed in breast, 
colorectal and lung cancer follow-up also applies to other cancer types. So, we can 
conclude that many unnecessary follow-up exams are performed and that only a 
small proportion of patients benefit from routine testing. Less intensive follow-up or 
targeted follow-up may decrease the burden on health care resources and budgets, 
without impact on the longevity.
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DEFINING THE OPTIMAL COMBINATION AND 
TIMING OF TESTS
If an earlier start of relapse treatment does increase the survival duration, the 
challenge is to develop the ideal follow-up schedule. The ideal follow-up schedule 
should detect the vast majority of relapses preclinically. Further, the quality adjusted 
life years gained by routine examinations should justify the costs of health care 
services. The incremental costs of a more frequent follow-up schedule should be 
legitimised by a larger gain in quality adjusted life years.
The proportion of relapses detected preclinically, given a certain combination of 
follow-up tests and frequencies, is dependent on the sojourn time and the sensitivity. 
The sojourn time is the period a relapse is detected before its clinical presentation 
(see Chapter 2). The length of the sojourn time is important because it defines the 
potential advancement in diagnosis and treatment. The sensitivity is the proportion 
of relapses detected by means of a certain screening test among all relapses. The 
sensitivity defines the proportion of patients who may benefit from routine testing. 
For the actual design of the optimal follow-up schedule we recommend to use a 
modelling approach.
Figure 9.1. Early detection of relapsed cancer: the sensitivity of history taking, physical 
examination, tumour marker measurement and imaging as a function of the disease 
course.
100%
50%
Test sensitivity
Recurrence development (time)
Patient complaints
Imaging
Physical examination
Tumour marker
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Sojourn time and sensitivity of follow-up tests
Routine follow-up schedules generally include patient history taking, physical 
examination and imaging or tumour marker assessment to detect a possible relapse 
early.2 By patient history taking the physician screens for symptoms of cancer 
relapse, which is already the clinical phase and the sojourn time approximates zero. 
Eventually, all relapses will become symptomatic, thus patient history taking will 
reach a sensitivity close to 100% (Figure 9.1). Physical examination by the medical 
specialist may detect a relapse before symptoms appear, but the sojourn time will 
be short. Further, not all relapses will be palpable, resulting in a lower sensitivity 
for physical examination than for patient history taking. Other detection modalities, 
including imaging and tumour marker measurements, may significantly advance the 
relapse diagnosis compared with patient history taking and physical examination. 
The sensitivity and sojourn time for tumour markers and imaging tests will differ 
between cancer types and patient subgroups. For the detection of ovarian cancer 
recurrences, it is known that tumour marker CA125 has a lower sensitivity, but higher 
specificity than imaging tests.9
A modelling approach
We define the ideal follow-up schedule as the combination of follow-up tests and 
frequencies with the best cost-effectiveness ratio. This type of evaluation research 
requires a simulation study.10 To describe the progression of the disease over time, 
a Markov model can be used.10 In the past, various models have been proposed 
to simulate the effectiveness of different intervals and modalities in primary 
screening11,12 and follow-up care.13-17 To perform a cost-effectiveness analysis 
and define the optimal follow-up schedule, detailed information is needed on the 
accuracy of the potential follow-up tests, the benefits and harms of routine testing 
and relapse treatment, and the costs of health care services.
The proportion of relapses detected preclinically depends on the frequency and timing 
of a single test or a combination of tests with corresponding sensitivity and sojourn 
time. The sensitivity and sojourn time of tests can be assessed using mathematical 
models. Among others, Prevost et al18 developed models to calculate the sojourn 
time and sensitivity based on population-based screening data. If the sojourn time 
is long, the test may be applied less frequently to achieve the same programme 
sensitivity compared with tests with a shorter sojourn time.
Information on the benefits and harms of routine examinations should come from 
clinical studies. Besides the effect of a more early initiation of treatment on survival 
time it is important to incorporate quality of life aspects as well. Quality of life may 
decrease during relapse treatment.4 Further, the follow-up examinations themselves 
may cause psychosocial and physical harm to patients due to false positive findings, 
unnecessary investigations and overtreatment.3,19
A more frequent follow-up may have only a small increase in effect on longevity, 
whereas the costs may increase largely.20,21 Costs of follow-up visits and tests are 
therefore important to incorporate in the design of optimal follow-up schedules. 
Further, the costs of other health-care resources, like relapse treatment and 
personnel, should be included.10
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PERSONALISED FOLLOW-UP
Both nationally and internationally, current follow-up regimes are becoming a burden 
on healthcare resources and budgets.22-25 The number of follow-up examinations 
should be set at a minimum in patients where no gain is expected.26 In patients where 
a more early initiation of relapse treatment does improve the survival time, the ideal 
programme should be defined. The effectiveness of routine follow-up depends on 
tumour type and may differ between and within patient-subgroups. This raises the 
question whether the current ‘one-size-fits-all’ programmes, serving all patients 
with one schedule, are optimal. More personalised follow-up, taking patient and 
tumour characteristics into account, may be more efficient. The term personalised 
medicine was brought to public attention by the American senator Barak Obama in 
2007.27 The Personalized Medicine Act focused on genomics, but is pivotal for the 
entire health care system. The premise is that a stratified follow-up schedule will 
optimise the survival duration, quality of life and use of health care resources.
Next we propose three approaches to select patient-subgroups to study the efficiency 
of stratified follow-up schedules.
Figure 9.2. Stratification of cancer patients according to their risk of relapse.
100%
50%
Risk of relapse (%)
Follow-up time
0 1 2 3 4 5
Patients at high risk
Patient population risk
Patients at low risk
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Stratification approach I: risk of relapse
A first approach for stratification is to classify patients based on their risk of relapse 
using a prognostic model. A prognostic model may be useful if it discriminates 
between patients with a low and those with a high risk of relapse, as illustrated 
in Figure 9.2. The value of a prognostic model can be expressed by the positive 
and negative likelihood ratio, based on the sensitivity and specificity of the model 
(Table 9.1). The purpose of risk stratification is to minimise the number of follow-
up examinations in the ‘model negative’ group and to intensify the follow-up 
schedule for patients in the ‘model positive’ group. In Table 9.1 ‘c+d’ represents 
the proportion of patients with a low risk of relapse in whom follow-up could be 
minimised. However, this group includes a proportion of patients who do relapse, 
the false negatives (‘c’ in Table 9.1). The proportion of patients who will receive 
intensified follow-up examinations, but remain disease-free through their life are the 
false positives, defined by the specificity of the prognostic model and expressed as 
‘b’ in Table 9.1. In Table 9.2 we present these three impact measures in bold for four 
combinations of sensitivity and specificity. A low sensitivity is associated with a large 
number of ‘false negatives’; patients who relapse but receive a minimal follow-up 
schedule. If routine examinations have an impact on patients’ life expectancies, it is 
important to detect most relapses early, requiring a high sensitivity of the prognostic 
model. A low specificity translates in a large proportion of ‘false positives’, which 
are patients who remain disease-free but receive intensive follow-up. Thus, a high 
specificity is needed to minimise the number of unnecessary follow-up examinations 
in patients who remain disease-free. The proportion of patients who may receive 
minimal follow-up after the application of the model are presented in the last column, 
in bold. This proportion is a result of the combination of sensitivity and specificity.
The impact of a prognostic profile on the discrimination between patients with low and 
high risk of relapse depends, besides the sensitivity and specificity, on the underlying 
population relapse risk. With Bayes’ theorem (Table 9.1), the positive and negative 
likelihood ratio can be used to calculate the risk of relapse in the ‘model positive’ and 
‘model negative’ groups, based on the underlying population risk of relapse. In Figure 
9.3, the post-test risk of relapse is presented for four combinations of sensitivity and 
specificity. The figure shows that a prognostic profile has less discriminating power 
in populations with a very high or very low underlying population risk of relapse. The 
intermediate risk group is more sensitive to the discriminating power of a prognostic 
profile.
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Relapse No Relapse Total
Model + a b a+b
Model - c d c+d
Total a+c b+d N
Table 9.1. The discerning power of a prognostic model can be evaluated based on the 
sensitivity and specificity of the model to predict cancer relapse
Diagnostic accuracy
Sensitivity = a/(a+c)
Specificity = d/(b+d) 
Positive predictive value = a/(a+b) 
Negative predictive value = d/(c+d)  
Positive likelihood ratio = Sensitivity/(1-Specificity)  
Negative likelihood ratio = (1-Sensitivity)/Specificity 
From the underlying risk of relapse, before the model is applied, to the post-test relapse 
risk, the model outcome
Underlying relapse odds = (a+c) / (b+d)
Post-test relapse odds = likelihood ratio * underlying relapse odds → Bayes’ theorem
Post-test relapse risk = post-test relapse odds / (1 + post-test relapse odds)
Table 9.2. The impact of a prognostic model to stratify patients according to risk of cancer 
relapse, illustrated for a relapse rate of 50% and four combinations of model sensitivity and 
specificity. In bold, from left to right, the proportion of false negative and false positive 
model findings and the proportion of patients receiving minimal follow-up
Relapse No relapse Total
Model + 30 20 50
Model - 20 30 50
Total 50 50 100
A         Sensitivity=0.60, Specificity=0.60
Relapse No relapse Total
Model + 30 5 35
Model - 20 45 65
Total 50 50 100
B         Sensitivity=0.60, Specificity=0.90
Relapse No relapse Total
Model + 45 20 65
Model - 5 30 35
Total 50 50 100
C         Sensitivity=0.90, Specificity=0.60
Relapse No relapse Total
Model + 45 5 50
Model - 5 45 50
Total 50 50 100
D         Sensitivity=0.90, Specificity=0.90
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Figure 9.3. Bayes’ theorem; the post-test risk of relapse depends on the underlying risk 
of relapse and the sensitivity and specificity of the prognostic test. Displayed for four 
combinations of sensitivity and specificity: 
(A) Sensitivity = 0.60, specificity = 0.60 (─)
(B) Sensitivity = 0.60, specificity = 0.90 (− − −) 
(C) Sensitivity = 0.90, specificity = 0.60 (∙ ∙ ∙)
(D) Sensitivity = 0.90, specificity = 0.90 (− ∙ ∙ −)
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Figure 9.4. Results following implementation of a prognostic model to stratify patients 
according to risk of relapse, illustrated for four combinations of model sensitivity and 
specificity. The proportion of patients receiving minimal follow-up and the proportion of 
patients misclassified, plotted against risk of cancer relapse.
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In Figure 9.4 we combine the above mentioned values, i.e. the prognostic model 
sensitivity and specificity and the underlying population risk of relapse, simultaneously. 
We present the impact on the proportion of patients receiving minimal follow-up and 
the proportion of patients who were misclassified, i.e. the false positives and false 
negatives. The proportion of patients identified for minimal follow-up (──) increases 
with an increasing model specificity and decreases with an increasing relapse risk. 
The proportion of patients who receive intensified follow-up but remain relapse-free 
(∙ ∙ ∙) decreased with an increasing model specificity and decreases with an increasing 
relapse risk. The proportion of patients who relapse but receive a minimal follow-up 
schedule (− −) decreases with an increasing model sensitivity and increases with an 
increasing relapse risk.
In conclusion, stratification of patients according to their relapse risk may be useful 
in designing more personalised follow-up schedules, but requires both a high model 
sensitivity and specificity. Furthermore, the underlying population risk of relapse 
should not be very low or very high. When a valid prognostic model for cancer relapse 
is identified, a cost-effectiveness analysis should be performed to weigh the benefits, 
harms and costs of stratified follow-up and compare the model results with current 
‘one-size-fits-all’ schedule.
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Table 9.3. Diagnostic accuracy of nine genetic prognostic profiles for local recurrence 
after breast cancer. Validation study by Kreike et al,28 based on 109 patients free of local 
recurrence and 56 patients with local recurrence within 10 years post-treatment
Gene signature Sensitivity Specificity
Positive 
likelihood ratio
Negative 
likelihood ratio
70-gene 0.59 0.64 1.64 0.64
76-gene 0.68 0.53 1.45 0.60
Wound response 0.75 0.41 1.27 0.61
Hypoxia 0.57 0.28 0.79 1.54
Radioresistance 0.52 0.54 1.13 0.89
Chromosomal instability 0.68 0.57 1.58 0.56
Proliferation 0.59 0.63 1.59 0.65
Local recurrence after 
breast-conserving therapy
0.55 0.42 0.95 1.07
111-gene 0.77 0.43 1.35 0.53
Source: Kreike et al.28
Breast cancer patients have a risk of locoregional recurrence and second primary 
breast cancer close to 1% per year. As shown in Figure 9.3, it may be difficult to 
categorise patients with respect to their relapse risk. To illustrate the discriminating 
power of currently available genetic profiles, we use the validation study by 
Kreike et al28 as an example. Based on the gene expression of tumours from 56 
women with and 109 women without a local recurrence, the prognostic value of 
nine different profiles was assessed. The findings are presented in Table 9.3. The 
sensitivity of the profiles examined ranged between 0.52 and 0.77, the specificity 
between 0.41 and 0.64. The positive likelihood ratio was 1.64 at the most, which 
means that, using the formulas in Table 9.1 and assuming an underlying five-year 
relapse risk of 5%, the relapse risk in the ‘model positive’ group would be 8%. The 
lowest negative predictive value observed was 0.53. If the underlying relapse risk 
is 5%, 3% of patients in the ‘model negative’ group will get a relapse. Thus, by 
using the prognostic model, the population relapse risk of 5% will be discerned in 
8% risk for the ‘model positive’ group and 3% for the ‘model negative’ group. We 
expect that relapse rates of 3% and 8% are too close to each other to result in a 
different optimal follow-up schedule.
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Stratification approach II: relapse characteristics
A second approach to start the design of stratified follow-up schemes is to distinguish 
patients based on the pace of the relapse development, i.e. the length of the sojourn 
time. Based on empirical studies, the ratio of relapses detected asymptomatically 
to symptomatically can be revealed. Patient subgroups in whom relapses are 
generally missed by follow-up tests, i.e. a low proportion of relapses detected 
asymptomatically, may have a more aggressive tumour and a shorter sojourn time 
and possibly also a lower test sensitivity compared with patient subgroups with a 
high asymptomatic to symptomatic relapse detection ratio. In the first patient group 
a narrow screening interval is needed to catch recurrences preclinically. However, a 
short preclinical phase implies, if any, a small impact on survival time. In patients who 
generally develop slow-growing relapses, a less intensive follow-up schedule may be 
sufficient, thereby decreasing the number of follow-up exams but achieving a similar 
benefit compared with more intensive follow-up. Stratified follow-up according to 
the length of the preclinical detectable phase seems promising and is expected to 
decrease the number of unnecessary follow-up exams.
We can determine which patient and tumour characteristics predict the detection of 
relapses in the preclinical phase by logistic regression analysis using observational 
cohort data. As discussed previously, the sojourn time and programme sensitivity for 
various patient-groups can then be estimated using mathematical models.18
Stratification of patients according to the relapse growth rate will be illustrated 
with a real life example: breast density as a factor in the design of mass screening 
for breast cancer. Chiu et al29 showed that women with dense breast tissue 
have tumours with a shorter mean sojourn time, being 2 years, compared with 
tumours in patients with non-dense breast tissue, being 3 years. Furthermore, 
mammography was less sensitive in dense breasts (63%) than non-dense breasts 
(82%). The authors suggest to use a shorter screening interval and alternative 
screening modalities in women with dense breasts. The sojourn times for breast 
cancer relapses and sensitivities for follow-up modalities, have, to our knowledge, 
not been defined and should be calculated to be able to develop the ideal follow-
up scheme for breast cancer patient.
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Stratification approach III: comorbidity and age
Besides stratification of follow-up based on relapse risks and characteristics, it may 
also be reasonable to classify patients according to their life expectancy. High age 
and comorbidity may prevent routine tests from improving longevity. Physicians can 
discern patients with a poor, good or excellent life expectancy, based on their age and 
presence and severity of concurrent comorbidity.30 Increasing age is associated with 
a higher proportion of patients with comorbidity31,32 and more severe conditions.32 
If an individual patient has a comorbidity or high age, with a corresponding short 
life expectancy, one may consider not bothering this patient with routine follow-up 
examinations.
In 2003-2009, 39% of breast cancer patients were aged 50-64 years, 25% were 
65-79 years and 11% were 80+ years (Chapter 8). In Southern Netherlands, 28% 
of breast cancer patients aged 50-64 years had at least 1 comorbidity.33 For the 
age category 65-79 years and 80+ years the rates were 52% and 67%, respectively. 
In total, at least 35% of breast cancer patients were aged 80+ years or had at 
least 1 comorbidity at diagnosis. Breast cancer patients with comorbidity have an 
increased risk of dying, independent of age, cancer stage and primary treatment.31 
The mortality rate increases with 20% in presence of 1 comorbidity and with 90% 
if a patient has 2 or more coexisting diseases compared with patients without 
comorbidity. This implies that age and presence of comorbidity have an impact 
on the survival of breast cancer patients, and should be taken into account when 
designing personalised follow-up programmes.
The usefulness of the subgroups identified by the three approaches described above 
requires further study. Stratified follow-up programmes can only be more efficient 
than the traditional ‘one-size-fits-all’ design if the differences in relapse risk or the 
sojourn time, or the impact of comorbidity on life expectancy are significantly large. 
Moreover, stratified follow-up can only give a significant reduction in health care 
resources and budgets if the number of patients per prognostic group are substantial.
149
Optimal cancer follow-up schedules
9
ACTIONS SUBSTANTIATED
Address all aims of routine follow-up
The early detection of relapses is considered of high importance, but not the only 
aim of routine follow-up.3,34,35 Other aims include the provision of information, 
psychosocial support and guidance, and monitoring and treatment of short and 
long-term side effects of primary treatment.
Armes et al36 studied the proportion of unmet supportive care needs in patients 
treated for breast, prostate, bowel, gynaecologic cancers and non-Hodgkin’s 
lymphoma in England. The survey included questions on the psychosocial, health 
system and information, physical and daily activity, patient care and support and 
sexuality domains. Further, fear of cancer recurrence, anxiety and depression were 
assessed. Only 30% of patients did not report any unmet need, whereas 30% reported 
more than 5 unmet needs. The most frequently reported needs were psychosocial 
and, in particular, fear of cancer recurrence.
A survey among breast cancer patients in the Netherlands showed that patients highly 
appreciated information about prognosis, side effects, life style habits and additional 
investigations.34 Important issues during post-treatment follow-up were fatigue, 
pain, genetic factors, prevention of breast cancer and lymph oedema. Patients did 
not appreciate information about: peers, conversations with psychologists or social 
workers, breast reconstruction, and acceptation by family members. Of note, one in 
six patients had an indication for psychological evaluation of anxiety or depression.
The need, timing and duration of interventions to aid all follow-up aims depend on 
the site of the tumour, the type of treatment given and the timing and duration of the 
expected side effects.2 
The distress thermometer, in Dutch ‘Lastmeter’, may be a useful instrument to select 
patients who may benefit from psychosocial care.37 The care need varies between 
patients and an individualised survivorship care plan, including actions concerning 
all three aims, should be designed and implemented. 2,38
Consider alternative follow-up settings
Optimal and possibly personalised follow-up schedules may decrease the number 
of follow-up exams and thereby decrease the use of health care resources. 
Additionally, the pressure may be relieved by the implementation of alternative 
follow-up strategies. Alternatives proposed previously include follow-up provided 
by specialised nurses or the general practitioner, possibly by telephone or it may be 
patient-initiated.22,23,39 The patient satisfaction of nurse-led follow-up is high, but 
data on safety are scarse.40,41 The alternative initiatives may lower personnel costs, 
whereas the number of tests performed and patient outcomes is expected to be 
similar.42,43 Patient preferences should play an important role in the decision how to 
follow-up the patient.34,44
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The ideal follow-up schedule for breast and prostate cancer
The largest part of the burden of follow-up is caused by breast and prostate cancer, 
followed by colorectal and skin cancer, especially melanoma. Ten-year prevalence 
estimates based on the Dutch incidence and mortality data showed that these four 
cancer sites account for 63% of the 420,000 cancer patients alive in 2009.1 Prostate 
cancer in men and breast cancer in women are extremely prevalent and are expected 
to rise with more than 50% between 2009 and 2020. Future studies should, therefore, 
prioritise on optimising follow-up care in these patients.
The quest for the ideal breast cancer follow-up programme
In the present thesis we studied the effectiveness of routine follow-up after 
curative-intent breast cancer treatment. Here we will summarise current knowledge 
and present our thoughts about the optimal follow-up schedule for breast cancer 
survivors.
Risk of locoregional breast cancer recurrence and second primary breast cancer is 
low, approximately 1% a year (Chapter 6). As a result, the number of tests needed 
to detect 1 relapse preclinically is high: 1349 for physical examination and 262 for 
mammography and breast MRI tests (Chapter 7). The yield of physical examination 
to detect relapses early is low and should therefore be omitted or, at least, be 
minimised in number. Further, despite current intensive follow-up only 34% of 
locoregional recurrences were detected asymptomatically (Chapter 7), indicating 
a short sojourn time and/or low sensitivity of the tests and a small impact on 
longevity. We consequently anticipate that breast cancer follow-up should focus 
on the early detection of second primary breast cancers, where current follow-up 
practice detects 75% asymptomatically (Chapter 7).
Two recent modelling studies revealed that a less frequent follow-up schedule 
without routine physical examination seems justifiable. Robertson et al45 compared 
the cost-effectiveness of no surveillance, mammography alone, mammography plus 
physical examination and MRI plus physical examination for various intervals: 12-, 
18-, 24- and 36-monthly. Using individual patient data and published literature, 
the highest net benefit was observed for mammography every 12-24 months. 
Evidence was, however, weak and many assumptions were made which limits its 
implementation in clinical practice. Lu et al16 compared current follow-up with 
three alternative scenarios using individual patient data and published findings. 
Current follow-up was defined as the Dutch guideline recommendations in 2008, 
comprising hospital follow-up with physical examination and mammography for 
at least five years.46 After five years, patients younger than 60 years remained in 
yearly hospital follow-up, whereas patients aged 60-75 years were referred to the 
national screening programme. Follow-up was ended in patients aged 75+ years. 
The three alternative scenarios were: shortening hospital follow-up from 5 to 2 
years, lowering age of referral to the national screening programme or general 
practitioner from 60 to 50 years and no physical examination. These scenarios had 
no impact on the effectiveness of follow-up, but decreased the costs considerably. 
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Both studies did not take potential harm of routine test into account. Further, Lu 
et al did not incorporate quality of life estimates and focussed on second primary 
breast cancers only. The pace of the development of locoregional recurrences 
and second primary breast cancer is unknown, which limits the design of optimal 
schedules. Estimates on the sojourn time and sensitivity of the routinely applied 
tests, that is physical examination, mammography and breast MRI, should be 
calculated by mathematical models using follow-up data.18 Furthermore, patient 
outcomes for alternative strategies are unknown and need further study.
Personalised breast cancer follow-up schedules may be designed based on specific 
patient and tumour characteristics, as seen for primary breast cancer screening.29 
We expect that stratification by relapse rate is not efficient because relapse rates 
are low. Minimal follow-up in elderly patients and patients with severe comorbidity 
may lead to a small reduction in the number of unnecessary follow-up tests, 
because breast cancer patients are relatively young and have a low prevalence 
of comorbidity (Chapter 8). The value of a more personalised follow-up schedule 
needs to be evaluated and the differences with current ‘one-size-fits-all’ follow-
up elucidated.
The optimal follow-up programme for breast cancer patients should, besides a 
schedule of follow-up tests, timing and duration, also include a plan for assessment 
of psychosocial care need and intervention, and a schedule to monitor ongoing 
hormonal treatment if applicable and side effects of cancer treatments.3 The need 
for psychosocial care is mainly present during the first year following treatment, 
with psychological distress rates close to 30%.47-49 The distress thermometer, in 
Dutch ‘Lastmeter’, is advised as screenings instrument and could be applied at 
every follow-up visit, with an interval of minimal 2-3 months.37,46,50 The expected 
occurrence of side effects depends on the type of treatment given and may include, 
for example, lymph oedema, post-mastectomy pain and osteoporosis.46,51 One 
follow-up visit a year is expected to be too infrequent to provide follow-up care, 
especially during the first year of follow-up. Evidence on the optimal frequency 
and duration is lacking, but we anticipate that a three-monthly screening for 
unmet needs and side effects by a specialised nurse might be offered during the 
first follow-up year. Monitoring adherence and side effects of ongoing hormonal 
treatment is needed for the full treatment period. For every patient an individualised 
survivorship care plan should be made including a schedule of follow-up visits and 
tests and a plan for psychosocial care and treatment monitoring.
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CONCLUSION
The number of unnecessary follow-up visits should be reduced to prevent harm from 
early relapse detection and prevent the stress and possible sense of false security 
caused by routine testing. A reduction in the number of visits and examinations would 
lead to an enormous reduction in costs. This economic benefit would be welcome in 
times of increasing health care costs and decreasing budgets. In situations where an 
earlier initiation of relapse treatment improves longevity, evidence-based follow-up 
schedules can be designed with modelling studies using individual patient data and 
published findings. Follow-up programmes may become less intensive if possible, 
and intensified if gain is expected, or personalised to improve cost-effectiveness. 
Early detection of cancer relapse is only one aspect of the follow-up programme. 
In all patients, the follow-up programme should include a systematic evaluation of 
ongoing treatment, immediate and late side-effects of primary treatment, and the 
need for psychosocial care.
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Cancer incidence is increasing rapidly in the Netherlands.1 Fortunately, in the 
last decades, the treatment options and consequently the survival rates and life 
expectancy have improved considerably. Despite curative-intent treatment patients 
are still at risk of a second primary cancer or a recurrence of the initial tumour.2 
In order to detect and treat possible relapses as early as possible, all patients are 
examined regularly, with the expectation of improving the patient’s life expectancy. 
There is limited support for this expectation and for most cancer types it is even 
an unrealistic expectation. In 2007, the Netherlands Health Council addressed the 
need for a systematic substantiation of the routine follow-up after treatment for 
cancer.2 This thesis forms part of this substantiation and provides evidence for the 
effectiveness of routine follow-up after treatment for cancer.
EVALUATION OF THE EFFECTIVENESS OF ROUTINE 
FOLLOW-UP AFTER TREATMENT FOR CANCER
Routine follow-up may improve longevity through early detection of locoregional 
recurrences or second primary cancers. This assumes the existence of a number 
of prerequisites. The first prerequisite for an effective follow-up programme is the 
availability of a functional screening test which enables the detection of relapses 
before patients present with symptoms (Chapter 2). Furthermore, effective relapse 
treatment options have to be available, whereby an earlier initiation of these options 
should improve treatment success. The impact of routine follow-up on survival time 
can be studied by comparing two patient groups: patients in whom the relapse was 
detected through routine tests and patients who had complaints indicating cancer 
relapse. The number of life years gained by a follow-up schedule depend on the 
tests and frequencies included, the survival gain achieved by earlier detection, the 
actual number of relapses detected early, and the risk of relapse. These determinants 
differ between cancer types. As a consequence, the effectiveness of routine follow-
up should be determined for all cancer types separately. In this thesis we evaluate 
routine follow-up after treatment for ovarian cancer and breast cancer.
Early detection and treatment of relapses with the hope of improving life expectancy 
is not the only aim of routine follow-up.2 Follow-up visits also aim at providing 
psychosocial care, as well as monitoring complications and late effects of primary 
treatment. How best to provide follow-up care needs further evaluation, especially 
in cases where routine follow-up tests have no impact on the duration of patients’ 
survival. These topics are important and require investigation, however they fall 
outside the scope of this thesis.
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TWO APPLICATIONS: OVARIAN AND BREAST CANCER
Ovarian cancer
In the Netherlands in 2010, more than 1400 women were diagnosed with ovarian 
cancer.3 Approximately half of these achieve complete clinical remission after 
primary treatment (Chapter 4). These patients have a five-year risk of relapse of 55% 
and a five-year survival rate of 59%. A retrospective study of 68 patients in complete 
clinical remission after ovarian cancer treatment showed a close adherence of follow-
up practice with guideline recommendations (Chapter 4).
In a literature review we identified five observational studies which included patients 
receiving follow-up through physical examination and tumour marker CA125 
measurements (Chapter 3). In these patients, 43% of the recurrences were detected 
asymptomatically. In another three observational studies, where routine follow-
up also included routine imaging, 78% of recurrences were detected early. In both 
follow-up programmes, physical examination only played a small role in the early 
detection of recurrences.
Pooling another 38 observational studies showed that a CA125 elevation occurred in 
65% of patients, a median of 3 months before the clinical presentation of a recurrence 
(Chapter 3). In the one and only experimental study, a preclinical period of 5 months 
was observed. No studies were found that estimated the preclinical phase achieved 
by imaging modalities.
A trend towards an improved survival time through early recurrence detection was 
noted in 3 of 6 observational studies (Chapter 3 and 4 and Tanner et al4). However, 
the difference in survival time found in these studies may be induced by differences in 
patient and tumour characteristics. The other 3 studies shed doubt on the effectiveness 
of routine follow-up after treatment for ovarian cancer, as did 2 simulation studies 
(Chapter 5 and Hopkins et al5) and one experimental study.6 In these studies early 
detection and treatment of recurrences did not improve survival time. Based on these 
findings, we conclude that the timing of detection of recurrent ovarian cancer is 
immaterial until markedly improved treatment options become available. Another 
important observation made by Rustin et al6 based on a randomised trial, is that 
initiation of recurrence treatment in the preclinical phase can actually harm patients, 
as it decreases patients’ quality of life without any gain in survival.
Routine follow-up examination resulting in increased longevity is not indicated for 
ovarian cancer, although patients and medical specialists may have other reasons for 
performing routine tests. We therefore advise medical specialists to first discuss the 
limitations and possible harms of routine follow-up examinations with their patients.
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Breast cancer
Breast cancer is the most common cancer in women. In 2010, over 13,000 women 
were diagnosed with invasive breast cancer in the Netherlands.3 The prognosis is 
favourable: 9 in 10 patients will survive the first five years. Five-year risk of relapse 
in patients treated with curative intent has decreased over the last decades, from 38% 
in 1972-1979 and 35% in 1980-1986 to 16% in 2003-2004 (Chapter 6).
An experimental study in the 1990s showed that screening for distant metastases 
did not improve longevity.7 Observational studies show that early detection and 
treatment of local and regional recurrences and second primary breast cancers are 
associated with a better survival time compared with diagnosis guided by patient 
complaints.8,9 To detect a relapse early-on, patients are examined regularly, both by 
physical examination and mammography, supplemented with breast MRI in patients 
with a genetic breast cancer predisposition.10-12 In a retrospective study of 144 
patients operated for non-metastasised breast cancer in 2003 or 2004, we observed 
an average of 13 follow-up visits during the first five years, whereas 9 visits were 
advised in the Dutch guidelines (Chapter 7). This discrepancy with the guideline 
increased with the number of medical disciplines involved in follow-up care. The use 
of mammography and MRI were in accordance with the guideline recommendations.
The five-year risk of locoregional recurrence in patients diagnosed in 2003 
or 2004 was 4% and the risk of a second primary breast cancer 2% (Chapter 6). 
Current follow-up practice diagnosed 34% of locoregional recurrences and 75% of 
second primary breast cancers in the asymptomatic phase (Chapter 7). To detect 1 
relapse asymptomatically, 1349 physical examinations were needed. The detection 
yield using mammography and breast MRI was higher; 262 tests were performed 
for every relapse detected asymptomatically. Given these findings, and considering 
the increasing prevalence of breast cancer and the decreasing risk of relapse, it is 
important to find ways of minimising the number of unnecessary follow-up exams.
In 2012, the follow-up guideline recommendations were changed; the new schedule 
recommends yearly physical examination and mammography, supplemented with 
breast MRI if indicated.11 Given the current evidence, we support the new guideline 
which reduces the number of follow-up examinations during the first five years from 
9 to 5. However, the new follow-up schedule is still consensus-based as current 
evidence for the optimal combination of tests and frequencies is lacking. We therefore 
recommend that modelling studies be performed to determine the optimal follow-up 
schedule, and to personalise it where possible (Chapter 9).
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EVIDENCE-BASED FOLLOW-UP
Patients treated for cancer with curative intent receive regular follow-up examinations 
five to ten years following primary treatment.13 The number of cancer patients is 
rapidly increasing, with a resulting escalation in the number of follow-up visits and 
tests, increasing the burden on health care resources and budgets. Furthermore, 
routine tests without a gain in life expectancy can lead to a decreased quality of life. It 
is therefore both economically and ethically essential that the number of unnecessary 
follow-up visits and tests be minimised.
Routine tests are not indicated if treatment initiated in the preclinical phase has the 
same outcome compared with treatment at time of symptoms. In addition, routine 
examinations are unlikely to impact prognosis in patients with a relatively short 
life expectancy, for example, due to high patient age and presence and severity of 
comorbidity (Chapter 8).
If routine examinations are to prolong longevity, the optimal combination of follow-up 
tests, frequency and duration has to be determined. Current follow-up schedules are 
generally ‘one-size-fits-all’, serving all patients with the same schedule, irrespective 
of patient and tumour characteristics.13 A more personalised schedule, for example 
based on risk of relapse or relapse characteristics, may increase the efficiency of 
routine follow-up (Chapter 9).
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In Nederland wordt steeds vaker de diagnose kanker gesteld.1 Gelukkig zijn er de 
afgelopen decennia betere behandelmogelijkheden gekomen, waardoor patiënten 
steeds vaker genezen en langer leven. Patiënten behandeld voor kanker hebben 
echter een kans op een nieuwe tweede primaire tumor of terugkeer van de initiële 
tumor, een ‘recidief’ genoemd.2 Mede daarom worden patiënten die een in opzet 
genezende behandeling voor kanker hebben ondergaan regelmatig gecontroleerd 
om een recidief zo vroeg mogelijk op te sporen. Het vroeg ontdekken van recidieven 
heeft als doel om de behandeling snel te kunnen herstarten en daarmee de 
levensverwachting van de patiënt te verlengen. Een verbetering in levensverwachting 
is voor de meeste kankersoorten echter niet bewezen. Daarom hield de Nederlandse 
Gezondheidsraad in 2007 een pleidooi voor meer onderbouwing van de effectiviteit 
van nacontrole na behandeling voor kanker.2 Met dit proefschrift dragen wij bij 
aan de wetenschappelijke kennis over het effect van routinematige nacontrole na 
behandeling voor kanker.
EVALUATIE VAN DE EFFECTIVITEIT VAN NACONTROLE 
NA BEHANDELING VOOR KANKER
Voor een effectieve nacontrole is de eerste vereiste om over een goede screeningstest 
te beschikken die een mogelijk recidief vroeg kan ontdekken, liefst ruim voordat de 
patiënt klachten krijgt (Hoofdstuk 2). Daarnaast dienen er effectieve behandelopties 
te zijn voor het recidief. Bovendien dient eerder behandelen succesvoller te zijn dan 
behandeling nadat klachten zijn ontstaan. De impact van routinematig testen op 
de levensverwachting van de patiënt kan bestudeerd worden door twee groepen 
patiënten met elkaar te vergelijken: patiënten bij wie het recidief vroeg ontdekt werd 
middels het routineonderzoek ten opzichte van patiënten bij wie het recidief ontdekt 
werd toen er klachten optraden.
Het succes van een nacontroleprogramma wordt bepaald door het aantal mensen 
dat een recidief krijgt, de eigenschappen van de tumor, de keuze voor een bepaalde 
combinatie van screeningstests en de frequentie van deze tests. De mate van succes 
wordt gemeten aan de hand van het aantal recidieven dat ontdekt is voordat de 
patiënt klachten ondervond. Het optimale nacontroleschema hangt af van de 
kenmerken van een tumor en het risico op een recidief en zal daarom verschillen per 
type kanker. Daarom zal de effectiviteit van routinematige nacontrole voor alle tumor 
typen in principe apart bekeken dienen te worden. In dit proefschrift evalueren we de 
nacontrole na behandeling voor eierstokkanker en borstkanker.
Naast het verbeteren van de levensverwachting kent de nacontrole nog twee andere 
doelen: het geven van psychosociale zorg en het monitoren van complicaties en 
late effecten van de primaire behandeling.2 Hoe deze doelen het best geïntegreerd 
kunnen worden in het nacontroleprogramma behoeft aandacht, vooral bij patiënten 
bij wie routinematige tests niet leiden tot een betere levensverwachting en nacontrole 
daardoor een andere focus krijgt.
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TWEE PRAKTIJKVOORBEELDEN: 
EIERSTOK- EN BORSTKANKER
In Nederland kregen in 2010 meer dan 1400 vrouwen de diagnose eierstokkanker.3 
Ongeveer de helft van de patiënten is tumorvrij na de primaire behandeling 
(Hoofdstuk 4). Deze patiënten hebben een kans van 55% om binnen 5 jaar na 
behandeling een recidief te krijgen en een kans van 41% om binnen 5 jaar te 
overlijden. Statusonderzoek van 68 patiënten behandeld voor eierstokkanker liet 
een goede overeenkomt zien tussen de nacontrolefrequentie in de praktijk en de 
Nederlandse richtlijn (Hoofdstuk 4).
Op basis van literatuuronderzoek vonden we vijf observationele studies waarin de 
nacontrole bestond uit lichamelijk onderzoek en bepaling van de tumor merkstof 
CA125 (Hoofdstuk 3). Van de patiënten die deelnamen aan deze studies werd 43% 
van de recidieven ontdekt in de asymptomatisch fase. In drie observationele studies, 
waar de nacontrole naast lichamelijk onderzoek en CA125 ook uit routinematige 
beeldvorming bestond, werd 78% van de recidieven vroeg ontdekt. In beide 
nacontroleschema’s had lichamelijk onderzoek slechts een kleine bijdrage aan de 
vroege detectie van het recidief. De waarde van lichamelijk onderzoek is daarom 
beperkt.
Het samenvoegen van 38 observationele studies liet zien dat CA125 bij 65% van de 
patiënten zo’n 3 maanden eerder verhoogd is voordat de patiënten klachten kregen 
(Hoofdstuk 3). Een experimentele studie liet een preklinische duur van 5 maanden 
zien. Over de preklinische periode van beeldvormende technieken zijn geen gegevens 
bekend.
In 3 van de 6 observationele studies was een trend voor een betere overleving te 
zien als het recidief in de asymptomatische fase werd ontdekt (Hoofdstuk 3 en 4 en 
Tanner et al4). Echter, verschillen in prognose tussen de recidieven zou dit verschil 
ook kunnen verklaren. Twijfel over de effectiviteit van nacontrole na behandeling 
van eierstokkanker wordt bevestigd door de overige 3 observationele studies, 2 
simulatiestudies (Hoofdstuk 5 en Hopkins et al5) en 1 experimentele studie.6 Deze 
studies toonden aan dat 3-5 maanden eerder starten met behandelen niet leidt tot 
een winst in levensverwachting. Wij denken dat de ineffectiviteit van nacontrole na 
behandeling voor eierstokkanker waarschijnlijk komt door de beperkte behandelopties 
voor eierstokkanker, en het missen van een in opzet curatieve behandeling voor het 
recidief.
Behandelen van een recidief voordat de patiënt klachten heeft kan nadelig zijn voor 
de patiënt. Eerder starten van de behandeling is in verband gebracht met verlies in 
kwaliteit van leven, zonder winst in overlevingsduur.6 Wij adviseren artsen om de 
beperkingen en nadelen van routinematige nacontroles te bespreken met de patiënt. 
Routine controles met als doel verbetering van de levensverwachting zijn momenteel 
niet geïndiceerd, ofschoon de patiënt en arts andere redenen kunnen hebben om 
routine tests uit te voeren.
Eierstokkanker
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Borstkanker
Borstkanker is de meest voorkomende tumor bij vrouwen. In 2010 hoorden 
ruim 13.000 Nederlandse vrouwen de diagnose borstkanker.3 De prognose van 
borstkanker is gunstig: 9 van de 10 patiënten overleeft de eerste 5 jaar. De kans op 
een borstkankerrecidief binnen 5 jaar na een in opzet curatieve behandeling is in de 
loop van de tijd sterk gedaald: van 38% in 1972-1979 en 35% in 1980-1986 tot 16% 
in 2003-2004 (Hoofdstuk 6).
In de jaren negentig toonde experimenteel onderzoek aan dat screenen naar 
metastasen op afstand niet zinvol is.7 Het opsporen van locale en regionale 
recidieven en tweede primaire borsttumoren is wel geassocieerd met een betere 
overlevingsduur in vergelijking met diagnose geleid door klachten.8,9 Om een recidief 
zo vroeg mogelijk te ontdekken worden de patiënten regelmatig gecontroleerd door 
de behandelend artsen middels lichamelijk onderzoek en mammografie, eventueel 
aangevuld met MRI onderzoek.10-12 In Nederland worden gedurende de eerste 5 jaar 
na diagnose 9 controlevisites geadviseerd. Na bestudering van de medische dossiers 
van 144 patiënten geopereerd voor borstkanker in 2003 of 2004 hebben wij gezien 
dat gemiddeld 13 controlevisites per patiënt werden uitgevoerd (Hoofdstuk 7). Het 
verschil met de richtlijn is groter indien meer specialismen betrokken zijn bij de 
nacontrole. Gebruik van mammografie en/of MRI is conform de richtlijn. Het is mogelijk 
om het aantal onnodige nacontroles te verminderen, door een monodisciplinaire 
opzet van de nacontrole, een betere afstemming tussen de uitvoerend specialismen 
en een gerichte patiëntenvoorlichting.
De 5-jaars kans op een locoregionaal recidief is 4% en de kans op een tweede primaire 
borstkanker 2% (Hoofdstuk 6). Het huidige uitgevoerde nacontroleschema ontdekt 
34% van de locoregionale recidieven en 75% van de tweede primaire borsttumoren 
in de asymptomatische fase (Hoofdstuk 7). Gemiddeld werden 1349 lichamelijke 
onderzoeken uitgevoerd om 1 recidief vroeg te ontdekken. Mammografie en/of MRI 
werd efficiënter ingezet: 262 tests werden uitgevoerd om 1 recidief vroeg te ontdekken. 
De waarde van lichamelijk onderzoek als routine test tijdens een nacontrolevisite is 
nog onduidelijk, maar met het oog op de toenemende borstkankerprevalentie en de 
dalende kans op recidief is vermindering van het aantal onnodige controles van groot 
belang.
In 2012 is het advies over de nacontrole in de Nederlandse richtlijn mammacarcinoom 
veranderd; het schema is nu een jaarlijkse controle middels lichamelijk onderzoek 
en mammografie, aangevuld met MRI onderzoek voor patiënten met een BRCA1 of 
2 genmutatie.11 Op basis van de huidige stand van zaken zijn wij het eens met dit 
advies. Toch is de richtlijn nog een resultaat van overeenstemming tussen medisch 
specialisten omdat het huidige wetenschappelijke bewijs tekort schiet. Wij adviseren 
om spoedig modelstudies uit te voeren gericht op het bepalen van het meest optimale 
nacontroleschema voor de individuele patiënt, waarbij rekening wordt gehouden met 
patiënt- en tumorkenmerken (Hoofdstuk 9).
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NACONTROLE KAN DOELMATIGER
Patiënten in opzet curatief behandeld voor kanker worden regelmatig 
gecontroleerd gedurende een periode van vijf tot tien jaar na diagnose.13 Het aantal 
kankerpatiënten en daarmee het aantal nacontrolevisites stijgt snel, waardoor huidige 
nacontroleprogramma’s een grote druk uitoefenen op de gezondheidszorg. Het is 
noodzakelijk om het aantal onnodige nacontrolevisites en tests te minimaliseren. Voor 
de meeste kankersoorten is een verbetering in levensverwachting door routine testen 
niet bewezen of onwaarschijnlijk. Routine tests zonder winst in levensverwachting 
voor de patiënt kunnen leiden tot een verminderde kwaliteit van leven.
Routine contoles zijn niet geïndiceerd indien recidiefbehandeling in de preklinische 
fase niet succesvoller is dan behandeling op het moment van klachten. Daarnaast 
is het onwaarschijnlijk dat routine tests invloed uitoefenen op de prognose van 
patiënten met een relatief korte levensverwachting, bijvoorbeeld gelet op de leeftijd 
van de patiënt en de aanwezigheid en ernst van eventuele comorbiditeit 
(Hoofdstuk 8).
Indien het aannemelijk is dat routinematige tests de levensverwachting van een patiënt 
gunstig beïnvloedt, dient de meest optimale combinatie van tests, frequentie en duur te 
worden vastgesteld. Op dit moment zijn de meeste nacontroleprogramma’s hetzelfde 
voor alle patiënten, ongeacht de verschillen in patiënt- en tumorkenmerken.13 De 
doelmatigheid van nacontroleprogramma’s zou mogelijkerwijs verhoogd kunnen 
worden indien het programma toegespitst wordt op het risico op recidief en de 
groeisnelheid van het recidief (Hoofdstuk 9). Deze overwegingen dienen bestudeerd 
te worden middels prognostisch epidemiologisch onderzoek en modelstudies.
171
Samenvatting
10
REFERENTIES
1. Signaleringscommissie Kanker van KWF Kankerbestrijding. Kanker in Nederland 
tot 2020: Trends en prognoses. Oisterwijk, Nederland: KWF Kankerbestrijding. 
September 2011.
2. Gezondheidsraad. Nacontrole in de oncologie: Doelen onderscheiden, inhoud 
onderbouwen. Publicatienr 2007/10. Den Haag, Nederland: Gezondheidsraad. 
2007.
3. Integraal Kankercentrum Nederland. Incidentie en mortaliteit. www.
cijfersoverkanker.nl. 2011. Geraadpleegd op 2 april 2012.
4. Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for the detection of recurrent 
ovarian cancer: Survival impact or lead-time bias? Gynecol Oncol. 2010;117:336-
340.
5. Hopkins ML, Coyle D, Le T, et al. Cancer antigen 125 in ovarian cancer 
surveillance: a decision analysis model. Curr Oncol. 2007;14:167-172.
6. Rustin GJ, van der Burg MEL, Griffin CL, et al. Early versus delayed treatment of 
relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 
2010;376:1155-1163.
7. Palli D, Russo A, Saieva C, et al. Intensive vs clinical follow-up after treatment of 
primary breast cancer: 10-year update of a randomized trial. National Research 
Council Project on Breast Cancer Follow-up. JAMA. 1999;281:1586.
8. Lu WL, Jansen L, Post WJ, et al. Impact on survival of early detection of isolated 
breast recurrences after the primary treatment for breast cancer: a meta-analysis. 
Breast Cancer Res Treat. 2009;114:403-412.
9. Houssami N, Ciatto S. Mammographic surveillance in women with a personal 
history of breast cancer: how accurate? How effective? Breast. 2010;19:439-445.
10. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Nationaal Borstkanker Overleg 
NABON. Mammacarcinoom. Landelijke richtlijn. www.oncoline.nl. 2008.
11. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Nationaal Borstkanker Overleg 
NABON. Mammacarcinoom. www.oncoline.nl. 2012.
12. Kwaliteitsinstituut voor de Gezondheidszorg CBO, Nationaal Borstkanker Overleg 
NABON. Richtlijn behandeling mammacarcinoom. www.oncoline.nl. 2002.
13. Integraal Kankercentrum Nederland. Richtlijnen oncologische zorg.  
www oncoline.nl. 2012. Geraadpleegd op 18 april 2012.

Chapter 10
Summary
Samenvatting
Co-author affiliations
Dankwoord
174
Chapter 10
175
Co-author affiliations
10
Katja K.H. Aben, PhD
Eddy M. Adang, PhD
Anne M. van Altena, MD, PhD
Jos A.A.M. van Dijck, PhD
Karin Flobbe, PhD
Margriet van der Heiden- 
van der Loo, MSc
Kim E.M. van Kessel, MD
Prof Leon F.A.G. Massuger, 
MD, PhD
Yvonne Paquay, MD
Sabine Siesling, PhD
Prof Ewout W. Steyerberg, PhD
Prof Vivianne C.G. Tjan-
Heijnen, MD, PhD
Femmie de Vegt, PhD
Prof André L.M. Verbeek, MD, 
PhD
Department for Health Evidence, Radboud University 
Medical Centre, Nijmegen, The Netherlands; 
Comprehensive Cancer Centre The Netherlands, 
Utrecht, The Netherlands
Department for Health Evidence, Radboud University 
Medical Centre, Nijmegen, The Netherlands
Department of Obstetrics and Gynaecology, Radboud 
University Medical Centre, Nijmegen, The Netherlands
Department for Health Evidence, Radboud University 
Medical Centre, Nijmegen, The Netherlands
Comprehensive Cancer Centre The Netherlands, 
Utrecht, The Netherlands
Comprehensive Cancer Centre The Netherlands, 
Utrecht, The Netherlands
Department of Public Health, Erasmus Medical Centre, 
Rotterdam, The Netherlands
Department of Obstetrics and Gynaecology, Radboud 
University Medical Centre, Nijmegen, The Netherlands
Department of Surgery, Hospital Bernhoven, Oss, The 
Netherlands
Comprehensive Cancer Centre The Netherlands, 
Utrecht, The Netherlands; Department of Health 
Technology and Services Research, Twente University, 
Enschede, The Netherlands
Department of Public Health, Erasmus Medical Centre, 
Rotterdam, The Netherlands
Division of Medical Oncology, Department of 
Internal Medicine, GROW – School for Oncology and 
Developmental Biology, Maastricht University Medical 
Centre, Maastricht, The Netherlands
Department for Health Evidence, Radboud University 
Medical Centre, Nijmegen, The Netherlands
Department for Health Evidence, Radboud University 
Medical Centre, Nijmegen, The Netherlands

Hoofdstuk 10
Summary
Samenvatting
Co-author affiliations
Dankwoord
178
Hoofdstuk 10
Een proefschrift schrijven doe je gelukkig niet alleen. Ik wil daarom ook iedereen 
bedanken die mij geholpen en gesteund heeft tijdens mijn promotietraject en het 
schrijven van dit proefschrift. Enkele personen wil ik in het bijzonder bedanken.
Allereerst mijn (co-)promotoren.
Beste André, Jos en Femmie, het was heerlijk om met jullie samen te werken. Jullie 
hebben mij altijd gestimuleerd bij mijn persoonlijke ontwikkeling, op het gebied van 
onderzoek, onderwijs en de Engelse taal. Dank voor jullie vertrouwen, luisterend oor, 
feedback en complimenten.
Vivianne, ik kijk altijd uit naar onze gesprekken. Door je enthousiasme, kritische blik 
en je klinische ervaring heb je mij altijd met vernieuwde inzichten verrijkt. Wat ten 
goede is gekomen aan de voortgang en de kwaliteit van het onderzoek.
Wij danken KWF Kankerbestrijding voor hun vertrouwen en het financieel mogelijke 
maken van dit promotieonderzoek. 
Ook een woord aan dank aan alle co-auteurs, in het bijzonder Leon Massuger en Anne 
van Altena. Fijn dat ik jullie prachtige dataset als basis heb mogen gebruiken. Onze 
samenwerking resulteerde in drie publicaties over nacontrole na behandeling voor 
eierstokkanker. Jullie klinische en kritische blik hebben mij daar enorm bij geholpen. 
Eddy Adang, dank voor je advies tijdens het uitvoeren van de modelleringstudie. 
Yvonne Paquay, fijn dat we de gegevens uit Oss mochten gebruiken en dank voor je 
inbreng. Roger Staats, thank you for your linguistic advice.
Verder ben ik dank verschuldigd aan de Nederlandse Kanker Registratie. In het 
bijzonder de registratiemedewerkers en data managers die mij hielpen met de 
registratie van de borstkankerpatiënten. Bedankt voor jullie inzet en de prettige 
samenwerking! Katja Aben, Margriet van der Heiden-van der Loo, Sabine Siesling en 
Karin Flobbe, dank voor jullie input en hulp bij de organisatie van de dataregistratie 
en het schrijven van de artikelen.
Dear professor Stephen W. Duffy, it was a pleasure working with you last April. Our 
conversations helped me to come up with a plan to determine the optimal follow-up 
schedule for cancer survivors (Chapter 9). I hope that we can continue the work we 
started! I would also like to thank the other researchers and staff for the inspiring 
talks and warm welcome. My stay at the Wolfson Institute of Preventive Medicine in 
London was very inspiring. Ik wil de René Vogels Stichting dan ook danken voor hun 
financiële ondersteuning.
Beste collega’s van EBH, bedankt voor jullie gezellige koffiepauzes, lunches en 
interesse! Beste promovendi, wat hebben we toch geluk gehad dat we met zoveel 
promovendi op één afdeling werken. Dit maakte de sfeer zeer prettig, zowel op als 
naast het werk. Ik hoop dat ik ook na het behalen van mijn PhD nog kan aansluiten bij 
de borrels, barbecue, karaoke, twister, enzovoorts. Beste Wim, het is niet voor niets 
dat jij in bijna ieder dankwoord voorkomt. Je deur staat altijd open voor een praatje 
of een SAS syntax vraag. Daar heb ik dan ook ruimschoots gebruik van gemaakt. 
Bedankt voor je hulp! Beste (ex-)kamergenoten: Linda, Ram, Marleen, Janine, Loes, 
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Marijn, bedankt voor jullie gezelligheid! Beste Linda, wat ben je toch een fijne 
kamergenoot! Je bent altijd bereid om mee te denken of een luisterend oor te bieden. 
Ik vind het mooi dat we elkaar af en toe inhuren, ik jou als taaladviseur, jij mij als 
secretaresse, al heb ik nooit een bloemetje op secretaressedag mogen ontvangen... 
Bedankt dat je mijn paranimf wilt zijn.
Anouk Meijs en Anke Richters, ik vond het leuk om jullie te begeleiden tijdens jullie 
bachelor stage. Ik heb veel van jullie geleerd en ik hoop jullie ook van mij! Dank 
voor jullie inzet en interesse in het project. Anouk, jij was mijn eerste stagiaire en 
hebt me enorm geholpen met de voorbereidingen voor de borstkankerregistratie. 
Nogmaals dank daarvoor! Anke, jij hebt je onder andere vastgebeten in de analyse 
methode die rekening houdt met ‘competing risks’. Deze kennis heb je niet voor 
jezelf gehouden; je hebt mij de methode geleerd en zelfs een presentatie gegeven op 
de WEON conferentie in 2012. Anke, wat mag jij trots op jezelf zijn!
Het doorlopen van het promotietraject was me niet gelukt zonder ontspanning. Het 
verenigingsleven is gezellig, maar kent ook zijn verplichtingen. Soms moest ik het 
werk voor laten gaan en de repetitie, concert, training of wedstrijd afzeggen. Beste 
collegae van de Fanfare Velden en teamgenoten van Swift 2, bedankt voor jullie 
begrip!
Lieve vrienden en familie, bedankt voor jullie interesse en gezelligheid. Het is nu tijd 
voor een feest!
Lieve pap en mam, wat fijn om zulke steunende ouders te hebben. Jullie leven altijd 
met me mee en zijn erg geïnteresseerd in wat ik doe. Al is de wetenschapswereld 
anders dan de salarisadministratie en metaal, jullie proberen het te begrijpen. Lieve 
broer en zus, beste Christian en Inge, al vinden jullie het vanzelfsprekend dat jullie 
grote zus zich weer eens uitslooft, jullie zijn altijd geïnteresseerd gebleven; dank 
daarvoor. Inge, leuk dat je mijn paranimf wilt zijn! Beste Marijn, Jorg, Herman, Marjo, 
Patrick, Willie en Stan bedankt voor jullie interesse en hulp, ik kan me geen betere 
schoonfamilie wensen!
Lieve Bas, bedankt voor je liefde, steun en geduld. Je hebt me op gezette tijden 
aardig moet remmen en je onuitputtende energie en humor hebben mij door het 
promotietraject heen laten fietsen. Fijn dat je mij zo stimuleert om verder te gaan 
in de onzekere wereld die wetenschap heet. Ik vond het erg leuk dat ik misbruik 
heb mogen maken van je grafische vaardigheden. De snelheid en kunde waarmee 
jij de kaft en het binnenwerk ontwierp en maakte zijn verbazingwekkend. Ik was 
vast de meest vervelende klant die je ooit gehad hebt, maar ben tevreden met het 
eindresultaat. Dat was me alleen nooit gelukt, thanks!

